101
|
Chen Q, Ursini G, Romer AL, Knodt AR, Mezeivtch K, Xiao E, Pergola G, Blasi G, Straub RE, Callicott JH, Berman KF, Hariri AR, Bertolino A, Mattay VS, Weinberger DR. Schizophrenia polygenic risk score predicts mnemonic hippocampal activity. Brain 2019; 141:1218-1228. [PMID: 29415119 DOI: 10.1093/brain/awy004] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Accepted: 11/21/2017] [Indexed: 01/01/2023] Open
Abstract
The use of polygenic risk scores has become a practical translational approach to investigating the complex genetic architecture of schizophrenia, but the link between polygenic risk scores and pathophysiological components of this disorder has been the subject of limited research. We investigated in healthy volunteers whether schizophrenia polygenic risk score predicts hippocampal activity during simple memory encoding, which has been proposed as a risk-associated intermediate phenotype of schizophrenia. We analysed the relationship between polygenic risk scores and hippocampal activity in a discovery sample of 191 unrelated healthy volunteers from the USA and in two independent replication samples of 76 and 137 healthy unrelated participants from Europe and the USA, respectively. Polygenic risk scores for each individual were calculated as the sum of the imputation probability of reference alleles weighted by the natural log of odds ratio from the recent schizophrenia genome-wide association study. We examined hippocampal activity during simple memory encoding of novel visual stimuli assessed using blood oxygen level-dependent functional MRI. Polygenic risk scores were significantly associated with hippocampal activity in the discovery sample [P = 0.016, family-wise error (FWE) corrected within Anatomical Automatic Labeling (AAL) bilateral hippocampal-parahippocampal mask] and in both replication samples (P = 0.033, FWE corrected within AAL right posterior hippocampal-parahippocampal mask in Bari sample, and P = 0.002 uncorrected in the Duke Neurogenetics Study sample). The relationship between polygenic risk scores and hippocampal activity was consistently negative, i.e. lower hippocampal activity in individuals with higher polygenic risk scores, consistent with previous studies reporting decreased hippocampal-parahippocampal activity during declarative memory tasks in patients with schizophrenia and in their healthy siblings. Polygenic risk scores accounted for more than 8% of variance in hippocampal activity during memory encoding in discovery sample. We conclude that polygenic risk scores derived from the most recent schizophrenia genome-wide association study predict significant variability in hippocampal activity during memory encoding in healthy participants. Our findings validate mnemonic hippocampal activity as a genetic risk associated intermediate phenotype of schizophrenia, indicating that the aggregate neurobiological effect of schizophrenia risk alleles converges on this pattern of neural activity.awy004media15749593779001.
Collapse
Affiliation(s)
- Qiang Chen
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, 855 North Wolfe Street, MD, USA
| | - Gianluca Ursini
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, 855 North Wolfe Street, MD, USA.,Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Adrienne L Romer
- Laboratory of NeuroGenetics, Department of Psychology and Neurosicence, Duke University, Durham, NC, USA
| | - Annchen R Knodt
- Laboratory of NeuroGenetics, Department of Psychology and Neurosicence, Duke University, Durham, NC, USA
| | - Karleigh Mezeivtch
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, 855 North Wolfe Street, MD, USA
| | - Ena Xiao
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, 855 North Wolfe Street, MD, USA
| | - Giulio Pergola
- Group of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari, Bari, Italy
| | - Giuseppe Blasi
- Group of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari, Bari, Italy
| | - Richard E Straub
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, 855 North Wolfe Street, MD, USA
| | - Joseph H Callicott
- Clinical and Translational Neuroscience Branch, National Institute of Mental Health Intramural Research Program, National Institutes of Health, Bethesda, MD, USA
| | - Karen F Berman
- Clinical and Translational Neuroscience Branch, National Institute of Mental Health Intramural Research Program, National Institutes of Health, Bethesda, MD, USA
| | - Ahmad R Hariri
- Laboratory of NeuroGenetics, Department of Psychology and Neurosicence, Duke University, Durham, NC, USA
| | - Alessandro Bertolino
- Group of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari, Bari, Italy
| | - Venkata S Mattay
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, 855 North Wolfe Street, MD, USA.,Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.,Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Daniel R Weinberger
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, 855 North Wolfe Street, MD, USA.,Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.,Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.,Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD USA.,Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
102
|
van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, Pearlson GD, Yao N, Fukunaga M, Hashimoto R, Okada N, Yamamori H, Clark VP, Mueller BA, de Zwarte SMC, Ophoff RA, van Haren NEM, Andreassen OA, Gurholt TP, Gruber O, Kraemer B, Richter A, Calhoun VD, Crespo-Facorro B, Roiz-Santiañez R, Tordesillas-Gutiérrez D, Loughland C, Catts S, Fullerton JM, Green MJ, Henskens F, Jablensky A, Mowry BJ, Pantelis C, Quidé Y, Schall U, Scott RJ, Cairns MJ, Seal M, Tooney PA, Rasser PE, Cooper G, Weickert CS, Weickert TW, Hong E, Kochunov P, Gur RE, Gur RC, Ford JM, Macciardi F, Mathalon DH, Potkin SG, Preda A, Fan F, Ehrlich S, King MD, De Haan L, Veltman DJ, Assogna F, Banaj N, de Rossi P, Iorio M, Piras F, Spalletta G, Pomarol-Clotet E, Kelly S, Ciufolini S, Radua J, Murray R, Marques TR, Simmons A, Borgwardt S, Schönborn-Harrisberger F, Riecher-Rössler A, Smieskova R, Alpert KI, Bertolino A, Bonvino A, Di Giorgio A, Neilson E, Mayer AR, Yun JY, Cannon DM, Lebedeva I, Tomyshev AS, Akhadov T, Kaleda V, Fatouros-Bergman H, Flyckt L, Rosa PGP, Serpa MH, Zanetti MV, Hoschl C, Skoch A, Spaniel F, Tomecek D, McIntosh AM, Whalley HC, Knöchel C, Oertel-Knöchel V, Howells FM, Stein DJ, Temmingh HS, Uhlmann A, Lopez-Jaramillo C, Dima D, Faskowitz JI, Gutman BA, Jahanshad N, Thompson PM, Turner JA. Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process? Biol Psychiatry 2019; 85:e35-e39. [PMID: 30470561 PMCID: PMC7041557 DOI: 10.1016/j.biopsych.2018.10.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Accepted: 10/05/2018] [Indexed: 10/27/2022]
Affiliation(s)
- Theo GM van Erp
- Department of Psychiatry and Human Behavior, University of
California, Irvine, Irvine, CA, USA,Corresponding Author: Theo G.M. van Erp, Clinical
Translational Neuroscience Laboratory, Department of Psychiatry and Human
Behavior, School of Medicine, University of California Irvine, 5251 California
Avenue, Suite 240, Irvine, CA 92617, voice: (949) 824-3331,
| | - Esther Walton
- Medical Research Council Integrative Epidemiology Unit and
Bristol Medical School, Population Health Sciences, University of Bristol, United
Kingdom
| | - Derrek P Hibar
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging
& Informatics Institute, Keck School of Medicine of the University of Southern
California, Marina del Rey, CA, USA,Janssen Research & Development, San Diego, CA,
USA
| | - Lianne Schmaal
- Orygen, The National Centre of Excellence in Youth Mental
Health, Melbourne, VIC, Australia,Centre for Youth Mental Health, The University of
Melbourne, Melbourne, VIC, Australia,Department of Psychiatry and Amsterdam Neuroscience, VU
University Medical Center, Amsterdam, The Netherlands
| | - Wenhao Jiang
- Department of Psychology, Georgia State University,
Atlanta, GA, USA
| | - David C Glahn
- Department of Psychiatry, Yale University, New Haven, CT,
USA,Olin Neuropsychiatric Research Center, Institute of
Living, Hartford Hospital, Hartford, CT, USA
| | - Godfrey D Pearlson
- Department of Psychiatry, Yale University, New Haven, CT,
USA,Olin Neuropsychiatric Research Center, Institute of
Living, Hartford Hospital, Hartford, CT, USA
| | - Nailin Yao
- Department of Psychiatry, Yale University, New Haven, CT,
USA,Olin Neuropsychiatric Research Center, Institute of
Living, Hartford Hospital, Hartford, CT, USA
| | - Masaki Fukunaga
- Division of Cerebral Integration, National Institute for
Physiological Sciences, Okazaki, Aichi, Japan
| | - Ryota Hashimoto
- Molecular Research Center for Children's Mental
Development, United Graduate School of Child Development, Osaka University, Suita,
Osaka, Japan,Department of Psychiatry, Osaka University Graduate
School of Medicine, Suita, Osaka, Japan
| | - Naohiro Okada
- Department of Neuropsychiatry, Graduate school of
Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - Hidenaga Yamamori
- Department of Psychiatry, Osaka University Graduate
School of Medicine, Suita, Osaka, Japan
| | - Vincent P Clark
- University of New Mexico, Albuquerque, NM, USA,Mind Research Network, Albuquerque, NM, USA
| | - Bryon A Mueller
- Department of Psychiatry, University of Minnesota,
Minneapolis, MN, USA
| | - Sonja MC de Zwarte
- Department of Psychiatry and Brain Center Rudolf Magnus,
University Medical Center Utrecht, Utrecht, The Netherlands
| | - Roel A Ophoff
- Department of Psychiatry and Brain Center Rudolf Magnus,
University Medical Center Utrecht, Utrecht, The Netherlands,University of California Los Angeles Center for
Neurobehavioral Genetics, Los Angeles, CA, USA
| | - Neeltje EM van Haren
- Department of Psychiatry and Brain Center Rudolf Magnus,
University Medical Center Utrecht, Utrecht, The Netherlands,Department of child and adolescent
psychiatry/psychology, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Ole A Andreassen
- Norwegian Centre for Mental Disorders Research (NORMENT),
K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine,
University of Oslo, Oslo, Norway,Norwegian Centre for Mental Disorders Research (NORMENT),
K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction,
Oslo University Hospital, Oslo, Norway
| | - Tiril P Gurholt
- Norwegian Centre for Mental Disorders Research (NORMENT),
K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine,
University of Oslo, Oslo, Norway,Department of Psychiatric Research, Diakonhjemmet
Hospital, Oslo, Norway
| | - Oliver Gruber
- Section for Experimental Psychopathology and
Neuroimaging, Department of General Psychiatry, Heidelberg University Hospital,
Heidelberg, Germany,Center for Translational Research in Systems Neuroscience
and Psychiatry, Department of Psychiatry, Georg August University, Göttingen,
Germany
| | - Bernd Kraemer
- Section for Experimental Psychopathology and
Neuroimaging, Department of General Psychiatry, Heidelberg University Hospital,
Heidelberg, Germany,Center for Translational Research in Systems Neuroscience
and Psychiatry, Department of Psychiatry, Georg August University, Göttingen,
Germany
| | - Anja Richter
- Section for Experimental Psychopathology and
Neuroimaging, Department of General Psychiatry, Heidelberg University Hospital,
Heidelberg, Germany,Center for Translational Research in Systems Neuroscience
and Psychiatry, Department of Psychiatry, Georg August University, Göttingen,
Germany
| | - Vince D Calhoun
- University of New Mexico, Albuquerque, NM, USA,Mind Research Network, Albuquerque, NM, USA
| | - Benedicto Crespo-Facorro
- Department of Psychiatry, University Hospital
Marqués de Valdecilla, School of Medicine, University of Cantabria-Valdecilla
Biomedical Research Institute, Marqués de Valdecilla Research Institute
(IDIVAL), Santander, Spain,Centro Investigación Biomédica en Red de
Salud Mental (CIBERSAM), Santander, Spain
| | - Roberto Roiz-Santiañez
- Department of Psychiatry, University Hospital
Marqués de Valdecilla, School of Medicine, University of Cantabria-Valdecilla
Biomedical Research Institute, Marqués de Valdecilla Research Institute
(IDIVAL), Santander, Spain,Centro Investigación Biomédica en Red de
Salud Mental (CIBERSAM), Santander, Spain
| | - Diana Tordesillas-Gutiérrez
- Department of Psychiatry, University Hospital
Marqués de Valdecilla, School of Medicine, University of Cantabria-Valdecilla
Biomedical Research Institute, Marqués de Valdecilla Research Institute
(IDIVAL), Santander, Spain,Centro Investigación Biomédica en Red de
Salud Mental (CIBERSAM), Santander, Spain,Neuroimaging Unit.Technological Facilities, Valdecilla
Biomedical Research Institute IDIVAL, Santander, Cantabria, Spain Dresden, Dresden,
Germany
| | - Carmel Loughland
- Hunter Medical Research Institute, Newcastle, NSW,
Australia,Priority Research Centre for Brain & Mental Health,
The University of Newcastle, Newcastle, NSW, Australia,Hunter New England Local Health District, Newcastle,
NSW, Australia
| | | | - Janice M Fullerton
- Neuroscience Research Australia, Sydney, NSW,
Australia,School of Medical Sciences, University of New South
Wales, Sydney, NSW, Australia
| | - Melissa J Green
- School of Psychiatry, University of New South Wales,
Sydney, NSW, Australia,Neuroscience Research Australia, Sydney, NSW,
Australia
| | - Frans Henskens
- Priority Research Center for Health Behaviour, The
University of Newcastle, Newcastle, NSW, Australia,Hunter Medical Research Institute, Newcastle, NSW,
Australia,School of Medicine and Public Health, The University of
Newcastle, Newcastle, NSW, Australia
| | | | - Bryan J Mowry
- Queensland Brain Institute, The University of Queensland,
Brisbane, QLD, Australia,Queensland Centre for Mental Health Research, The
University of Queensland, Brisbane, QLD, Australia
| | - Christos Pantelis
- Melbourne Neuropsychiatry Centre, University of Melbourne
& Melbourne Health, Melbourne, VIC, Australia,Florey Institute of Neuroscience and Mental Health,
University of Melbourne, VIC, Australia
| | - Yann Quidé
- School of Psychiatry, University of New South Wales,
Sydney, NSW, Australia,Neuroscience Research Australia, Sydney, NSW,
Australia
| | - Ulrich Schall
- Priority Research Centres for Brain & Mental Health
and Grow Up Well, The University of Newcastle, Newcastle, NSW, Australia,Hunter Medical Research Institute, Newcastle, NSW,
Australia
| | - Rodney J Scott
- School of Biomedical Sciences and Pharmacy, The
University of Newcastle, Newcastle, NSW, Australia,Hunter Medical Research Institute, Newcastle, NSW,
Australia
| | - Murray J Cairns
- School of Biomedical Sciences and Pharmacy, The
University of Newcastle, Newcastle, NSW, Australia,Hunter Medical Research Institute, Newcastle, NSW,
Australia
| | - Marc Seal
- Murdoch Children's Research Institute, Melbourne,
VIC, Australia
| | - Paul A Tooney
- School of Biomedical Sciences and Pharmacy, The
University of Newcastle, Newcastle, NSW, Australia,Hunter Medical Research Institute, Newcastle, NSW,
Australia,Priority Research Centre for Brain & Mental Health,
The University of Newcastle, Newcastle, NSW, Australia
| | - Paul E Rasser
- Priority Research Centre for Brain & Mental Health,
The University of Newcastle, Newcastle, NSW, Australia
| | - Gavin Cooper
- Priority Research Centre for Brain & Mental Health,
The University of Newcastle, Newcastle, NSW, Australia
| | - Cynthia Shannon Weickert
- School of Psychiatry, University of New South Wales,
Sydney, NSW, Australia,Neuroscience Research Australia, Sydney, NSW,
Australia
| | - Thomas W Weickert
- School of Psychiatry, University of New South Wales,
Sydney, NSW, Australia,Neuroscience Research Australia, Sydney, NSW,
Australia
| | - Elliot Hong
- Maryland Psychiatric Research Center, University of
Maryland School of Medicine, Baltimore, MD, USA
| | - Peter Kochunov
- Maryland Psychiatric Research Center, University of
Maryland School of Medicine, Baltimore, MD, USA
| | - Raquel E Gur
- Department of Psychiatry, University of Pennsylvania,
Philadelphia, PA, USA
| | - Ruben C Gur
- Department of Psychiatry, University of Pennsylvania,
Philadelphia, PA, USA
| | - Judith M Ford
- Department of Psychiatry, University of California, San
Francisco, San Francisco, CA, USA,San Francisco VA Medical Center, San Francisco, CA,
USA
| | - Fabio Macciardi
- Department of Psychiatry and Human Behavior, University of
California, Irvine, Irvine, CA, USA
| | - Daniel H Mathalon
- Department of Psychiatry, University of California, San
Francisco, San Francisco, CA, USA,San Francisco VA Medical Center, San Francisco, CA,
USA
| | - Steven G Potkin
- Department of Psychiatry and Human Behavior, University of
California, Irvine, Irvine, CA, USA
| | - Adrian Preda
- Department of Psychiatry and Human Behavior, University of
California, Irvine, Irvine, CA, USA
| | - Fengmei Fan
- Psychiatry Research Center, Beijing Huilongguan Hospital,
Beijing, China
| | - Stefan Ehrlich
- Division of Psychological and Social Medicine and
Developmental Neurosciences, Faculty of Medicine, TU Dresden, Germany, Dresden,
Germany,Massachusetts General Hospital/ Harvard Medical School,
Athinoula A. Martinos Center for Biomedical Imaging, Psychiatric Neuroimaging
Research Program
| | | | - Lieuwe De Haan
- Department of psychiatry, Academic Medical Center,
University of Amsterdam, Amsterdam, The Netherlands
| | - Dick J Veltman
- Department of Psychiatry, Vrije Universiteit Medical
Center, Amsterdam, The Netherlands
| | - Francesca Assogna
- Laboratory of Neuropsychiatry, Department of Clinical and
Behavioral Neurology, Istituto Di Ricovero e Cura a Carattere Scientifico Santa
Lucia Foundation, Rome, Italy,Centro Fermi - Museo Storico della Fisica e Centro Studi
e Ricerche “Enrico Fermi”, Rome, Italy
| | - Nerisa Banaj
- Laboratory of Neuropsychiatry, Department of Clinical and
Behavioral Neurology, Istituto Di Ricovero e Cura a Carattere Scientifico Santa
Lucia Foundation, Rome, Italy
| | - Pietro de Rossi
- Laboratory of Neuropsychiatry, Department of Clinical and
Behavioral Neurology, Istituto Di Ricovero e Cura a Carattere Scientifico Santa
Lucia Foundation, Rome, Italy,Dipartimento di Neuroscienze, Salute Mentale e Organi di
Senso (NESMOS) Department, Faculty of Medicine and Psychology, University
“Sapienza” of Rome, Rome, Italy,Department of Neurology and Psychiatry, Sapienza
University of Rome, Rome, Italy
| | - Mariangela Iorio
- Laboratory of Neuropsychiatry, Department of Clinical and
Behavioral Neurology, Istituto Di Ricovero e Cura a Carattere Scientifico Santa
Lucia Foundation, Rome, Italy
| | - Fabrizio Piras
- Laboratory of Neuropsychiatry, Department of Clinical and
Behavioral Neurology, Istituto Di Ricovero e Cura a Carattere Scientifico Santa
Lucia Foundation, Rome, Italy,Centro Fermi - Museo Storico della Fisica e Centro Studi
e Ricerche “Enrico Fermi”, Rome, Italy
| | - Gianfranco Spalletta
- Laboratory of Neuropsychiatry, Department of Clinical and
Behavioral Neurology, Istituto Di Ricovero e Cura a Carattere Scientifico Santa
Lucia Foundation, Rome, Italy,Beth K. and Stuart C. Yudofsky Division of
Neuropsychiatry, Menninger Department of Psychiatry and Behavioral Sciences, Baylor
College of Medicine, Houston, Tx USA
| | - Edith Pomarol-Clotet
- Fundación para la Investigación y Docencia
Maria Angustias Giménez (FIDMAG) Germanes Hospitalaries Research Foundation,
Barcelona, Spain,Centro Investigación Biomédica en Red de
Salud Mental (CIBERSAM), Barcelona, Spain
| | - Sinead Kelly
- Department of Psychiatry, Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, MA, USA,Psychiatry Neuroimaging Laboratory, Brigham and
Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Simone Ciufolini
- Department of Psychosis Studies, Institute of Psychiatry,
Psychology and Neuroscience, King's College London, London, United
Kingdom
| | - Joaquim Radua
- Department of Clinical Neuroscience, Centre for
Psychiatric Research, Karolinska Institutet, Stockholm, Sweden,Fundación para la Investigación y Docencia
Maria Angustias Giménez (FIDMAG) Germanes Hospitalaries Research Foundation,
Barcelona, Spain,Centro Investigación Biomédica en Red de
Salud Mental (CIBERSAM), Barcelona, Spain,Department of Psychosis Studies, Institute of Psychiatry,
Psychology and Neuroscience, King's College London, London, United
Kingdom,Institut d'Investigacions Biomediques August Pi i
Sunyer (IDIBAPS), Barcelona, Spain
| | - Robin Murray
- Department of Psychosis Studies, Institute of Psychiatry,
Psychology and Neuroscience, King's College London, London, United
Kingdom
| | - Tiago Reis Marques
- Department of Psychosis Studies, Institute of Psychiatry,
Psychology and Neuroscience, King's College London, London, United
Kingdom
| | - Andrew Simmons
- Department of Psychosis Studies, Institute of Psychiatry,
Psychology and Neuroscience, King's College London, London, United
Kingdom
| | | | | | | | | | - Kathryn I Alpert
- Department of Psychiatry and Behavioral Sciences,
Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Alessandro Bertolino
- Department of Basic Medical Science, Neuroscience and
Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - Aurora Bonvino
- Istituto Di Ricovero e Cura a Carattere Scientifico Casa
Sollievo della Sofferenza, San Giovanni Rotondo, Italy
| | - Annabella Di Giorgio
- Istituto Di Ricovero e Cura a Carattere Scientifico Casa
Sollievo della Sofferenza, San Giovanni Rotondo, Italy
| | - Emma Neilson
- Division of Psychiatry, University of Edinburgh,
Edinburgh, United Kingdom
| | | | - Je-Yeon Yun
- Seoul National University Hospital, Seoul, Republic of
Korea,Yeongeon Student Support Center, Seoul National
University College of Medicine, Seoul, Republic of Korea
| | - Dara M Cannon
- Centre for Neuroimaging & Cognitive Genomics (NICOG),
Clinical Neuroimaging Laboratory, National Centre for Biomedical Engineering Galway
Neuroscience Centre, College of Medicine Nursing and Health Sciences, National
University of Ireland Galway, H91 TK33 Galway, Ireland
| | | | | | - Tolibjohn Akhadov
- Children's Clinical and Research Institute of
Emergency Surgery and Trauma, Moscow, Russia
| | | | - Helena Fatouros-Bergman
- Centre for Psychiatry Research, Department of Clinical
Neuroscience, Karolinska Institutet, & Stockholm Health Care Services, Stockholm
County Council, Stockholm, Sweden
| | - Lena Flyckt
- Centre for Psychiatry Research, Department of Clinical
Neuroscience, Karolinska Institutet, & Stockholm Health Care Services, Stockholm
County Council, Stockholm, Sweden
| | | | - Pedro GP Rosa
- Laboratory of Psychiatric Neuroimaging (LIM 21),
Department of Psychiatry, Faculty of Medicine, University of São Paulo,
São Paulo, Brazil,Center for Interdisciplinary Research on Applied
Neurosciences (NAPNA), University of São Paulo, São Paulo,
Brazil
| | - Mauricio H Serpa
- Laboratory of Psychiatric Neuroimaging (LIM 21),
Department of Psychiatry, Faculty of Medicine, University of São Paulo,
São Paulo, Brazil,Center for Interdisciplinary Research on Applied
Neurosciences (NAPNA), University of São Paulo, São Paulo,
Brazil
| | - Marcus V Zanetti
- Laboratory of Psychiatric Neuroimaging (LIM 21),
Department of Psychiatry, Faculty of Medicine, University of São Paulo,
São Paulo, Brazil,Center for Interdisciplinary Research on Applied
Neurosciences (NAPNA), University of São Paulo, São Paulo,
Brazil
| | - Cyril Hoschl
- National Institute of Mental Health, Klecany, Czech
Republic
| | - Antonin Skoch
- National Institute of Mental Health, Klecany, Czech
Republic,MR Unit, Department of Diagnostic and Interventional
Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech
Republic
| | - Filip Spaniel
- National Institute of Mental Health, Klecany, Czech
Republic
| | - David Tomecek
- National Institute of Mental Health, Klecany, Czech
Republic,Institute of Computer Science, Czech Academy of
Sciences, Prague, Czech Republic,Faculty of Electrical Engineering, Czech Technical
University in Prague, Prague, Czech Republic
| | - Andrew M McIntosh
- Division of Psychiatry, University of Edinburgh,
Edinburgh, United Kingdom,Centre for Cognitive Ageing and Cognitive Epidemiology,
University of Edinburgh, Edinburgh, United Kingdom
| | - Heather C Whalley
- Division of Psychiatry, University of Edinburgh,
Edinburgh, United Kingdom
| | - Christian Knöchel
- Department of Psychiatry, Psychosomatic Medicine and
Psychotherapy, University Hospital Frankfurt, Goethe University Frankfurt,
Frankfurt, Germany
| | - Viola Oertel-Knöchel
- Department of Psychiatry, Psychosomatic Medicine and
Psychotherapy, University Hospital Frankfurt, Goethe University Frankfurt,
Frankfurt, Germany
| | - Fleur M Howells
- University of Cape Town Dept of Psychiatry, Groote
Schuur Hospital (J2), Cape Town South Africa
| | - Dan J Stein
- University of Cape Town Dept of Psychiatry, Groote
Schuur Hospital (J2), Cape Town South Africa,Medical Research Council Unit on Risk & Resilience
in Mental Disorders, Department of Psychiatry, University of Cape Town, Cape Town,
South Africa
| | - Henk S Temmingh
- University of Cape Town Dept of Psychiatry, Groote
Schuur Hospital (J2), Cape Town South Africa
| | - Anne Uhlmann
- University of Cape Town Dept of Psychiatry, Groote
Schuur Hospital (J2), Cape Town South Africa,MRC Unit on Risk & Resilience in Mental Disorders,
Department of Psychiatry, Stellenbosch University, Cape Town, South Africa
| | - Carlos Lopez-Jaramillo
- Research Group in Psychiatry, Department of Psychiatry,
Faculty of Medicine, Universidad de Antioquia, Medellin, Colombia
| | - Danai Dima
- Department of Psychology, City, University of London,
London, United Kingdom,Department of Neuroimaging, IOPPN, King's College
London, London, United Kingdom
| | - Joshua I Faskowitz
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging
& Informatics Institute, Keck School of Medicine of the University of Southern
California, Marina del Rey, CA, USA
| | - Boris A Gutman
- Department of Biomedical Engineering, Illinois Institute
of Technology, Chicago, Illinois
| | - Neda Jahanshad
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging
& Informatics Institute, Keck School of Medicine of the University of Southern
California, Marina del Rey, CA, USA
| | - Paul M Thompson
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging
& Informatics Institute, Keck School of Medicine of the University of Southern
California, Marina del Rey, CA, USA
| | - Jessica A Turner
- Mind Research Network, Albuquerque, NM, USA,Imaging Genetics and Neuroinformatics Lab, Department of
Psychology, Georgia State University, Atlanta, GA, USA
| |
Collapse
|
103
|
Lorio S, Sambataro F, Bertolino A, Draganski B, Dukart J. The Combination of DAT-SPECT, Structural and Diffusion MRI Predicts Clinical Progression in Parkinson's Disease. Front Aging Neurosci 2019; 11:57. [PMID: 30930768 PMCID: PMC6428714 DOI: 10.3389/fnagi.2019.00057] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Accepted: 02/26/2019] [Indexed: 12/13/2022] Open
Abstract
There is an increasing interest in identifying non-invasive biomarkers of disease severity and prognosis in idiopathic Parkinson’s disease (PD). Dopamine-transporter SPECT (DAT-SPECT), diffusion tensor imaging (DTI), and structural magnetic resonance imaging (sMRI) provide unique information about the brain’s neurotransmitter and microstructural properties. In this study, we evaluate the relative and combined capability of these imaging modalities to predict symptom severity and clinical progression in de novo PD patients. To this end, we used MRI, SPECT, and clinical data of de novo drug-naïve PD patients (n = 205, mean age 61 ± 10) and age-, sex-matched healthy controls (n = 105, mean age 58 ± 12) acquired at baseline. Moreover, we employed clinical data acquired at 1 year follow-up for PD patients with or without L-Dopa treatment in order to predict the progression symptoms severity. Voxel-based group comparisons and covariance analyses were applied to characterize baseline disease-related alterations for DAT-SPECT, DTI, and sMRI. Cortical and subcortical alterations in de novo PD patients were found in all evaluated imaging modalities, in line with previously reported midbrain-striato-cortical network alterations. The combination of these imaging alterations was reliably linked to clinical severity and disease progression at 1 year follow-up in this patient population, providing evidence for the potential use of these modalities as imaging biomarkers for disease severity and prognosis that can be integrated into clinical trials.
Collapse
Affiliation(s)
- Sara Lorio
- Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.,Roche Pharma and Early Development, Neuroscience, Ophthalmology and Rare Diseases, F. Hoffmann-La Roche Ltd., Basel, Switzerland.,Laboratory for Research in Neuroimaging, Department of Clinical Neurosciences, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Fabio Sambataro
- Roche Pharma and Early Development, Neuroscience, Ophthalmology and Rare Diseases, F. Hoffmann-La Roche Ltd., Basel, Switzerland.,Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy
| | - Alessandro Bertolino
- Roche Pharma and Early Development, Neuroscience, Ophthalmology and Rare Diseases, F. Hoffmann-La Roche Ltd., Basel, Switzerland.,Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari, Bari, Italy
| | - Bogdan Draganski
- Laboratory for Research in Neuroimaging, Department of Clinical Neurosciences, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.,Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
| | - Juergen Dukart
- Roche Pharma and Early Development, Neuroscience, Ophthalmology and Rare Diseases, F. Hoffmann-La Roche Ltd., Basel, Switzerland.,Institute of Neuroscience and Medicine, Brain and Behaviour (INM-7), Research Centre Jülich, Jülich, Germany.,Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| |
Collapse
|
104
|
Punzi G, Ursini G, Viscanti G, Radulescu E, Shin JH, Quarto T, Catanesi R, Blasi G, Jaffe AE, Deep-Soboslay A, Hyde TM, Kleinman JE, Bertolino A, Weinberger DR. Association of a Noncoding RNA Postmortem With Suicide by Violent Means and In Vivo With Aggressive Phenotypes. Biol Psychiatry 2019; 85:417-424. [PMID: 30600091 DOI: 10.1016/j.biopsych.2018.11.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Revised: 10/29/2018] [Accepted: 11/06/2018] [Indexed: 11/24/2022]
Abstract
BACKGROUND Previous findings suggest that differences in brain expression of a human-specific long intergenic noncoding RNA (LINC01268; GRCh37/hg19: LOC285758) may be linked to suicide by violent methods. We sought to replicate and extend these findings in a new sample and translate the results to the behavioral level in living healthy subjects. METHODS We examined RNA sequencing data in human brains to confirm the prior postmortem association of the long intergenic noncoding RNA specifically with suicide by violent means. In addition, we used a genetic variant associated with LINC01268 expression to detect association in healthy subjects with trait aggression and with in vivo prefrontal physiology related to behavioral control. Finally, we performed weighted gene coexpression network analysis and gene ontology analysis to identify biological processes associated with a LINC01268 coexpression network. RESULTS In the replication sample, prefrontal expression of LINC01268 was again higher in suicides by violent means (n = 65) than in both nonsuicides (n = 78; p = 1.29 × 10-6) and suicides by nonviolent means (n = 46; p = 1.4 × 10-6). In the living cohort, carriers of the minor allele of a single nucleotide polymorphism associated with increased LINC01268 expression in brain scored higher on a lifetime aggression questionnaire and show diminished engagement of prefrontal cortex (Brodmann area 10) when viewing angry faces during functional magnetic resonance imaging. Weighted gene coexpression network analysis highlighted the immune response. CONCLUSIONS These results suggest that LINC01268 influences emotional regulation, aggressive behavior, and suicide by violent means; the underlying biological dynamics may include modulation of genes potentially engaged in the immune response.
Collapse
Affiliation(s)
- Giovanna Punzi
- Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, Maryland; Section of Forensic Psychiatry and Criminology, Institute of Legal Medicine, Interdisciplinary Department of Medicine, Bari, Italy; Group of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, Aldo Moro University, Bari, Italy
| | - Gianluca Ursini
- Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, Maryland; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland; Group of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, Aldo Moro University, Bari, Italy
| | - Giovanna Viscanti
- Group of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, Aldo Moro University, Bari, Italy
| | - Eugenia Radulescu
- Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, Maryland
| | - Joo Heon Shin
- Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, Maryland
| | - Tiziana Quarto
- Group of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, Aldo Moro University, Bari, Italy
| | - Roberto Catanesi
- Section of Forensic Psychiatry and Criminology, Institute of Legal Medicine, Interdisciplinary Department of Medicine, Bari, Italy
| | - Giuseppe Blasi
- Group of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, Aldo Moro University, Bari, Italy
| | - Andrew E Jaffe
- Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, Maryland; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
| | - Amy Deep-Soboslay
- Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, Maryland
| | - Thomas M Hyde
- Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, Maryland; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Joel E Kleinman
- Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, Maryland
| | - Alessandro Bertolino
- Group of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, Aldo Moro University, Bari, Italy
| | - Daniel R Weinberger
- Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, Baltimore, Maryland; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland; McKusick Nathans Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
| |
Collapse
|
105
|
Selvaggi P, Hawkins PC, Dipasquale O, Rizzo G, Bertolino A, Dukart J, Sambataro F, Pergola G, Williams SC, Turkheimer F, Zelaya F, Veronese M, Mehta MA. Increased cerebral blood flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles. Neuroimage 2019; 188:774-784. [DOI: 10.1016/j.neuroimage.2018.12.028] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 12/05/2018] [Accepted: 12/12/2018] [Indexed: 12/11/2022] Open
|
106
|
Ahmed AO, Kirkpatrick B, Galderisi S, Mucci A, Rossi A, Bertolino A, Rocca P, Maj M, Kaiser S, Bischof M, Hartmann-Riemer MN, Kirschner M, Schneider K, Garcia-Portilla MP, Mane A, Bernardo M, Fernandez-Egea E, Jiefeng C, Jing Y, Shuping T, Gold JM, Allen DN, Strauss GP. Cross-cultural Validation of the 5-Factor Structure of Negative Symptoms in Schizophrenia. Schizophr Bull 2019; 45:305-314. [PMID: 29912473 PMCID: PMC6403061 DOI: 10.1093/schbul/sby050] [Citation(s) in RCA: 87] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
OBJECTIVE Negative symptoms are currently viewed as having a 2-dimensional structure, with factors reflecting diminished expression (EXP) and motivation and pleasure (MAP). However, several factor-analytic studies suggest that the consensus around a 2-dimensional model is premature. The current study investigated and cross-culturally validated the factorial structure of BNSS-rated negative symptoms across a range of cultures and languages. METHOD Participants included individuals diagnosed with a psychotic disorder who had been rated on the Brief Negative Symptom Scale (BNSS) from 5 cross-cultural samples, with a total N = 1691. First, exploratory factor analysis was used to extract up to 6 factors from the data. Next, confirmatory factor analysis evaluated the fit of 5 models: (1) a 1-factor model, 2) a 2-factor model with factors of MAP and EXP, 3) a 3-factor model with inner world, external, and alogia factors; 4) a 5-factor model with separate factors for blunted affect, alogia, anhedonia, avolition, and asociality, and 5) a hierarchical model with 2 second-order factors reflecting EXP and MAP, as well as 5 first-order factors reflecting the 5 aforementioned domains. RESULTS Models with 4 factors or less were mediocre fits to the data. The 5-factor, 6-factor, and the hierarchical second-order 5-factor models provided excellent fit with an edge to the 5-factor model. The 5-factor structure demonstrated invariance across study samples. CONCLUSIONS Findings support the validity of the 5-factor structure of BNSS-rated negative symptoms across diverse cultures and languages. These findings have important implications for the diagnosis, assessment, and treatment of negative symptoms.
Collapse
Affiliation(s)
- Anthony O Ahmed
- Department of Psychiatry, Weill Cornell Medicine, White Plains, NY,To whom correspondence should be addressed; tel: 914-997-5251, fax: 914-682-6906, e-mail:
| | - Brian Kirkpatrick
- Department of Psychiatry and Behavioral Sciences, University of Nevada, Reno School of Medicine, Reno, NV
| | - Silvana Galderisi
- Department of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Armida Mucci
- Department of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Alessandro Rossi
- Department of Biotechnological and Applied Clinical Sciences, Section of Psychiatry, University of L’Aquila, L’Aquila, Italy
| | - Alessandro Bertolino
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - Paola Rocca
- Department of Neuroscience, Section of Psychiatry, University of Turin, Turin, Italy
| | - Mario Maj
- Department of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Stefan Kaiser
- Division of Adult Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Geneva, Switzerland
| | - Martin Bischof
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland
| | - Matthias N Hartmann-Riemer
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland
| | - Matthias Kirschner
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland
| | - Karoline Schneider
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland
| | - Maria Paz Garcia-Portilla
- Department of Psychiatry, University of Oviedo, Oviedo, Spain,Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Madrid, Spain
| | - Anna Mane
- Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Madrid, Spain,Institut de Neuropsiquiatria i Adiccions, Parc de Salut Mar, Barcelona, Spain,Fundació IMIM, Barcelona, Spain
| | - Miguel Bernardo
- Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Madrid, Spain,Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Barcelona, Spain,Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain,Psychiatry Unit, Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Emilio Fernandez-Egea
- Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Madrid, Spain,Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain,Department of Psychiatry, Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK,Clozapine Clinic. Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK
| | - Cui Jiefeng
- Psychiatry Research Center, Beijing Huilongguan Hospital, Peking University Huilongguan Clinical College, Beijing, China
| | - Yao Jing
- Psychiatry Research Center, Beijing Huilongguan Hospital, Peking University Huilongguan Clinical College, Beijing, China
| | - Tan Shuping
- Psychiatry Research Center, Beijing Huilongguan Hospital, Peking University Huilongguan Clinical College, Beijing, China
| | - James M Gold
- Department of Psychiatry, University of Maryland School of Medicine and Maryland Psychiatric Research Center, Baltimore, MD
| | - Daniel N Allen
- Department of Psychology, University of Nevada, Las Vegas, Las Vegas, NV
| | | |
Collapse
|
107
|
Holiga Š, Hipp JF, Chatham CH, Garces P, Spooren W, D’Ardhuy XL, Bertolino A, Bouquet C, Buitelaar JK, Bours C, Rausch A, Oldehinkel M, Bouvard M, Amestoy A, Caralp M, Gueguen S, Ly-Le Moal M, Houenou J, Beckmann CF, Loth E, Murphy D, Charman T, Tillmann J, Laidi C, Delorme R, Beggiato A, Gaman A, Scheid I, Leboyer M, d’Albis MA, Sevigny J, Czech C, Bolognani F, Honey GD, Dukart J. Patients with autism spectrum disorders display reproducible functional connectivity alterations. Sci Transl Med 2019. [DOI: 10.1126/scitranslmed.aat9223 order by 39635--] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Affiliation(s)
- Štefan Holiga
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Joerg F. Hipp
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Christopher H. Chatham
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Pilar Garces
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Will Spooren
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Xavier Liogier D’Ardhuy
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Alessandro Bertolino
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari ‘Aldo Moro’, 70121 Bari, Italy
| | - Céline Bouquet
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Jan K. Buitelaar
- Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University Nijmegen Medical center, Nijmegen 6525 EN, Netherlands
| | - Carsten Bours
- Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University Nijmegen Medical center, Nijmegen 6525 EN, Netherlands
| | - Annika Rausch
- Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University Nijmegen Medical center, Nijmegen 6525 EN, Netherlands
| | - Marianne Oldehinkel
- Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University Nijmegen Medical center, Nijmegen 6525 EN, Netherlands
- Brain & Mental Health Laboratory, Monash Institute of Cognitive and Clinical Neurosciences and School of Psychological Sciences, Monash University, Clayton, VIC 3800, Australia
| | - Manuel Bouvard
- Pôle Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital Charles Perrens Bordeaux, 33076 Bordeaux, France
| | - Anouck Amestoy
- Pôle Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital Charles Perrens Bordeaux, 33076 Bordeaux, France
| | - Mireille Caralp
- INSERM, National Biobank Infrastructure, 75013 Paris, France
| | - Sonia Gueguen
- INSERM, Clinical Research Department, 75014 Paris, France
| | | | - Josselin Houenou
- Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France
- NeuroSpin, UNIACT Lab, Psychiatry Team, CEA Saclay, 91191 Gif-Sur-Yvette, France
| | - Christian F. Beckmann
- Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging, Radboud University Nijmegen Medical center, Nijmegen 6525 EN, Netherlands
| | - Eva Loth
- Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
| | - Declan Murphy
- Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
| | - Tony Charman
- Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
| | - Julian Tillmann
- Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
- Department of Applied Psychology: Health, Development, Enhancement, and Intervention, University of Vienna, 1010 Vienna, Austria
| | - Charles Laidi
- Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France
| | - Richard Delorme
- APHP, Robert Debré Hospital, Child and Adolescent Psychiatry Department, Paris, France
- Pasteur Institute, 75019 Paris, France
| | - Anita Beggiato
- APHP, Robert Debré Hospital, Child and Adolescent Psychiatry Department, Paris, France
- Pasteur Institute, 75019 Paris, France
| | - Alexandru Gaman
- Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France
| | - Isabelle Scheid
- Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France
| | - Marion Leboyer
- Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France
| | - Marc-Antoine d’Albis
- Hôpitaux Universitaires Mondor, DHU PePSY, Pôle de psychiatrie, Faculté de Médecine, Université Paris Est, INSERM U955, IMRB, Equipe 15, Psychiatrie Translationnelle, Fondation FondaMental, 94000 Créteil, France
- NeuroSpin, UNIACT Lab, Psychiatry Team, CEA Saclay, 91191 Gif-Sur-Yvette, France
| | - Jeff Sevigny
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Christian Czech
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Federico Bolognani
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
- Therachon AG, Aeschenvorstadt 36, 4051 Basel, Switzerland
| | - Garry D. Honey
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Juergen Dukart
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
- Institute of Neuroscience and Medicine, Brain & Behaviour (INM-7), Research Centre Jülich, 52428 Jülich, Germany
- Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf, 40223 Düsseldorf, Germany
| |
Collapse
|
108
|
Holiga Š, Hipp JF, Chatham CH, Garces P, Spooren W, D’Ardhuy XL, Bertolino A, Bouquet C, Buitelaar JK, Bours C, Rausch A, Oldehinkel M, Bouvard M, Amestoy A, Caralp M, Gueguen S, Ly-Le Moal M, Houenou J, Beckmann CF, Loth E, Murphy D, Charman T, Tillmann J, Laidi C, Delorme R, Beggiato A, Gaman A, Scheid I, Leboyer M, d’Albis MA, Sevigny J, Czech C, Bolognani F, Honey GD, Dukart J. Patients with autism spectrum disorders display reproducible functional connectivity alterations. Sci Transl Med 2019; 11:11/481/eaat9223. [DOI: 10.1126/scitranslmed.aat9223] [Citation(s) in RCA: 80] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2018] [Revised: 11/22/2018] [Accepted: 02/05/2019] [Indexed: 01/16/2023]
Abstract
Despite the high clinical burden, little is known about pathophysiology underlying autism spectrum disorder (ASD). Recent resting-state functional magnetic resonance imaging (rs-fMRI) studies have found atypical synchronization of brain activity in ASD. However, no consensus has been reached on the nature and clinical relevance of these alterations. Here, we addressed these questions in four large ASD cohorts. Using rs-fMRI, we identified functional connectivity alterations associated with ASD. We tested for associations of these imaging phenotypes with clinical and demographic factors such as age, sex, medication status, and clinical symptom severity. Our results showed reproducible patterns of ASD-associated functional hyper- and hypoconnectivity. Hypoconnectivity was primarily restricted to sensory-motor regions, whereas hyperconnectivity hubs were predominately located in prefrontal and parietal cortices. Shifts in cortico-cortical between-network connectivity from outside to within the identified regions were shown to be a key driver of these abnormalities. This reproducible pathophysiological phenotype was partially associated with core ASD symptoms related to communication and daily living skills and was not affected by age, sex, or medication status. Although the large effect sizes in standardized cohorts are encouraging with respect to potential application as a treatment and for patient stratification, the moderate link to clinical symptoms and the large overlap with healthy controls currently limit the usability of identified alterations as diagnostic or efficacy readout.
Collapse
|
109
|
Piluso G, Monteleone P, Galderisi S, Giugliano T, Bertolino A, Rocca P, Rossi A, Mucci A, Aguglia E, Andriola I, Bellomo A, Comparelli A, Gambi F, Fagiolini A, Marchesi C, Roncone R, Sacchetti E, Santonastaso P, Siracusano A, Stratta P, Tortorella A, Steardo L, Bucci P, Nigro V, Maj M. Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements. World J Biol Psychiatry 2019; 20:126-136. [PMID: 29069978 DOI: 10.1080/15622975.2017.1395072] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVES Variants appearing de novo in genes regulating key neurodevelopmental processes and/or in non-coding cis-regulatory elements (CREs), as enhancers, may increase the risk for schizophrenia. However, CREs involvement in schizophrenia needs to be explored more deeply. METHODS We investigated de novo copy-number variations (CNVs) in the whole-genomic DNA obtained from 46 family trios of schizophrenia probands by using the Enhancer Chip, a customised array CGH able to investigate the whole genome with a 300-kb resolution, specific disease loci at a ten-fold higher resolution, and which was highly enriched in probes in more than 1,250 enhancer elements selected from Vista Enhancer Browser. RESULTS In seven patients, we found de novo CNVs, two of which overlapped VISTA enhancer elements. De novo CNVs encompass genes (CNTNAP2, MAGI1, TSPAN7 and MET) involved in brain development, while that involving the enhancer element hs1043, also includes ZIC1, which plays a role in neural development and is responsible of behavioural abnormalities in Zic mutant mice. CONCLUSIONS These findings provide further evidence for the involvement of de novo CNVs in the pathogenesis of schizophrenia and suggest that CNVs affecting regulatory enhancer elements could contribute to the genetic vulnerability to the disorder.
Collapse
Affiliation(s)
- Giulio Piluso
- a Department of Biochemistry, Biophysics and General Pathology , University of Campania "Luigi Vanvitelli" , Naples , Italy
| | - Palmiero Monteleone
- b Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Section of Neuroscience , University of Salerno , Salerno , Italy
| | - Silvana Galderisi
- c Department of Psychiatry , University of Campania "Luigi Vanvitelli" , Naples , Italy
| | - Teresa Giugliano
- a Department of Biochemistry, Biophysics and General Pathology , University of Campania "Luigi Vanvitelli" , Naples , Italy
| | - Alessandro Bertolino
- d Department of Neurological and Psychiatric Sciences , University of Bari , Bari , Italy
| | - Paola Rocca
- e Department of Neuroscience, Section of Psychiatry , University of Turin , Turin , Italy
| | - Alessandro Rossi
- f Department of Biotechnological and Applied Clinical Sciences, Section of Psychiatry , University of L'Aquila , L'Aquila , Italy
| | - Armida Mucci
- c Department of Psychiatry , University of Campania "Luigi Vanvitelli" , Naples , Italy
| | - Eugenio Aguglia
- g Department of Clinical and Molecular Biomedicine, Psychiatry Unit , University of Catania , Catania , Italy
| | - Ileana Andriola
- d Department of Neurological and Psychiatric Sciences , University of Bari , Bari , Italy
| | - Antonello Bellomo
- h Department of Medical Sciences, Psychiatry Unit , University of Foggia , Foggia , Italy
| | - Anna Comparelli
- i Department of Neurosciences, Mental Health and Sensory Organs , S. Andrea Hospital, Sapienza University of Rome , Rome , Italy
| | - Francesco Gambi
- j Department of Neuroscience and Imaging, Chair of Psychiatry , G. D'Annunzio University , Chieti , Italy
| | - Andrea Fagiolini
- k Department of Molecular Medicine and Clinical Department of Mental Health , University of Siena , Siena , Italy
| | - Carlo Marchesi
- l Department of Neuroscience, Psychiatry Unit , University of Parma , Parma , Italy
| | - Rita Roncone
- m Department of Life, Health and Environmental Sciences, Unit of Psychiatry , University of L'Aquila , L'Aquila , Italy
| | - Emilio Sacchetti
- n Psychiatric Unit, School of Medicine, Department of Mental Health , University of Brescia and Spedali Civili Hospital , Brescia , Italy
| | - Paolo Santonastaso
- o Psychiatric Clinic, Department of Neurosciences , University of Padua , Padua , Italy
| | - Alberto Siracusano
- p Department of Systems Medicine, Chair of Psychiatry , Tor Vergata University of Rome , Rome , Italy
| | - Paolo Stratta
- f Department of Biotechnological and Applied Clinical Sciences, Section of Psychiatry , University of L'Aquila , L'Aquila , Italy
| | | | - Luca Steardo
- c Department of Psychiatry , University of Campania "Luigi Vanvitelli" , Naples , Italy
| | - Paola Bucci
- c Department of Psychiatry , University of Campania "Luigi Vanvitelli" , Naples , Italy
| | - Vincenzo Nigro
- a Department of Biochemistry, Biophysics and General Pathology , University of Campania "Luigi Vanvitelli" , Naples , Italy
| | - Mario Maj
- c Department of Psychiatry , University of Campania "Luigi Vanvitelli" , Naples , Italy
| | | |
Collapse
|
110
|
Schwarz E, Doan NT, Pergola G, Westlye LT, Kaufmann T, Wolfers T, Brecheisen R, Quarto T, Ing AJ, Di Carlo P, Gurholt TP, Harms RL, Noirhomme Q, Moberget T, Agartz I, Andreassen OA, Bellani M, Bertolino A, Blasi G, Brambilla P, Buitelaar JK, Cervenka S, Flyckt L, Frangou S, Franke B, Hall J, Heslenfeld DJ, Kirsch P, McIntosh AM, Nöthen MM, Papassotiropoulos A, de Quervain DJF, Rietschel M, Schumann G, Tost H, Witt SH, Zink M, Meyer-Lindenberg A. Reproducible grey matter patterns index a multivariate, global alteration of brain structure in schizophrenia and bipolar disorder. Transl Psychiatry 2019; 9:12. [PMID: 30664633 PMCID: PMC6341112 DOI: 10.1038/s41398-018-0225-4] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Accepted: 07/16/2018] [Indexed: 12/18/2022] Open
Abstract
Schizophrenia is a severe mental disorder characterized by numerous subtle changes in brain structure and function. Machine learning allows exploring the utility of combining structural and functional brain magnetic resonance imaging (MRI) measures for diagnostic application, but this approach has been hampered by sample size limitations and lack of differential diagnostic data. Here, we performed a multi-site machine learning analysis to explore brain structural patterns of T1 MRI data in 2668 individuals with schizophrenia, bipolar disorder or attention-deficit/ hyperactivity disorder, and healthy controls. We found reproducible changes of structural parameters in schizophrenia that yielded a classification accuracy of up to 76% and provided discrimination from ADHD, through it lacked specificity against bipolar disorder. The observed changes largely indexed distributed grey matter alterations that could be represented through a combination of several global brain-structural parameters. This multi-site machine learning study identified a brain-structural signature that could reproducibly differentiate schizophrenia patients from controls, but lacked specificity against bipolar disorder. While this currently limits the clinical utility of the identified signature, the present study highlights that the underlying alterations index substantial global grey matter changes in psychotic disorders, reflecting the biological similarity of these conditions, and provide a roadmap for future exploration of brain structural alterations in psychiatric patients.
Collapse
Affiliation(s)
- Emanuel Schwarz
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
| | - Nhat Trung Doan
- Norwegian Centre for Mental Disorders Research (NORMENT), KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Giulio Pergola
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Lars T Westlye
- Norwegian Centre for Mental Disorders Research (NORMENT), KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Department of Psychology, University of Oslo, Oslo, Norway
| | - Tobias Kaufmann
- Norwegian Centre for Mental Disorders Research (NORMENT), KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Thomas Wolfers
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
- Donders Center for Cognitive Neuroimaging, Radboud University, Nijmegen, The Netherlands
| | - Ralph Brecheisen
- Maastricht University Medical Center, Maastricht, The Netherlands
| | - Tiziana Quarto
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
- Cognitive Brain Research Unit, Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - Alex J Ing
- Centre for Population Neuroscience and Stratified Medicine (PONS) and MRC-SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Pasquale Di Carlo
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Tiril P Gurholt
- Norwegian Centre for Mental Disorders Research (NORMENT), KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | | | | | - Torgeir Moberget
- Norwegian Centre for Mental Disorders Research (NORMENT), KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Ingrid Agartz
- Norwegian Centre for Mental Disorders Research (NORMENT), KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm County Council, Stockholm, Sweden
- Department of Psychiatry Research, Diakonhjemmet Hospital, Oslo, Norway
| | - Ole A Andreassen
- Norwegian Centre for Mental Disorders Research (NORMENT), KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Marcella Bellani
- Section of Psychiatry, Azienda Ospedaliera Universitaria Integrata Verona, Verona, VR, Italy
- Department of Neurosciences, Biomedicine and Movements Sciences, University of Verona, Verona, VR, Italy
| | - Alessandro Bertolino
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
- Institute of Psichiatry, Policlinico Bari, Azienda Ospedaliero Universitaria Consorziale Policlinico Bari, Bari, BA, Italy
| | - Giuseppe Blasi
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
- Azienda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy
| | - Paolo Brambilla
- Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | - Jan K Buitelaar
- Donders Institute for Brain, Cognition and Behaviour, Radboudumc, Nijmegen, The Netherlands
- Karakter Child and Adolescent Psychiatry University Center, Nijmegen, The Netherlands
| | - Simon Cervenka
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm County Council, Stockholm, Sweden
| | - Lena Flyckt
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm County Council, Stockholm, Sweden
| | - Sophia Frangou
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Barbara Franke
- Donders Institute for Brain, Cognition and Behaviour, Radboudumc, Nijmegen, The Netherlands
- Departments of Human Genetics and Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Jeremy Hall
- Neuroscience and Mental Health Research Institute, Cardiff University, Maindy Road, Cardiff, CF24 4HQ, UK
| | - Dirk J Heslenfeld
- Department of Cognitive Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Peter Kirsch
- Department of Clinical Psychology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany
- Bernstein Center for Computational Neuroscience Heidelberg-Mannheim, Mannheim, Germany
| | - Andrew M McIntosh
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, EH10 5HF, UK
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, George Square, Edinburgh, EH8 9JZ, UK
| | - Markus M Nöthen
- Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany
- Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany
| | - Andreas Papassotiropoulos
- Division of Molecular Neuroscience, Department of Psychology, University of Basel, CH-4055, Basel, Switzerland
- Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland
- Psychiatric University Clinics, University of Basel, CH-4055, Basel, Switzerland
- Department Biozentrum, Life Sciences Training Facility, University of Basel, CH-4056, Basel, Switzerland
| | - Dominique J-F de Quervain
- Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland
- Psychiatric University Clinics, University of Basel, CH-4055, Basel, Switzerland
- Division of Cognitive Neuroscience, Department of Psychology, University of Basel, CH-4055, Basel, Switzerland
| | - Marcella Rietschel
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany
| | - Gunter Schumann
- Centre for Population Neuroscience and Stratified Medicine (PONS) and MRC-SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Heike Tost
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Stephanie H Witt
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany
| | - Mathias Zink
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
- District Hospital Mittelfranken, Department of Psychiatry, Psychotherapy and Psychosomatics, Ansbach, Germany
| | - Andreas Meyer-Lindenberg
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
| |
Collapse
|
111
|
van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, Pearlson GD, Yao N, Fukunaga M, Hashimoto R, Okada N, Yamamori H, Bustillo JR, Clark VP, Agartz I, Mueller BA, Cahn W, de Zwarte SMC, Hulshoff Pol HE, Kahn RS, Ophoff RA, van Haren NEM, Andreassen OA, Dale AM, Doan NT, Gurholt TP, Hartberg CB, Haukvik UK, Jørgensen KN, Lagerberg TV, Melle I, Westlye LT, Gruber O, Kraemer B, Richter A, Zilles D, Calhoun VD, Crespo-Facorro B, Roiz-Santiañez R, Tordesillas-Gutiérrez D, Loughland C, Carr VJ, Catts S, Cropley VL, Fullerton JM, Green MJ, Henskens F, Jablensky A, Lenroot RK, Mowry BJ, Michie PT, Pantelis C, Quidé Y, Schall U, Scott RJ, Cairns MJ, Seal M, Tooney PA, Rasser PE, Cooper G, Weickert CS, Weickert TW, Morris DW, Hong E, Kochunov P, Beard LM, Gur RE, Gur RC, Satterthwaite TD, Wolf DH, Belger A, Brown GG, Ford JM, Macciardi F, Mathalon DH, O’Leary DS, Potkin SG, Preda A, Voyvodic J, Lim KO, McEwen S, Yang F, Tan Y, Tan S, Wang Z, Fan F, Chen J, Xiang H, Tang S, Guo H, Wan P, Wei D, Bockholt HJ, Ehrlich S, Wolthusen RPF, King MD, Shoemaker JM, Sponheim SR, De Haan L, Koenders L, Machielsen MW, van Amelsvoort T, Veltman DJ, Assogna F, Banaj N, de Rossi P, Iorio M, Piras F, Spalletta G, McKenna PJ, Pomarol-Clotet E, Salvador R, Corvin A, Donohoe G, Kelly S, Whelan CD, Dickie EW, Rotenberg D, Voineskos A, Ciufolini S, Radua J, Dazzan P, Murray R, Marques TR, Simmons A, Borgwardt S, Egloff L, Harrisberger F, Riecher-Rössler A, Smieskova R, Alpert KI, Wang L, Jönsson EG, Koops S, Sommer IEC, Bertolino A, Bonvino A, Di Giorgio A, Neilson E, Mayer AR, Stephen JM, Kwon JS, Yun JY, Cannon DM, McDonald C, Lebedeva I, Tomyshev AS, Akhadov T, Kaleda V, Fatouros-Bergman H, Flyckt L, Busatto GF, Rosa PGP, Serpa MH, Zanetti MV, Hoschl C, Skoch A, Spaniel F, Tomecek D, Hagenaars SP, McIntosh AM, Whalley HC, Lawrie SM, Knöchel C, Oertel-Knöchel V, Stäblein M, Howells FM, Stein DJ, Temmingh H, Uhlmann A, Lopez-Jaramillo C, Dima D, McMahon A, Faskowitz JI, Gutman BA, Jahanshad N, Thompson PM, Turner JA. Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biol Psychiatry 2018; 84:644-654. [PMID: 29960671 PMCID: PMC6177304 DOI: 10.1016/j.biopsych.2018.04.023] [Citation(s) in RCA: 488] [Impact Index Per Article: 81.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 04/19/2018] [Accepted: 04/20/2018] [Indexed: 12/31/2022]
Abstract
BACKGROUND The profile of cortical neuroanatomical abnormalities in schizophrenia is not fully understood, despite hundreds of published structural brain imaging studies. This study presents the first meta-analysis of cortical thickness and surface area abnormalities in schizophrenia conducted by the ENIGMA (Enhancing Neuro Imaging Genetics through Meta Analysis) Schizophrenia Working Group. METHODS The study included data from 4474 individuals with schizophrenia (mean age, 32.3 years; range, 11-78 years; 66% male) and 5098 healthy volunteers (mean age, 32.8 years; range, 10-87 years; 53% male) assessed with standardized methods at 39 centers worldwide. RESULTS Compared with healthy volunteers, individuals with schizophrenia have widespread thinner cortex (left/right hemisphere: Cohen's d = -0.530/-0.516) and smaller surface area (left/right hemisphere: Cohen's d = -0.251/-0.254), with the largest effect sizes for both in frontal and temporal lobe regions. Regional group differences in cortical thickness remained significant when statistically controlling for global cortical thickness, suggesting regional specificity. In contrast, effects for cortical surface area appear global. Case-control, negative, cortical thickness effect sizes were two to three times larger in individuals receiving antipsychotic medication relative to unmedicated individuals. Negative correlations between age and bilateral temporal pole thickness were stronger in individuals with schizophrenia than in healthy volunteers. Regional cortical thickness showed significant negative correlations with normalized medication dose, symptom severity, and duration of illness and positive correlations with age at onset. CONCLUSIONS The findings indicate that the ENIGMA meta-analysis approach can achieve robust findings in clinical neuroscience studies; also, medication effects should be taken into account in future genetic association studies of cortical thickness in schizophrenia.
Collapse
Affiliation(s)
- Theo GM. van Erp
- Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, USA
| | - Esther Walton
- Imaging Genetics and Neuroinformatics Lab, Department of Psychology, Georgia State University, Atlanta, GA, USA
| | - Derrek P. Hibar
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA, USA,Janssen Research & Development, San Diego, CA, USA
| | - Lianne Schmaal
- Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, VIC, Australia,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia,Department of Psychiatry and Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands
| | - Wenhao Jiang
- Department of Psychology, Georgia State University, Atlanta, GA, USA
| | - David C. Glahn
- Department of Psychiatry, Yale University, New Haven, CT, USA,Olin Neuropsychiatric Research Center, Institute of Living, Hartford Hospital, Hartford, CT, USA
| | - Godfrey D. Pearlson
- Department of Psychiatry, Yale University, New Haven, CT, USA,Olin Neuropsychiatric Research Center, Institute of Living, Hartford Hospital, Hartford, CT, USA
| | - Nailin Yao
- Department of Psychiatry, Yale University, New Haven, CT, USA,Olin Neuropsychiatric Research Center, Institute of Living, Hartford Hospital, Hartford, CT, USA
| | - Masaki Fukunaga
- Division of Cerebral Integration, National Institute for Physiological Sciences, Okazaki, Aichi, Japan
| | - Ryota Hashimoto
- Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Suita, Osaka, Japan,Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Naohiro Okada
- Department of Neuropsychiatry, Graduate school of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - Hidenaga Yamamori
- Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | | | - Vincent P. Clark
- University of New Mexico, Albuquerque, NM, USA,Mind Research Network, Albuquerque, NM, USA
| | - Ingrid Agartz
- Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway,Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway,Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden
| | - Bryon A. Mueller
- Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA
| | - Wiepke Cahn
- Department of Psychiatry and Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Sonja MC. de Zwarte
- Department of Psychiatry and Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Hilleke E. Hulshoff Pol
- Department of Psychiatry and Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - René S. Kahn
- Department of Psychiatry and Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Roel A. Ophoff
- Department of Psychiatry and Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands,UCLA Center for Neurobehavioral Genetics, Los Angeles, CA, USA
| | - Neeltje EM. van Haren
- Department of Psychiatry and Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Ole A. Andreassen
- Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway,Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
| | - Anders M. Dale
- Departments of Neurosciences, Radiology, Psychiatry, and Cognitive Science, UCSD, La Jolla, CA, USA,Center for Translational Imaging and Precision Medicine, San Diego, CA, USA
| | - Nhat Trung Doan
- Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Tiril P. Gurholt
- Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Cecilie B. Hartberg
- Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Unn K. Haukvik
- Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway,Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
| | - Kjetil N. Jørgensen
- Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway,Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway
| | - Trine V. Lagerberg
- Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
| | - Ingrid Melle
- Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway,Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
| | - Lars T. Westlye
- Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway,Department of Psychology, University of Oslo, Oslo, Norway
| | - Oliver Gruber
- Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University Hospital, Heidelberg, Germany,Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry, Georg August University, Göttingen, Germany
| | - Bernd Kraemer
- Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University Hospital, Heidelberg, Germany,Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry, Georg August University, Göttingen, Germany
| | - Anja Richter
- Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University Hospital, Heidelberg, Germany,Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry, Georg August University, Göttingen, Germany
| | - David Zilles
- Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry, Georg August University, Göttingen, Germany,Department of Psychiatry, University Medical Center Göttingen, Gottingen, Germany
| | - Vince D. Calhoun
- University of New Mexico, Albuquerque, NM, USA,Mind Research Network, Albuquerque, NM, USA
| | - Benedicto Crespo-Facorro
- Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria-IDIVAL, Santander, Spain,CIBERSAM, Centro Investigación Biomédica en Red de Salud Mental, Santander, Spain
| | - Roberto Roiz-Santiañez
- Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria-IDIVAL, Santander, Spain,CIBERSAM, Centro Investigación Biomédica en Red de Salud Mental, Santander, Spain
| | - Diana Tordesillas-Gutiérrez
- Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria-IDIVAL, Santander, Spain,CIBERSAM, Centro Investigación Biomédica en Red de Salud Mental, Santander, Spain,Neuroimaging Unit.Technological Facilities, Valdecilla Biomedical Research Institute IDIVAL, Santander, Cantabria, Spain, Dresden, Dresden, Germany
| | - Carmel Loughland
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia
| | - Vaughan J. Carr
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia,Monash University, Melbourne, Australia
| | | | - Vanessa L. Cropley
- Melbourne Neuropsychiatry Centre, University of Melbourne & Melbourne Health, Melbourne, VIC, Australia
| | - Janice M. Fullerton
- Neuroscience Research Australia, Sydney, NSW, Australia,School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
| | - Melissa J. Green
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia,Neuroscience Research Australia, Sydney, NSW, Australia
| | - Frans Henskens
- PRC for Health Behaviour, and FEBE, University of Newcastle Australia, Newcastle, NSW, Australia
| | | | - Rhoshel K. Lenroot
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia,Neuroscience Research Australia, Sydney, NSW, Australia
| | - Bryan J. Mowry
- Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia,Queensland Centre for Mental Health Research, The University of Queensland, Brisbane, QLD, Australia
| | - Patricia T. Michie
- School of Psychology, University of Newcastle, Newcastle, NSW, Australia
| | - Christos Pantelis
- Melbourne Neuropsychiatry Centre, University of Melbourne & Melbourne Health, Melbourne, VIC, Australia,Florey Institute of Neuroscience and Mental Health, University of Melbourne, VIC, Australia
| | - Yann Quidé
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia,Neuroscience Research Australia, Sydney, NSW, Australia
| | - Ulrich Schall
- The University of Newcastle, Priority Research Centres for Brain & Mental Health and Grow Up Well, Newcastle, NSW, Australia,Hunter Medical Research Institute, Newcastle, NSW, Australia
| | - Rodney J. Scott
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia,Hunter Medical Research Institute, Newcastle, NSW, Australia
| | - Murray J. Cairns
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia,Hunter Medical Research Institute, Newcastle, NSW, Australia
| | - Marc Seal
- Murdoch Children’s Research Institute, Melbourne, VIC, Australia
| | - Paul A. Tooney
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia,The University of Newcastle, Priority Research Centres for Brain & Mental Health and Grow Up Well, Newcastle, NSW, Australia,The University of Newcastle, Priority Research Centre for Brain & Mental Health, Newcastle, NSW, Australia
| | - Paul E. Rasser
- The University of Newcastle, Priority Research Centre for Brain & Mental Health, Newcastle, NSW, Australia
| | - Gavin Cooper
- The University of Newcastle, Priority Research Centre for Brain & Mental Health, Newcastle, NSW, Australia
| | - Cynthia Shannon Weickert
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia,Neuroscience Research Australia, Sydney, NSW, Australia
| | - Thomas W. Weickert
- School of Psychiatry, University of New South Wales, Sydney, NSW, Australia,Neuroscience Research Australia, Sydney, NSW, Australia
| | - Derek W. Morris
- Centre for Neuroimaging & Cognitive Genomics, School of Psychology and Department of Biochemistry, National University of Ireland Galway, Galway, Ireland,Neuropsychiatric Genetics Research Group, Department of Psychiatry and Trinity College Institute of Neuroscience, Trinity College, Dublin, Ireland
| | - Elliot Hong
- Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Peter Kochunov
- Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Lauren M. Beard
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
| | - Raquel E. Gur
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
| | - Ruben C. Gur
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
| | | | - Daniel H. Wolf
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
| | - Aysenil Belger
- Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA,Brain Imaging and Analysis Center, Duke University Medical Center, Durham, NC, USA
| | - Gregory G. Brown
- Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
| | - Judith M. Ford
- University of California, San Francisco, San Francisco, CA, USA,San Francisco VA Medical Center, San Francisco, CA, USA
| | - Fabio Macciardi
- Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, USA
| | - Daniel H. Mathalon
- University of California, San Francisco, San Francisco, CA, USA,San Francisco VA Medical Center, San Francisco, CA, USA
| | | | - Steven G. Potkin
- Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, USA
| | - Adrian Preda
- Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, USA
| | - James Voyvodic
- Brain Imaging and Analysis Center, Duke University Medical Center, Durham, NC, USA
| | - Kelvin O. Lim
- Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA
| | - Sarah McEwen
- Department of Psychiatry & Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA
| | - Fude Yang
- Psychiatry Research Center, Beijing Huilongguan hospital, Beijing, China
| | - Yunlong Tan
- Psychiatry Research Center, Beijing Huilongguan hospital, Beijing, China
| | - Shuping Tan
- Psychiatry Research Center, Beijing Huilongguan hospital, Beijing, China
| | - Zhiren Wang
- Psychiatry Research Center, Beijing Huilongguan hospital, Beijing, China
| | - Fengmei Fan
- Psychiatry Research Center, Beijing Huilongguan hospital, Beijing, China
| | - Jingxu Chen
- Psychiatry Research Center, Beijing Huilongguan hospital, Beijing, China
| | - Hong Xiang
- Chongqing Three Gorges Central Hospital, Chongqing, China
| | - Shiyou Tang
- Chongqing Three Gorges Central Hospital, Chongqing, China
| | - Hua Guo
- Zhumadian Psychiatry Hospital, Henan province, Zhumadian, China
| | - Ping Wan
- Zhumadian Psychiatry Hospital, Henan province, Zhumadian, China
| | - Dong Wei
- Luoyang Fifth People’s Hospital, Henan province, Luoyang, China
| | - Henry J. Bockholt
- Mind Research Network, Albuquerque, NM, USA,Department of Psychiatry, University of Iowa, Iowa City, IA, USA,Advanced Biomedical Informatics Group, LLC, Iowa City, IA, USA
| | - Stefan Ehrlich
- Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, TU Dresden, Germany, Dresden, Germany,Massachusetts General Hospital/Harvard Medical School, Athinoula A. Martinos Center for Biomedical Imaging, Psychiatric Neuroimaging Research Program
| | - Rick PF. Wolthusen
- Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, TU Dresden, Germany, Dresden, Germany,Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA,Emotion and Social Neuroscience Laboratory, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, USA
| | | | | | - Scott R. Sponheim
- Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA,Minneapolis VA HCS, Minneapolis, MN, USA
| | - Lieuwe De Haan
- Department of psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Laura Koenders
- Department of psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Marise W. Machielsen
- Department of psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Therese van Amelsvoort
- Department of Psychiatry & Psychology, Maastricht University, Maastricht, The Netherlands
| | - Dick J. Veltman
- Department of Psychiatry, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
| | - Francesca Assogna
- Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy,Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche “Enrico Fermi”, Rome, Italy
| | - Nerisa Banaj
- Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy
| | - Pietro de Rossi
- Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy,NESMOS Department, Faculty of Medicine and Psychology, University “Sapienza” of Rome, Rome, Italy,Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy
| | - Mariangela Iorio
- Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy
| | - Fabrizio Piras
- Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy,Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche “Enrico Fermi”, Rome, Italy
| | - Gianfranco Spalletta
- Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy,Beth K. and Stuart C. Yudofsky Division of Neuropsychiatry, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Tx USA
| | - Peter J. McKenna
- FIDMAG Germanes Hospitalaries Research Foundation, Barcelona, Spain,CIBERSAM, Centro Investigación Biomédica en Red de Salud Mental, Barcelona, Spain
| | - Edith Pomarol-Clotet
- FIDMAG Germanes Hospitalaries Research Foundation, Barcelona, Spain,CIBERSAM, Centro Investigación Biomédica en Red de Salud Mental, Barcelona, Spain
| | - Raymond Salvador
- FIDMAG Germanes Hospitalaries Research Foundation, Barcelona, Spain,CIBERSAM, Centro Investigación Biomédica en Red de Salud Mental, Barcelona, Spain
| | - Aiden Corvin
- Neuropsychiatric Genetics Research Group, Department of Psychiatry and Trinity College Institute of Neuroscience, Trinity College, Dublin, Ireland
| | - Gary Donohoe
- Centre for Neuroimaging & Cognitive Genomics, School of Psychology and Department of Biochemistry, National University of Ireland Galway, Galway, Ireland,Neuropsychiatric Genetics Research Group, Department of Psychiatry and Trinity College Institute of Neuroscience, Trinity College, Dublin, Ireland
| | - Sinead Kelly
- Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA,Psychiatry Neuroimaging Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Christopher D. Whelan
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA, USA
| | | | | | | | - Simone Ciufolini
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
| | - Joaquim Radua
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden,FIDMAG Germanes Hospitalaries Research Foundation, Barcelona, Spain,CIBERSAM, Centro Investigación Biomédica en Red de Salud Mental, Barcelona, Spain,Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
| | - Paola Dazzan
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom,National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust
| | - Robin Murray
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
| | - Tiago Reis Marques
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
| | - Andrew Simmons
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
| | | | - Laura Egloff
- University of Basel Psychiatric Hospital, Basel, Switzerland
| | | | | | | | - Kathryn I. Alpert
- Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Lei Wang
- Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA,Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Erik G. Jönsson
- Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway,Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden
| | - Sanne Koops
- Department of Psychiatry and Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Iris EC. Sommer
- Department of Psychiatry and Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Alessandro Bertolino
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Aurora Bonvino
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | | | - Emma Neilson
- Division of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom
| | | | | | - Jun Soo Kwon
- Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea,Department of Brain & Cognitive Sciences, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea
| | - Je-Yeon Yun
- Seoul National University Hospital, Seoul, Republic of Korea,Yeongeon Student Support Center, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Dara M. Cannon
- Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway, H91 TK33 Galway, Ireland
| | - Colm McDonald
- Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway, H91 TK33 Galway, Ireland
| | | | | | - Tolibjohn Akhadov
- Children’s Clinical and Research Institute of Emergency Surgery and Trauma, Moscow, Russia
| | | | - Helena Fatouros-Bergman
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden
| | - Lena Flyckt
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden
| | | | - Geraldo F. Busatto
- Laboratory of Psychiatric Neuroimaging (LIM 21), Department of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo, Brazil,Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of São Paulo, São Paulo, Brazil
| | - Pedro GP. Rosa
- Laboratory of Psychiatric Neuroimaging (LIM 21), Department of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo, Brazil,Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of São Paulo, São Paulo, Brazil
| | - Mauricio H. Serpa
- Laboratory of Psychiatric Neuroimaging (LIM 21), Department of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo, Brazil,Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of São Paulo, São Paulo, Brazil
| | - Marcus V. Zanetti
- Laboratory of Psychiatric Neuroimaging (LIM 21), Department of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo, Brazil,Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of São Paulo, São Paulo, Brazil
| | - Cyril Hoschl
- National Institute of Mental Health, Klecany, Czech Republic
| | - Antonin Skoch
- National Institute of Mental Health, Klecany, Czech Republic,MR Unit, Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Filip Spaniel
- National Institute of Mental Health, Klecany, Czech Republic
| | - David Tomecek
- National Institute of Mental Health, Klecany, Czech Republic
| | - Saskia P. Hagenaars
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, United Kingdom,Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom
| | - Andrew M. McIntosh
- Division of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom,Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, United Kingdom
| | - Heather C. Whalley
- Division of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom
| | - Stephen M. Lawrie
- Division of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom
| | - Christian Knöchel
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University Frankfurt, Frankfurt, Germany
| | - Viola Oertel-Knöchel
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University Frankfurt, Frankfurt, Germany
| | - Michael Stäblein
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University Frankfurt, Frankfurt, Germany
| | - Fleur M. Howells
- University of Cape Town Dept of Psychiatry, Groote Schuur Hospital (J2), Cape Town South Africa
| | - Dan J. Stein
- University of Cape Town Dept of Psychiatry, Groote Schuur Hospital (J2), Cape Town South Africa,MRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry, University of Cape Town, Cape Town, South Africa
| | - Henk Temmingh
- University of Cape Town Dept of Psychiatry, Groote Schuur Hospital (J2), Cape Town South Africa
| | - Anne Uhlmann
- University of Cape Town Dept of Psychiatry, Groote Schuur Hospital (J2), Cape Town South Africa,MRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry, Stellenbosch University, Cape Town, South Africa
| | - Carlos Lopez-Jaramillo
- Research Group in Psychiatry, Department of Psychiatry, Faculty of Medicine, Universidad de Antioquia, Medellin, Colombia
| | - Danai Dima
- Department of Psychology, City, University of London, London, United Kingdom,Department of Neuroimaging, IOPPN, King’s College London, London, United Kingdom
| | - Agnes McMahon
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA, USA
| | - Joshua I. Faskowitz
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA, USA
| | - Boris A. Gutman
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA, USA
| | - Neda Jahanshad
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA, USA
| | - Paul M. Thompson
- Imaging Genetics Center, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA, USA
| | - Jessica A. Turner
- Imaging Genetics and Neuroinformatics Lab, Department of Psychology, Georgia State University, Atlanta, GA, USA,Mind Research Network, Albuquerque, NM, USA
| |
Collapse
|
112
|
Taylor KI, Sambataro F, Boess F, Bertolino A, Dukart J. Progressive Decline in Gray and White Matter Integrity in de novo Parkinson's Disease: An Analysis of Longitudinal Parkinson Progression Markers Initiative Diffusion Tensor Imaging Data. Front Aging Neurosci 2018; 10:318. [PMID: 30349475 PMCID: PMC6186956 DOI: 10.3389/fnagi.2018.00318] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Accepted: 09/21/2018] [Indexed: 12/01/2022] Open
Abstract
Background: Progressive neuronal loss in neurodegenerative diseases such as Parkinson's disease (PD) is associated with progressive degeneration of associated white matter tracts as measured by diffusion tensor imaging (DTI). These findings may have diagnostic and functional implications but their value in de novo PD remains unknown. Here we analyzed longitudinal DTI data from Parkinson's Progression Markers Initiative de novo PD patients for changes over time relative to healthy control (HC) participants. Methods: Baseline and 1-year follow-up DTI MRI data from 71 PD patients and 45 HC PPMI participants were included in the analyses. Whole-brain fractional anisotropy (FA) and mean diffusivity (MD) images were compared for baseline group differences and group-by-time interactions. Baseline and 1-year changes in DTI values were correlated with changes in DTI measures and symptom severity, respectively. Results: At baseline, PD patients showed significantly increased FA in brainstem, cerebellar, anterior corpus callosal, inferior frontal and inferior fronto-occipital white matter and increased MD in primary sensorimotor and supplementary motor regions. Over 1 year PD patients showed a significantly stronger decline in FA compared to HC in the optic radiation and corpus callosum and parietal, occipital, posterior temporal, posterior thalamic, and vermis gray matter. Significant increases in MD were observed in white matter of the midbrain, optic radiation and corpus callosum, while gray matter of prefrontal, insular and posterior thalamic regions. Baseline brainstem FA white matter (WM) values predicted 1-year changes in FA white matter and MD gray matter values. White but not gray matter changes in both FA and MD were significantly associated with changes in symptom severity. Conclusion: Significant gray and white matter DTI alterations are observable at the time of PD diagnosis and expand in the first year of de novo PD to other cortical and white matter regions. This pattern of DTI changes is in line with preclinical and neuroanatomical studies suggesting that the increased spatial spread of alpha-synuclein neuropathology is the key mechanism of PD progression. Taken together, these findings suggest that DTI may serve as a sensitive biomarker of disease progression in early-stage PD.
Collapse
Affiliation(s)
- Kirsten I. Taylor
- Neuroscience, Ophthalmology, and Rare Diseases, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Fabio Sambataro
- Neuroscience, Ophthalmology, and Rare Diseases, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
- Department of Experimental and Clinical Medical Sciences (DISM), University of Udine, Udine, Italy
| | - Frank Boess
- Neuroscience, Ophthalmology, and Rare Diseases, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Alessandro Bertolino
- Neuroscience, Ophthalmology, and Rare Diseases, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
- Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari, Bari, Italy
- Psychiatry Unit, Bari University Hospital, Bari, Italy
| | - Juergen Dukart
- Neuroscience, Ophthalmology, and Rare Diseases, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
| |
Collapse
|
113
|
Bucci P, Galderisi S, Mucci A, Rossi A, Rocca P, Bertolino A, Aguglia E, Amore M, Andriola I, Bellomo A, Biondi M, Cuomo A, dell'Osso L, Favaro A, Gambi F, Giordano GM, Girardi P, Marchesi C, Monteleone P, Montemagni C, Niolu C, Oldani L, Pacitti F, Pinna F, Roncone R, Vita A, Zeppegno P, Maj M. Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition. Acta Psychiatr Scand 2018; 138:253-266. [PMID: 29984409 DOI: 10.1111/acps.12938] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/14/2018] [Indexed: 12/11/2022]
Abstract
OBJECTIVE The study aimed to explore premorbid academic and social functioning in patients with schizophrenia, and its associations with the severity of negative symptoms and neurocognitive impairment. METHOD Premorbid adjustment (PA) in patients with schizophrenia was compared to early adjustment in unaffected first-degree relatives and healthy controls. Its associations with psychopathology, cognition, and real-life functioning were investigated. The associations of PA with primary negative symptoms and their two factors were explored. RESULTS We found an impairment of academic and social PA in patients (P ≤ 0.000001) and an impairment of academic aspects of early adjustment in relatives (P ≤ 0.01). Patients with poor PA showed greater severity of negative symptoms (limited to avolition after excluding the effect of depression/parkinsonism), working memory, social cognition, and real-life functioning (P ≤ 0.01 to ≤0.000001). Worse academic and social PA were associated with greater severity of psychopathology, cognitive impairment, and real-life functioning impairment (P ≤ 0.000001). Regression analyses showed that worse PA in the academic domain was mainly associated to the impairment of working memory, whereas worse PA in the social domain to avolition (P ≤ 0.000001). CONCLUSION Our findings suggest that poor early adjustment may represent a marker of vulnerability to schizophrenia and highlight the need for preventive/early interventions based on psychosocial and/or cognitive programs.
Collapse
Affiliation(s)
- P Bucci
- Department of Psychiatry, University of Campania L. Vanvitelli, Naples, Italy
| | - S Galderisi
- Department of Psychiatry, University of Campania L. Vanvitelli, Naples, Italy
| | - A Mucci
- Department of Psychiatry, University of Campania L. Vanvitelli, Naples, Italy
| | - A Rossi
- Section of Psychiatry, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - P Rocca
- Section of Psychiatry, Department of Neuroscience, University of Turin, Turin, Italy
| | - A Bertolino
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - E Aguglia
- Department of Clinical and Molecular Biomedicine, Psychiatry Unit, University of Catania, Catania, Italy
| | - M Amore
- Section of Psychiatry, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, University of Genoa, Genoa, Italy
| | - I Andriola
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - A Bellomo
- Psychiatry Unit, Department of Medical Sciences, University of Foggia, Foggia, Italy
| | - M Biondi
- Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy
| | - A Cuomo
- Department of Molecular Medicine and Clinical Department of Mental Health, University of Siena, Siena, Italy
| | - L dell'Osso
- Section of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - A Favaro
- Department of Neurosciences, Psychiatric Clinic, University of Padua, Padua, Italy
| | - F Gambi
- Chair of Psychiatry, Department of Neuroscience and Imaging, G. d'Annunzio University, Chieti, Italy
| | - G M Giordano
- Department of Psychiatry, University of Campania L. Vanvitelli, Naples, Italy
| | - P Girardi
- Department of Neurosciences, Mental Health and Sensory Organs, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy
| | - C Marchesi
- Department of Neuroscience, Psychiatry Unit, University of Parma, Parma, Italy
| | - P Monteleone
- Chair of Psychiatry, Department of Medicine and Surgery, University of Salerno, Salerno, Italy
| | - C Montemagni
- Section of Psychiatry, Department of Neuroscience, University of Turin, Turin, Italy
| | - C Niolu
- Chair of Psychiatry, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy
| | - L Oldani
- Department of Psychiatry, University of Milan, Milan, Italy
| | - F Pacitti
- Section of Psychiatry, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - F Pinna
- Section of Psychiatry, Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy
| | - R Roncone
- Unit of Psychiatry, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - A Vita
- Psychiatric Unit, School of Medicine, University of Brescia, Brescia, Italy.,Department of Mental Health, Spedali Civili Hospital, Brescia, Italy
| | - P Zeppegno
- Psychiatric Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - M Maj
- Department of Psychiatry, University of Campania L. Vanvitelli, Naples, Italy
| | | |
Collapse
|
114
|
Quarto T, Paparella I, De Tullio D, Viscanti G, Fazio L, Taurisano P, Romano R, Rampino A, Masellis R, Popolizio T, Selvaggi P, Pergola G, Bertolino A, Blasi G. Familial Risk and a Genome-Wide Supported DRD2 Variant for Schizophrenia Predict Lateral Prefrontal-Amygdala Effective Connectivity During Emotion Processing. Schizophr Bull 2018; 44:834-843. [PMID: 28981847 PMCID: PMC6007415 DOI: 10.1093/schbul/sbx128] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The brain functional mechanisms translating genetic risk into emotional symptoms in schizophrenia (SCZ) may include abnormal functional integration between areas key for emotion processing, such as the amygdala and the lateral prefrontal cortex (LPFC). Indeed, investigation of these mechanisms is also complicated by emotion processing comprising different subcomponents and by disease-associated state variables. Here, our aim was to investigate the relationship between risk for SCZ and effective connectivity between the amygdala and the LPFC during different subcomponents of emotion processing. Thus, we first characterized with dynamic causal modeling (DCM) physiological patterns of LPFC-amygdala effective connectivity in healthy controls (HC) during implicit and explicit emotion processing. Then, we compared DCM patterns in a subsample of HC, in patients with SCZ and in healthy siblings of patients (SIB), matched for demographics. Finally, we investigated in HC association of LPFC-amygdala effective connectivity with a genome-wide supported variant increasing genetic risk for SCZ and possibly relevant to emotion processing (DRD2 rs2514218). In HC, we found that a "bottom-up" amygdala-to-LPFC pattern during implicit processing and a "top-down" LPFC-to-amygdala pattern during explicit processing were the most likely directional models of effective connectivity. Differently, implicit emotion processing in SIB, SCZ, and HC homozygous for the SCZ risk rs2514218 C allele was associated with decreased probability for the "bottom-up" as well as with increased probability for the "top-down" model. These findings suggest that task-specific anomaly in the directional flow of information or disconnection between the amygdala and the LPFC is a good candidate endophenotype of SCZ.
Collapse
Affiliation(s)
- Tiziana Quarto
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy,Cognitive Brain Research Unit, Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - Isabella Paparella
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Davide De Tullio
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Giovanna Viscanti
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Leonardo Fazio
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Paolo Taurisano
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Raffaella Romano
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Antonio Rampino
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Rita Masellis
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Teresa Popolizio
- IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, Italy
| | - Pierluigi Selvaggi
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy,Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Giulio Pergola
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Alessandro Bertolino
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Giuseppe Blasi
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy,To whom correspondence should be addressed; tel: +390 8055 93629; fax: +390 8055 93204; e-mail:
| |
Collapse
|
115
|
Mucci A, Galderisi S, Green MF, Nuechterlein K, Rucci P, Gibertoni D, Rossi A, Rocca P, Bertolino A, Bucci P, Hellemann G, Spisto M, Palumbo D, Aguglia E, Amodeo G, Amore M, Bellomo A, Brugnoli R, Carpiniello B, Dell'Osso L, Di Fabio F, di Giannantonio M, Di Lorenzo G, Marchesi C, Monteleone P, Montemagni C, Oldani L, Romano R, Roncone R, Stratta P, Tenconi E, Vita A, Zeppegno P, Maj M. Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives. Psychol Med 2018; 48:1359-1366. [PMID: 29017620 DOI: 10.1017/s0033291717002902] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND The increased use of the MATRICS Consensus Cognitive Battery (MCCB) to investigate cognitive dysfunctions in schizophrenia fostered interest in its sensitivity in the context of family studies. As various measures of the same cognitive domains may have different power to distinguish between unaffected relatives of patients and controls, the relative sensitivity of MCCB tests for relative-control differences has to be established. We compared MCCB scores of 852 outpatients with schizophrenia (SCZ) with those of 342 unaffected relatives (REL) and a normative Italian sample of 774 healthy subjects (HCS). We examined familial aggregation of cognitive impairment by investigating within-family prediction of MCCB scores based on probands' scores. METHODS Multivariate analysis of variance was used to analyze group differences in adjusted MCCB scores. Weighted least-squares analysis was used to investigate whether probands' MCCB scores predicted REL neurocognitive performance. RESULTS SCZ were significantly impaired on all MCCB domains. REL had intermediate scores between SCZ and HCS, showing a similar pattern of impairment, except for social cognition. Proband's scores significantly predicted REL MCCB scores on all domains except for visual learning. CONCLUSIONS In a large sample of stable patients with schizophrenia, living in the community, and in their unaffected relatives, MCCB demonstrated sensitivity to cognitive deficits in both groups. Our findings of significant within-family prediction of MCCB scores might reflect disease-related genetic or environmental factors.
Collapse
Affiliation(s)
- A Mucci
- Department of Psychiatry,Campania University "Luigi Vanvitelli",Naples,Italy
| | - S Galderisi
- Department of Psychiatry,Campania University "Luigi Vanvitelli",Naples,Italy
| | - M F Green
- Department of Psychiatry and Biobehavioral Sciences,Semel Institute for Neuroscience and Human Behavior,University of California Los Angeles,Los Angeles,CA,USA
| | - K Nuechterlein
- Department of Psychiatry and Biobehavioral Sciences,Semel Institute for Neuroscience and Human Behavior,University of California Los Angeles,Los Angeles,CA,USA
| | - P Rucci
- Department of Biomedical and Neuromotor Sciences,University of Bologna,Bologna,Italy
| | - D Gibertoni
- Department of Biomedical and Neuromotor Sciences,University of Bologna,Bologna,Italy
| | - A Rossi
- Department of Biotechnological and Applied Clinical Sciences,Section of Psychiatry,University of L'Aquila,L'Aquila,Italy
| | - P Rocca
- Department of Neuroscience,Section of Psychiatry,University of Turin,Turin,Italy
| | - A Bertolino
- Department of Neurological and Psychiatric Sciences,University of Bari,Bari,Italy
| | - P Bucci
- Department of Psychiatry,Campania University "Luigi Vanvitelli",Naples,Italy
| | - G Hellemann
- Department of Psychiatry and Biobehavioral Sciences,Semel Institute for Neuroscience and Human Behavior,University of California Los Angeles,Los Angeles,CA,USA
| | - M Spisto
- Department of Psychiatry,Campania University "Luigi Vanvitelli",Naples,Italy
| | - D Palumbo
- Department of Psychiatry,Campania University "Luigi Vanvitelli",Naples,Italy
| | - E Aguglia
- Department of Clinical and Molecular Biomedicine,Psychiatry Unit,University of Catania,Catania,Italy
| | - G Amodeo
- Department of Molecular Medicine and Clinical Department of Mental Health,University of Siena,Siena,Italy
| | - M Amore
- Department of Neurosciences,Rehabilitation,Ophthalmology,Genetics and Maternal and Child Health,Section of Psychiatry,University of Genoa,Genoa,Italy
| | - A Bellomo
- Department of Medical Sciences,Psychiatry Unit,University of Foggia,Foggia,Italy
| | - R Brugnoli
- Department of Neurosciences,Mental Health and Sensory Organs,S. Andrea Hospital,Sapienza University of Rome,Rome,Italy
| | - B Carpiniello
- Department of Public Health,Clinical and Molecular Medicine,Section of Psychiatry,University of Cagliari,Cagliari,Italy
| | - L Dell'Osso
- Department of Clinical and Experimental Medicine,Section of Psychiatry,University of Pisa,Pisa,Italy
| | - F Di Fabio
- Department of Neurology and Psychiatry,Sapienza University of Rome,Rome,Italy
| | - M di Giannantonio
- Department of Neuroscience and Imaging,Chair of Psychiatry,G. d'Annunzio University,Chieti,Italy
| | - G Di Lorenzo
- Department of Systems Medicine,Chair of Psychiatry,Tor Vergata University of Rome,Rome,Italy
| | - C Marchesi
- Department of Neuroscience,Psychiatry Unit,University of Parma,Parma,Italy
| | - P Monteleone
- Department of Medicine and Surgery,Chair of Psychiatry,University of Salerno,Salerno,Italy
| | - C Montemagni
- Department of Neuroscience,Section of Psychiatry,University of Turin,Turin,Italy
| | - L Oldani
- Department of Psychiatry,University of Milan,Milan,Italy
| | - R Romano
- Department of Neurological and Psychiatric Sciences,University of Bari,Bari,Italy
| | - R Roncone
- Department of Life,Health and Environmental Sciences,Unit of Psychiatry,University of L'Aquila,L'Aquila,Italy
| | - P Stratta
- Department of Biotechnological and Applied Clinical Sciences,Section of Psychiatry,University of L'Aquila,L'Aquila,Italy
| | - E Tenconi
- Psychiatric Clinic,Department of Neurosciences,University of Padua,Padua,Italy
| | - A Vita
- Department of Mental Health,Psychiatric Unit,School of Medicine,University of Brescia,Spedali Civili Hospital,Brescia,Italy
| | - P Zeppegno
- Department of Translational Medicine,Psychiatric Unit,University of Eastern Piedmont,Novara,Italy
| | - M Maj
- Department of Psychiatry,Campania University "Luigi Vanvitelli",Naples,Italy
| |
Collapse
|
116
|
Reed JL, D’Ambrosio E, Marenco S, Ursini G, Zheutlin AB, Blasi G, Spencer BE, Romano R, Hochheiser J, Reifman A, Sturm J, Berman KF, Bertolino A, Weinberger DR, Callicott JH. Interaction of childhood urbanicity and variation in dopamine genes alters adult prefrontal function as measured by functional magnetic resonance imaging (fMRI). PLoS One 2018; 13:e0195189. [PMID: 29634738 PMCID: PMC5892884 DOI: 10.1371/journal.pone.0195189] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Accepted: 03/13/2018] [Indexed: 12/29/2022] Open
Abstract
Brain phenotypes showing environmental influence may help clarify unexplained associations between urban exposure and psychiatric risk. Heritable prefrontal fMRI activation during working memory (WM) is such a phenotype. We hypothesized that urban upbringing (childhood urbanicity) would alter this phenotype and interact with dopamine genes that regulate prefrontal function during WM. Further, dopamine has been hypothesized to mediate urban-associated factors like social stress. WM-related prefrontal function was tested for main effects of urbanicity, main effects of three dopamine genes-catechol-O-methyltransferase (COMT), dopamine receptor D1 (DRD1), and dopamine receptor D2 (DRD2)-and, importantly, dopamine gene-by-urbanicity interactions. For COMT, three independent human samples were recruited (total n = 487). We also studied 253 subjects genotyped for DRD1 and DRD2. 3T fMRI activation during the N-back WM task was the dependent variable, while childhood urbanicity, dopamine genotype, and urbanicity-dopamine interactions were independent variables. Main effects of dopamine genes and of urbanicity were found. Individuals raised in an urban environment showed altered prefrontal activation relative to those raised in rural or town settings. For each gene, dopamine genotype-by-urbanicity interactions were shown in prefrontal cortex-COMT replicated twice in two independent samples. An urban childhood upbringing altered prefrontal function and interacted with each gene to alter genotype-phenotype relationships. Gene-environment interactions between multiple dopamine genes and urban upbringing suggest that neural effects of developmental environmental exposure could mediate, at least partially, increased risk for psychiatric illness in urban environments via dopamine genes expressed into adulthood.
Collapse
Affiliation(s)
- Jessica L. Reed
- Clinical and Translational Neuroscience Branch, Division of Intramural Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States of America
- Interdisciplinary Program in Neuroscience, Georgetown University Medical Center, Washington, District of Columbia, United States of America
- Experimental Therapeutics & Pathophysiology Branch, Division of Intramural Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Enrico D’Ambrosio
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland, United States of America
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Stefano Marenco
- Clinical and Translational Neuroscience Branch, Division of Intramural Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Gianluca Ursini
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland, United States of America
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Amanda B. Zheutlin
- Clinical and Translational Neuroscience Branch, Division of Intramural Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Giuseppe Blasi
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Barbara E. Spencer
- Clinical and Translational Neuroscience Branch, Division of Intramural Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Raffaella Romano
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Jesse Hochheiser
- Clinical and Translational Neuroscience Branch, Division of Intramural Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Ann Reifman
- Clinical and Translational Neuroscience Branch, Division of Intramural Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Justin Sturm
- Clinical and Translational Neuroscience Branch, Division of Intramural Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Karen F. Berman
- Clinical and Translational Neuroscience Branch, Division of Intramural Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Alessandro Bertolino
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Daniel R. Weinberger
- Clinical and Translational Neuroscience Branch, Division of Intramural Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States of America
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland, United States of America
- Departments of Psychiatry, Neurology, Neuroscience and the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
| | - Joseph H. Callicott
- Clinical and Translational Neuroscience Branch, Division of Intramural Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, United States of America
| |
Collapse
|
117
|
Galderisi S, Rucci P, Kirkpatrick B, Mucci A, Gibertoni D, Rocca P, Rossi A, Bertolino A, Strauss GP, Aguglia E, Bellomo A, Murri MB, Bucci P, Carpiniello B, Comparelli A, Cuomo A, De Berardis D, Dell’Osso L, Di Fabio F, Gelao B, Marchesi C, Monteleone P, Montemagni C, Orsenigo G, Pacitti F, Roncone R, Santonastaso P, Siracusano A, Vignapiano A, Vita A, Zeppegno P, Maj M. Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia: A Network Analysis. JAMA Psychiatry 2018; 75:396-404. [PMID: 29450447 PMCID: PMC5875306 DOI: 10.1001/jamapsychiatry.2017.4607] [Citation(s) in RCA: 187] [Impact Index Per Article: 31.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Accepted: 12/17/2017] [Indexed: 12/20/2022]
Abstract
Importance Enhanced understanding of factors associated with symptomatic and functional recovery is instrumental to designing personalized treatment plans for people with schizophrenia. To date, this is the first study using network analysis to investigate the associations among cognitive, psychopathologic, and psychosocial variables in a large sample of community-dwelling individuals with schizophrenia. Objective To assess the interplay among psychopathologic variables, cognitive dysfunctions, functional capacity, personal resources, perceived stigma, and real-life functioning in individuals with schizophrenia, using a data-driven approach. Design, Setting, and Participants This multicenter, cross-sectional study involved 26 university psychiatric clinics and/or mental health departments. A total of 921 community-dwelling individuals with a DSM-IV diagnosis of schizophrenia who were stabilized on antipsychotic treatment were recruited from those consecutively presenting to the outpatient units of the sites between March 1, 2012, and September 30, 2013. Statistical analysis was conducted between July 1 and September 30, 2017. Main Outcomes and Measures Measures covered psychopathologic variables, neurocognition, social cognition, functional capacity, real-life functioning, resilience, perceived stigma, incentives, and service engagement. Results Of 740 patients (221 women and 519 men; mean [SD] age, 40.0 [10.9] years) with complete data on the 27 study measures, 163 (22.0%) were remitted (with a score of mild or better on 8 core symptoms). The network analysis showed that functional capacity and everyday life skills were the most central and highly interconnected nodes in the network. Psychopathologic variables split in 2 domains, with positive symptoms being one of the most peripheral and least connected nodes. Functional capacity bridged cognition with everyday life skills; the everyday life skills node was connected to disorganization and expressive deficits. Interpersonal relationships and work skills were connected to avolition; the interpersonal relationships node was also linked to social competence, and the work skills node was linked to social incentives and engagement with mental health services. A case-dropping bootstrap procedure showed centrality indices correlations of 0.75 or greater between the original and randomly defined samples up to 481 of 740 case-dropping (65.0%). No difference in the network structure was found between men and women. Conclusions and Relevance The high centrality of functional capacity and everyday life skills in the network suggests that improving the ability to perform tasks relevant to everyday life is critical for any therapeutic intervention in schizophrenia. The pattern of network node connections supports the implementation of personalized interventions.
Collapse
Affiliation(s)
- Silvana Galderisi
- Department of Psychiatry, Campania University “Luigi Vanvitelli,” Naples, Italy
| | - Paola Rucci
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | - Brian Kirkpatrick
- Department of Psychiatry and Behavioral Sciences, University of Nevada, Reno School of Medicine, Reno
| | - Armida Mucci
- Department of Psychiatry, Campania University “Luigi Vanvitelli,” Naples, Italy
| | - Dino Gibertoni
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | - Paola Rocca
- Department of Neuroscience, Section of Psychiatry, University of Turin, Turin, Italy
| | - Alessandro Rossi
- Section of Psychiatry, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
| | - Alessandro Bertolino
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | | | - Eugenio Aguglia
- Department of Clinical and Molecular Biomedicine, Psychiatry Unit, University of Catania, Catania, Italy
| | - Antonello Bellomo
- Psychiatry Unit, Department of Medical Sciences, University of Foggia, Foggia, Italy
| | - Martino Belvederi Murri
- Section of Psychiatry, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, University of Genoa, Genoa, Italy
| | - Paola Bucci
- Department of Psychiatry, Campania University “Luigi Vanvitelli,” Naples, Italy
| | - Bernardo Carpiniello
- Section of Psychiatry, Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy
| | - Anna Comparelli
- Department of Neurosciences, Mental Health and Sensory Organs, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy
| | - Alessandro Cuomo
- Department of Molecular Medicine and Clinical Department of Mental Health, University of Siena, Siena, Italy
| | | | - Liliana Dell’Osso
- Section of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Fabio Di Fabio
- Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy
| | - Barbara Gelao
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - Carlo Marchesi
- Department of Neuroscience, Psychiatry Unit, University of Parma, Parma, Italy
| | - Palmiero Monteleone
- Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana,” Section of Neuroscience, University of Salerno, Salerno, Italy
| | - Cristiana Montemagni
- Department of Neuroscience, Section of Psychiatry, University of Turin, Turin, Italy
| | | | - Francesca Pacitti
- Section of Psychiatry, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
| | - Rita Roncone
- Unit of Psychiatry, Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy
| | - Paolo Santonastaso
- Psychiatric Clinic, Department of Neurosciences, University of Padua, Padua, Italy
| | - Alberto Siracusano
- Department of Systems Medicine, Psychiatry and Clinical Psychology Unit, Tor Vergata University of Rome, Rome, Italy
| | - Annarita Vignapiano
- Department of Psychiatry, Campania University “Luigi Vanvitelli,” Naples, Italy
| | - Antonio Vita
- Psychiatric Unit, School of Medicine, University of Brescia, Brescia, Italy
- Department of Mental Health, Spedali Civili Hospital, Brescia, Italy
| | - Patrizia Zeppegno
- Department of Translational Medicine, Psychiatric Unit, University of Eastern Piedmont, Novara, Italy
| | - Mario Maj
- Department of Psychiatry, Campania University “Luigi Vanvitelli,” Naples, Italy
| |
Collapse
|
118
|
Dukart J, Holiga Š, Chatham C, Hawkins P, Forsyth A, McMillan R, Myers J, Lingford-Hughes AR, Nutt DJ, Merlo-Pich E, Risterucci C, Boak L, Umbricht D, Schobel S, Liu T, Mehta MA, Zelaya FO, Williams SC, Brown G, Paulus M, Honey GD, Muthukumaraswamy S, Hipp J, Bertolino A, Sambataro F. Cerebral blood flow predicts differential neurotransmitter activity. Sci Rep 2018; 8:4074. [PMID: 29511260 PMCID: PMC5840131 DOI: 10.1038/s41598-018-22444-0] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Accepted: 02/23/2018] [Indexed: 12/13/2022] Open
Abstract
Application of metabolic magnetic resonance imaging measures such as cerebral blood flow in translational medicine is limited by the unknown link of observed alterations to specific neurophysiological processes. In particular, the sensitivity of cerebral blood flow to activity changes in specific neurotransmitter systems remains unclear. We address this question by probing cerebral blood flow in healthy volunteers using seven established drugs with known dopaminergic, serotonergic, glutamatergic and GABAergic mechanisms of action. We use a novel framework aimed at disentangling the observed effects to contribution from underlying neurotransmitter systems. We find for all evaluated compounds a reliable spatial link of respective cerebral blood flow changes with underlying neurotransmitter receptor densities corresponding to their primary mechanisms of action. The strength of these associations with receptor density is mediated by respective drug affinities. These findings suggest that cerebral blood flow is a sensitive brain-wide in-vivo assay of metabolic demands across a variety of neurotransmitter systems in humans.
Collapse
Affiliation(s)
- Juergen Dukart
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
| | - Štefan Holiga
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland
| | - Christopher Chatham
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland
| | - Peter Hawkins
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Anna Forsyth
- School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Rebecca McMillan
- School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Jim Myers
- Neuropsychopharmacology Unit, Imperial College London, London, United Kingdom
| | | | - David J Nutt
- Veterans Affairs San Diego Healthcare System, San Diego, USA
| | - Emilio Merlo-Pich
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland
| | - Celine Risterucci
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland
| | - Lauren Boak
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland
| | - Daniel Umbricht
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland
| | - Scott Schobel
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland
| | - Thomas Liu
- Center for Functional MRI, University of California San Diego, 9500 Gilman Drive MC 0677, La Jolla, CA 92093, United States
- Departments of Radiology, Psychiatry and Bioengineering, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States
| | - Mitul A Mehta
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Fernando O Zelaya
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Steve C Williams
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Gregory Brown
- University of California, San Diego, La Jolla, USA
- Veterans Affairs San Diego Healthcare System, San Diego, USA
| | - Martin Paulus
- University of California, San Diego, La Jolla, USA
- Veterans Affairs San Diego Healthcare System, San Diego, USA
| | - Garry D Honey
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland
| | - Suresh Muthukumaraswamy
- School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Joerg Hipp
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland
| | - Alessandro Bertolino
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland
- Institute Of Psychiatry, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy
| | - Fabio Sambataro
- F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland
- Department of Experimental and Clinical Medical Sciences (DISM), University of Udine, Udine, Italy
| |
Collapse
|
119
|
Rossi A, Amore M, Galderisi S, Rocca P, Bertolino A, Aguglia E, Amodeo G, Bellomo A, Bucci P, Buzzanca A, Carpiniello B, Comparelli A, Dell'Osso L, di Giannantonio M, Mancini M, Marchesi C, Monteleone P, Montemagni C, Oldani L, Roncone R, Siracusano A, Stratta P, Tenconi E, Vignapiano A, Vita A, Zeppegno P, Maj M. The complex relationship between self-reported 'personal recovery' and clinical recovery in schizophrenia. Schizophr Res 2018; 192:108-112. [PMID: 28495492 DOI: 10.1016/j.schres.2017.04.040] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Revised: 04/19/2017] [Accepted: 04/22/2017] [Indexed: 11/29/2022]
Abstract
Self-reported 'personal recovery' and clinical recovery in schizophrenia (SRPR and CR, respectively) reflect different perspectives in schizophrenia outcome, not necessarily concordant with each other and usually representing the consumer's or the therapist's point of view. By means of a cluster analysis on SRPR-related variables, we identified three clusters. The first and third cluster included subjects with the best and the poorest clinical outcome respectively. The second cluster was characterized by better insight, higher levels of depression and stigma, lowest self-esteem and personal strength, and highest emotional coping. The first cluster showed positive features of recovery, while the third cluster showed negative features. The second cluster, with the most positive insight, showed a more complex pattern, a somewhat 'paradoxical' mixture of positive and negative personal and clinical features of recovery. The present results suggest the need for a characterization of persons with schizophrenia along SRPR and CR dimensions to design individualized and integrated treatment programs aimed to improve insight and coping strategies, reduce stigma, and shape recovery styles.
Collapse
Affiliation(s)
- Alessandro Rossi
- Department of Biotechnological and Applied Clinical Sciences, Section of Psychiatry, University of L'Aquila, L'Aquila, Italy.
| | - Mario Amore
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, Section of Psychiatry, University of Genoa, Genoa, Italy
| | | | - Paola Rocca
- Department of Neuroscience, Section of Psychiatry, University of Turin, Turin, Italy
| | - Alessandro Bertolino
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - Eugenio Aguglia
- Department of Clinical and Molecular Biomedicine, Psychiatry Unit, University of Catania, Catania, Italy
| | - Giovanni Amodeo
- Department of Molecular Medicine and Clinical Department of Mental Health, University of Siena, Siena, Italy
| | - Antonello Bellomo
- Department of Medical Sciences, Psychiatry Unit, University of Foggia, Foggia, Italy
| | - Paola Bucci
- Department of Psychiatry, University of Campania, Naples, Italy
| | - Antonino Buzzanca
- Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy
| | - Bernardo Carpiniello
- Department of Public Health, Clinical and Molecular Medicine, Section of Psychiatry, University of Cagliari, Cagliari, Italy
| | - Anna Comparelli
- Department of Neurosciences, Mental Health and Sensory Organs, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy
| | - Liliana Dell'Osso
- Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, Pisa, Italy
| | - Massimo di Giannantonio
- Department of Neuroscience and Imaging, Chair of Psychiatry, G. d'Annunzio University, Chieti, Italy
| | - Marina Mancini
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - Carlo Marchesi
- Department of Neuroscience, Psychiatry Unit, University of Parma, Parma, Italy
| | - Palmiero Monteleone
- Department of Medicine and Surgery, Chair of Psychiatry, University of Salerno, Salerno, Italy
| | - Cristiana Montemagni
- Department of Neuroscience, Section of Psychiatry, University of Turin, Turin, Italy
| | - Lucio Oldani
- Department of Psychiatry, University of Milan, Milan, Italy
| | - Rita Roncone
- Department of Life, Health and Environmental Sciences, Unit of Psychiatry, University of L'Aquila, L'Aquila, Italy
| | - Alberto Siracusano
- Department of Systems Medicine, Chair of Psychiatry, Tor Vergata University of Rome, Rome, Italy
| | - Paolo Stratta
- Department of Biotechnological and Applied Clinical Sciences, Section of Psychiatry, University of L'Aquila, L'Aquila, Italy
| | - Elena Tenconi
- Psychiatric Clinic, Department of Neurosciences, University of Padua, Padua, Italy
| | | | - Antonio Vita
- Psychiatric Unit, School of Medicine, University of Brescia, and Department of Mental Health, Spedali Civili Hospital, Brescia, Italy
| | - Patrizia Zeppegno
- Department of Translational Medicine, Psychiatric Unit, University of Eastern Piedmont, Novara, Italy
| | - Mario Maj
- Department of Psychiatry, University of Campania, Naples, Italy
| | | |
Collapse
|
120
|
Walton E, Hibar DP, van Erp TGM, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, Suarez-Pinilla P, Van Haren NEM, de Zwarte SMC, Kahn RS, Cahn W, Doan NT, Jørgensen KN, Gurholt TP, Agartz I, Andreassen OA, Westlye LT, Melle I, Berg AO, Morch-Johnsen L, Færden A, Flyckt L, Fatouros-Bergman H, Jönsson EG, Hashimoto R, Yamamori H, Fukunaga M, Jahanshad N, De Rossi P, Piras F, Banaj N, Spalletta G, Gur RE, Gur RC, Wolf DH, Satterthwaite TD, Beard LM, Sommer IE, Koops S, Gruber O, Richter A, Krämer B, Kelly S, Donohoe G, McDonald C, Cannon DM, Corvin A, Gill M, Di Giorgio A, Bertolino A, Lawrie S, Nickson T, Whalley HC, Neilson E, Calhoun VD, Thompson PM, Turner JA, Ehrlich S. Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium. Psychol Med 2018; 48:82-94. [PMID: 28545597 PMCID: PMC5826665 DOI: 10.1017/s0033291717001283] [Citation(s) in RCA: 92] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND Our understanding of the complex relationship between schizophrenia symptomatology and etiological factors can be improved by studying brain-based correlates of schizophrenia. Research showed that impairments in value processing and executive functioning, which have been associated with prefrontal brain areas [particularly the medial orbitofrontal cortex (MOFC)], are linked to negative symptoms. Here we tested the hypothesis that MOFC thickness is associated with negative symptom severity. METHODS This study included 1985 individuals with schizophrenia from 17 research groups around the world contributing to the ENIGMA Schizophrenia Working Group. Cortical thickness values were obtained from T1-weighted structural brain scans using FreeSurfer. A meta-analysis across sites was conducted over effect sizes from a model predicting cortical thickness by negative symptom score (harmonized Scale for the Assessment of Negative Symptoms or Positive and Negative Syndrome Scale scores). RESULTS Meta-analytical results showed that left, but not right, MOFC thickness was significantly associated with negative symptom severity (β std = -0.075; p = 0.019) after accounting for age, gender, and site. This effect remained significant (p = 0.036) in a model including overall illness severity. Covarying for duration of illness, age of onset, antipsychotic medication or handedness weakened the association of negative symptoms with left MOFC thickness. As part of a secondary analysis including 10 other prefrontal regions further associations in the left lateral orbitofrontal gyrus and pars opercularis emerged. CONCLUSIONS Using an unusually large cohort and a meta-analytical approach, our findings point towards a link between prefrontal thinning and negative symptom severity in schizophrenia. This finding provides further insight into the relationship between structural brain abnormalities and negative symptoms in schizophrenia.
Collapse
Affiliation(s)
- Esther Walton
- Department of Psychology, Georgia State University, Atlanta GA 30302
- Translational Developmental Neuroscience Section, Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany
- Department of Psychology, Institute of Psychology, Psychiatry and Neuroscience, King’s College London, London, SE5 8AF, United Kingdom
| | - Derrek P Hibar
- Imaging Genetics Center, Keck School of Medicine, University of Southern California, Marina del Rey, CA, United States
| | - Theo GM van Erp
- Department of Psychiatry and Human Behavior, University of California, Irvine, California
| | - Steven G Potkin
- Department of Psychiatry and Human Behavior, University of California, Irvine, California
| | - Roberto Roiz-Santiañez
- Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria–IDIVAL, Avda. Valdecilla s/n, 39008, Santander, Spain
- Cibersam (Centro Investigación Biomédica en Red Salud Mental), Avda. Valdecilla s/n, 39008, Santander, Spain
| | - Benedicto Crespo-Facorro
- Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria–IDIVAL, Avda. Valdecilla s/n, 39008, Santander, Spain
- Cibersam (Centro Investigación Biomédica en Red Salud Mental), Avda. Valdecilla s/n, 39008, Santander, Spain
| | - Paula Suarez-Pinilla
- Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria–IDIVAL, Avda. Valdecilla s/n, 39008, Santander, Spain
- Cibersam (Centro Investigación Biomédica en Red Salud Mental), Avda. Valdecilla s/n, 39008, Santander, Spain
| | - Neeltje EM Van Haren
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Sonja MC de Zwarte
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Rene S Kahn
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Wiepke Cahn
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Nhat Trung Doan
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway
| | - Kjetil N Jørgensen
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway
- Department of Psychiatric Research, Diakonhjemmet Hospital, P.O. Box 85 Vinderen, 0319 Oslo, Norway
| | - Tiril P Gurholt
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway
| | - Ingrid Agartz
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway
- Department of Psychiatric Research, Diakonhjemmet Hospital, P.O. Box 85 Vinderen, 0319 Oslo, Norway
- Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Ole A Andreassen
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway
| | - Lars T Westlye
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway
| | - Ingrid Melle
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway
| | - Akiah O Berg
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway
| | - Lynn Morch-Johnsen
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway
- Department of Psychiatric Research, Diakonhjemmet Hospital, P.O. Box 85 Vinderen, 0319 Oslo, Norway
| | - Ann Færden
- Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway
| | - Lena Flyckt
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Norra Stationsgatan 69, 113 64 Stockholm, Sweden
| | - Helena Fatouros-Bergman
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Norra Stationsgatan 69, 113 64 Stockholm, Sweden
| | | | - Erik G Jönsson
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway
- Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Ryota Hashimoto
- Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University D3, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan
- Department of Psychiatry, Osaka University Graduate School of Medicine D3, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Hidenaga Yamamori
- Department of Psychiatry, Osaka University Graduate School of Medicine D3, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Masaki Fukunaga
- Division of Cerebral Integration, National Institute for Physiological Sciences, 38 Nishigonaka Myodaiji, Okazaki, Aichi, 444-8585, Japan
| | - Neda Jahanshad
- Imaging Genetics Center, Keck School of Medicine, University of Southern California, Marina del Rey, CA, United States
| | - Pietro De Rossi
- NESMOS Department (Neurosciences, Mental Health and Sensory Functions), School of Medicine and Psychology, Sapienza University, Rome, Italy
- Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 00179, Rome, Italy
| | - Fabrizio Piras
- Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 00179, Rome, Italy
| | - Nerisa Banaj
- Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 00179, Rome, Italy
| | - Gianfranco Spalletta
- Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 00179, Rome, Italy
- Beth K. and Stuart C. Yudofsky Division of Neuropsychiatry Menninger Department of Psychiatry and Behavioral Sciences Baylor College of Medicine Houston, TX, USA
| | - Raquel E Gur
- Brain Behavior Laboratory, University of Pennsylvania, Philadelphia PA USA 19104
| | - Ruben C Gur
- Brain Behavior Laboratory, University of Pennsylvania, Philadelphia PA USA 19104
| | - Daniel H Wolf
- Brain Behavior Laboratory, University of Pennsylvania, Philadelphia PA USA 19104
| | | | - Lauren M Beard
- Brain Behavior Laboratory, University of Pennsylvania, Philadelphia PA USA 19104
| | - Iris E Sommer
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Sanne Koops
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Oliver Gruber
- Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Von-Siebold-Str. 5, 37075 Göttingen, Germany
| | - Anja Richter
- Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Von-Siebold-Str. 5, 37075 Göttingen, Germany
| | - Bernd Krämer
- Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Von-Siebold-Str. 5, 37075 Göttingen, Germany
| | - Sinead Kelly
- Imaging Genetics Center, Keck School of Medicine, University of Southern California, Marina del Rey, CA, United States
- Trinity College, Dublin, Ireland
| | - Gary Donohoe
- Neuroimaging and Cognitive Genomics Centre, NCBES Galway Neuroscience Centre, National University of Ireland Galway, Galway, Ireland
| | - Colm McDonald
- Neuroimaging and Cognitive Genomics Centre, NCBES Galway Neuroscience Centre, National University of Ireland Galway, Galway, Ireland
| | - Dara M Cannon
- Neuroimaging and Cognitive Genomics Centre, NCBES Galway Neuroscience Centre, National University of Ireland Galway, Galway, Ireland
| | | | | | - Annabella Di Giorgio
- Section of Psychiatry and Psychology, IRCCS Casa Sollievo della Sofferenza, S.G. Rotondo (FG), 71013 Italy
| | - Alessandro Bertolino
- Psychiatric Neuroscience Group, University of Bari ‘Aldo Moro’, Bari, 70124 Italy
| | - Stephen Lawrie
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Morningside, Edinburgh, EH10 5HF
| | - Thomas Nickson
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Morningside, Edinburgh, EH10 5HF
| | - Heather C Whalley
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Morningside, Edinburgh, EH10 5HF
| | - Emma Neilson
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Morningside, Edinburgh, EH10 5HF
| | - Vince D Calhoun
- The Mind Research Network, Albuquerque, NM 87106, United States
- Department of Electrical and Computer Engineering, University of New Mexico, Albuquerque, NM 87131, United States
| | - Paul M Thompson
- Imaging Genetics Center, Keck School of Medicine, University of Southern California, Marina del Rey, CA, United States
| | - Jessica A Turner
- Department of Psychology and Neuroscience Institute, Georgia State University, Atlanta GA 30302
| | - Stefan Ehrlich
- Translational Developmental Neuroscience Section, Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany
| |
Collapse
|
121
|
Errico F, Nuzzo T, Carella M, Bertolino A, Usiello A. The Emerging Role of Altered d-Aspartate Metabolism in Schizophrenia: New Insights From Preclinical Models and Human Studies. Front Psychiatry 2018; 9:559. [PMID: 30459655 PMCID: PMC6232865 DOI: 10.3389/fpsyt.2018.00559] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Accepted: 10/17/2018] [Indexed: 01/08/2023] Open
Abstract
Besides d-serine, another d-amino acid with endogenous occurrence in the mammalian brain, d-aspartate, has been recently shown to influence NMDA receptor (NMDAR)-mediated transmission. d-aspartate is present in the brain at extracellular level in nanomolar concentrations, binds to the agonist site of NMDARs and activates this subclass of glutamate receptors. Along with its direct effect on NMDARs, d-aspartate can also evoke considerable l-glutamate release in specific brain areas through the presynaptic activation of NMDA, AMPA/kainate and mGlu5 receptors. d-aspartate is enriched in the embryonic brain of rodents and humans and its concentration strongly decreases after birth, due to the post-natal expression of the catabolising enzyme d-aspartate oxidase (DDO). Based on the hypothesis of NMDAR hypofunction in schizophrenia pathogenesis, recent preclinical and clinical studies suggested a relationship between perturbation of d-aspartate metabolism and this psychiatric disorder. Consistently, neurophysiological and behavioral characterization of Ddo knockout (Ddo -/-) and d-aspartate-treated mice highlighted that abnormally higher endogenous d-aspartate levels significantly increase NMDAR-mediated synaptic plasticity, neuronal spine density and memory. Remarkably, increased d-aspartate levels influence schizophrenia-like phenotypes in rodents, as indicated by improved fronto-hippocampal connectivity, attenuated prepulse inhibition deficits and reduced activation of neuronal circuitry induced by phencyclidine exposure. In healthy humans, a genetic polymorphism associated with reduced prefrontal DDO gene expression predicts changes in prefrontal phenotypes including greater gray matter volume and enhanced functional activity during working memory. Moreover, neurochemical detections in post-mortem brain of schizophrenia-affected patients have shown significantly reduced d-aspartate content in prefrontal regions, associated with increased DDO mRNA expression or DDO enzymatic activity. Overall, these findings suggest a possible involvement of dysregulated embryonic d-aspartate metabolism in schizophrenia pathophysiology and, in turn, highlight the potential use of free d-aspartate supplementation as a new add-on therapy for treating the cognitive symptoms of this mental illness.
Collapse
Affiliation(s)
- Francesco Errico
- Department of Agricultural Sciences, University of Naples "Federico II", Portici, Italy
| | - Tommaso Nuzzo
- Translational Neuroscience Unit, IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy
| | - Massimo Carella
- Translational Neuroscience Unit, IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy
| | - Alessandro Bertolino
- Group of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience and Sense Organs, Aldo Moro University, Bari, Italy
| | - Alessandro Usiello
- Laboratory of Behavioural Neuroscience, Ceinge Biotecnologie Avanzate, Naples, Italy.,Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università Degli Studi Della Campania "Luigi Vanvitelli", Caserta, Italy
| |
Collapse
|
122
|
Hawkins PCT, Wood TC, Vernon AC, Bertolino A, Sambataro F, Dukart J, Merlo-Pich E, Risterucci C, Silber-Baumann H, Walsh E, Mazibuko N, Zelaya FO, Mehta MA. An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers. Hum Brain Mapp 2017; 39:319-331. [PMID: 29058358 DOI: 10.1002/hbm.23844] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Revised: 09/13/2017] [Accepted: 10/02/2017] [Indexed: 01/05/2023] Open
Abstract
Chronic administration of antipsychotic drugs has been linked to structural brain changes observed in patients with schizophrenia. Recent MRI studies have shown rapid changes in regional brain volume following just a single dose of these drugs. However, it is not clear if these changes represent real volume changes or are artefacts ("apparent" volume changes) due to drug-induced physiological changes, such as increased cerebral blood flow (CBF). To address this, we examined the effects of a single, clinical dose of three commonly prescribed antipsychotics on quantitative measures of T1 and regional blood flow of the healthy human brain. Males (n = 42) were randomly assigned to one of two parallel groups in a double-blind, placebo-controlled, randomized, three-period cross-over study design. One group received a single oral dose of either 0.5 or 2 mg of risperidone or placebo during each visit. The other received olanzapine (7.5 mg), haloperidol (3 mg), or placebo. MR measures of quantitative T1, CBF, and T1-weighted images were acquired at the estimated peak plasma concentration of the drug. All three drugs caused localized increases in striatal blood flow, although drug and region specific effects were also apparent. In contrast, all assessments of T1 and brain volume remained stable across sessions, even in those areas experiencing large changes in CBF. This illustrates that a single clinically relevant oral dose of an antipsychotic has no detectable acute effect on T1 in healthy volunteers. We further provide a methodology for applying quantitative imaging methods to assess the acute effects of other compounds on structural MRI metrics. Hum Brain Mapp 39:319-331, 2018. © 2017 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Peter C T Hawkins
- Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Tobias C Wood
- Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Anthony C Vernon
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.,MRC Centre for Neurodevelopmental Disorders, King's College London, London, United Kingdom
| | - Alessandro Bertolino
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari BA, Italy
| | - Fabio Sambataro
- Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy
| | - Juergen Dukart
- Translational Medicine Neuroscience and Biomarkers, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Emilio Merlo-Pich
- CNS Therapeutic Area Unit, Takeda Development Centre Europe, London, United Kingdom
| | - Celine Risterucci
- Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Hanna Silber-Baumann
- Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Eamonn Walsh
- Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
| | - Ndabezinhle Mazibuko
- Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Fernando O Zelaya
- Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Mitul A Mehta
- Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| |
Collapse
|
123
|
Rampino A, Taurisano P, Fanelli G, Attrotto M, Torretta S, Antonucci LA, Miccolis G, Pergola G, Ursini G, Maddalena G, Romano R, Masellis R, Di Carlo P, Pignataro P, Blasi G, Bertolino A. A Polygenic Risk Score of glutamatergic SNPs associated with schizophrenia predicts attentional behavior and related brain activity in healthy humans. Eur Neuropsychopharmacol 2017; 27:928-939. [PMID: 28651857 DOI: 10.1016/j.euroneuro.2017.06.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 04/13/2017] [Accepted: 06/10/2017] [Indexed: 11/17/2022]
Abstract
Multiple genetic variations impact on risk for schizophrenia. Recent analyses by the Psychiatric Genomics Consortium (PGC2) identified 128 SNPs genome-wide associated with the disorder. Furthermore, attention and working memory deficits are core features of schizophrenia, are heritable and have been associated with variation in glutamatergic neurotransmission. Based on this evidence, in a sample of healthy volunteers, we used SNPs associated with schizophrenia in PGC2 to construct a Polygenic-Risk-Score (PRS) reflecting the cumulative risk for schizophrenia, along with a Polygenic-Risk-Score including only SNPs related to genes implicated in glutamatergic signaling (Glu-PRS). We performed Factor Analysis for dimension reduction of indices of cognitive performance. Furthermore, both PRS and Glu-PRS were used as predictors of cognitive functioning in the domains of Attention, Speed of Processing and Working Memory. The association of the Glu-PRS on brain activity during the Variable Attention Control (VAC) task was also explored. Finally, in a second independent sample of healthy volunteers we sought to confirm the association between the Glu-PRS and both performance in the domain of Attention and brain activity during the VAC.We found that performance in Speed of Processing and Working Memory was not associated with any of the Polygenic-Risk-Scores. The Glu-PRS, but not the PRS was associated with Attention and brain activity during the VAC. The specific effects of Glu-PRS on Attention and brain activity during the VAC were also confirmed in the replication sample.Our results suggest a pathway specificity in the relationship between genetic risk for schizophrenia, the associated cognitive dysfunction and related brain processing.
Collapse
Affiliation(s)
- Antonio Rampino
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Paolo Taurisano
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Giuseppe Fanelli
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Mariateresa Attrotto
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy; Psychiatry Unit - Bari University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Silvia Torretta
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Linda Antonella Antonucci
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Grazia Miccolis
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Giulio Pergola
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Gianluca Ursini
- Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, 21205 Baltimore, MD, USA
| | - Giancarlo Maddalena
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy; Psychiatry Unit - Bari University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Raffaella Romano
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Rita Masellis
- Psychiatry Unit - Bari University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Pasquale Di Carlo
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Patrizia Pignataro
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Giuseppe Blasi
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy; Psychiatry Unit - Bari University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Alessandro Bertolino
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy; Psychiatry Unit - Bari University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy.
| |
Collapse
|
124
|
Breen G, Li Q, Roth BL, O'Donnell P, Didriksen M, Dolmetsch R, O'Reilly PF, Gaspar HA, Manji H, Huebel C, Kelsoe JR, Malhotra D, Bertolino A, Posthuma D, Sklar P, Kapur S, Sullivan PF, Collier DA, Edenberg HJ. Translating genome-wide association findings into new therapeutics for psychiatry. Nat Neurosci 2017; 19:1392-1396. [PMID: 27786187 DOI: 10.1038/nn.4411] [Citation(s) in RCA: 91] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Genome-wide association studies (GWAS) in psychiatry, once they reach sufficient sample size and power, have been enormously successful. The Psychiatric Genomics Consortium (PGC) aims for mega-analyses with sample sizes that will grow to >1 million individuals in the next 5 years. This should lead to hundreds of new findings for common genetic variants across nine psychiatric disorders studied by the PGC. The new targets discovered by GWAS have the potential to restart largely stalled psychiatric drug development pipelines, and the translation of GWAS findings into the clinic is a key aim of the recently funded phase 3 of the PGC. This is not without considerable technical challenges. These approaches complement the other main aim of GWAS studies, risk prediction approaches for improving detection, differential diagnosis, and clinical trial design. This paper outlines the motivations, technical and analytical issues, and the plans for translating PGC phase 3 findings into new therapeutics.
Collapse
Affiliation(s)
- Gerome Breen
- MRC Social, Genetic &Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &Neuroscience, King's College London, London, UK.,UK National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health, South London and Maudsley Hospital, London, UK
| | - Qingqin Li
- Neuroscience Therapeutic Area, Janssen Research &Development, LLC, Titusville, New Jersey, USA
| | - Bryan L Roth
- Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.,National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.,Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | | | - Michael Didriksen
- H. Lundbeck A/S, Synaptic Transmission, Neuroscience Research DK, Valby, Denmark
| | - Ricardo Dolmetsch
- Department of Neuroscience, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA
| | - Paul F O'Reilly
- MRC Social, Genetic &Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &Neuroscience, King's College London, London, UK
| | - Héléna A Gaspar
- MRC Social, Genetic &Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &Neuroscience, King's College London, London, UK.,UK National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health, South London and Maudsley Hospital, London, UK
| | - Husseini Manji
- Neuroscience Therapeutic Area, Janssen Research &Development, LLC, Titusville, New Jersey, USA
| | - Christopher Huebel
- MRC Social, Genetic &Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &Neuroscience, King's College London, London, UK.,UK National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health, South London and Maudsley Hospital, London, UK
| | - John R Kelsoe
- Department of Psychiatry, University of California San Diego, and Veterans Affairs San Diego Healthcare System, La Jolla, California, USA
| | - Dheeraj Malhotra
- Neuroscience Discovery and Translational Area, Pharma Research &Early Development, F. Hoffmann - La Roche, Basel, Switzerland
| | - Alessandro Bertolino
- Institute of Psychiatry, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy
| | - Danielle Posthuma
- Department of Complex Trait Genetics, Centre for Neurogenomics and Cognitive Research/VU University Amsterdam, Amsterdam, the Netherlands.,Department of Clinical Genetics, VU University Medical Centre Amsterdam, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands
| | - Pamela Sklar
- Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.,Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.,Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Shitij Kapur
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Patrick F Sullivan
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.,Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | - David A Collier
- MRC Social, Genetic &Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &Neuroscience, King's College London, London, UK.,UK National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health, South London and Maudsley Hospital, London, UK.,Discovery Neuroscience Research, Eli Lilly and Company Ltd, Windlesham, Surrey, UK
| | - Howard J Edenberg
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.,Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA
| |
Collapse
|
125
|
Dukart J, Sambataro F, Bertolino A. Distinct Role of Striatal Functional Connectivity and Dopaminergic Loss in Parkinson's Symptoms. Front Aging Neurosci 2017; 9:151. [PMID: 28588475 PMCID: PMC5441129 DOI: 10.3389/fnagi.2017.00151] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Accepted: 05/03/2017] [Indexed: 11/22/2022] Open
Abstract
Degeneration of dopaminergic neurons is a hallmark of Parkinson's disease. However, its link to Parkinson's disease symptoms remains unclear. Striatal resting state functional connectivity differentiates between Parkinson's disease patients and healthy controls and might be a potential mediator of the effects of striatal dopaminergic degeneration onto Parkinson's disease symptoms. Here, we evaluated the relationship between dopaminergic deficits, striatal functional connectivity (SFC) at rest and different Parkinson's disease clinical symptoms in the largest currently established cohort of de novo Parkinson's disease patients. We show that SFC is an independent predictor of symptom severity in Parkinson's disease in addition to striatal dopaminergic deficits. Furthermore, we find that distinct SFC networks are associated with symptoms reflecting the ability to perform daily routine automatized motor tasks and clinician-rated Parkinson's disease motor symptoms. We find that reduced SFC is a major and independent predictor of Parkinson's disease symptoms going beyond the mere reflection of striatal dopaminergic input loss. These findings indicate the high value of SFC as a clinically relevant biomarker in Parkinson's disease.
Collapse
Affiliation(s)
- Juergen Dukart
- Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Discovery and Translational Area, Roche Innovation Center BaselBasel, Switzerland
| | - Fabio Sambataro
- Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Discovery and Translational Area, Roche Innovation Center BaselBasel, Switzerland
- Department of Experimental and Clinical Medical Sciences, University of UdineUdine, Italy
| | - Alessandro Bertolino
- Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Discovery and Translational Area, Roche Innovation Center BaselBasel, Switzerland
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo MoroBari, Italy
| |
Collapse
|
126
|
Walton E, Hibar DP, van Erp TGM, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, Suarez-Pinilla P, Van Haren NEM, de Zwarte SMC, Kahn RS, Cahn W, Doan NT, Jørgensen KN, Gurholt TP, Agartz I, Andreassen OA, Westlye LT, Melle I, Berg AO, Mørch-Johnsen L, Færden A, Flyckt L, Fatouros-Bergman H, Jönsson EG, Hashimoto R, Yamamori H, Fukunaga M, Preda A, De Rossi P, Piras F, Banaj N, Piras F, Ciullo V, Spalletta G, Gur RE, Gur RC, Wolf DH, Satterthwaite TD, Beard LM, Sommer IE, Koops S, Gruber O, Richter A, Krämer B, Kelly S, Donohoe G, McDonald C, Cannon DM, Corvin A, Gill M, Di Giorgio A, Bertolino A, Lawrie S, Nickson T, Whalley HC, Neilson E, Calhoun VD, Thompson PM, Turner JA, Ehrlich S. Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium. Acta Psychiatr Scand 2017; 135:439-447. [PMID: 28369804 PMCID: PMC5399182 DOI: 10.1111/acps.12718] [Citation(s) in RCA: 65] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/19/2016] [Indexed: 12/22/2022]
Abstract
OBJECTIVE Based on the role of the superior temporal gyrus (STG) in auditory processing, language comprehension and self-monitoring, this study aimed to investigate the relationship between STG cortical thickness and positive symptom severity in schizophrenia. METHOD This prospective meta-analysis includes data from 1987 individuals with schizophrenia collected at seventeen centres around the world that contribute to the ENIGMA Schizophrenia Working Group. STG thickness measures were extracted from T1-weighted brain scans using FreeSurfer. The study performed a meta-analysis of effect sizes across sites generated by a model predicting left or right STG thickness with a positive symptom severity score (harmonized SAPS or PANSS-positive scores), while controlling for age, sex and site. Secondary models investigated relationships between antipsychotic medication, duration of illness, overall illness severity, handedness and STG thickness. RESULTS Positive symptom severity was negatively related to STG thickness in both hemispheres (left: βstd = -0.052; P = 0.021; right: βstd = -0.073; P = 0.001) when statistically controlling for age, sex and site. This effect remained stable in models including duration of illness, antipsychotic medication or handedness. CONCLUSION Our findings further underline the important role of the STG in hallmark symptoms in schizophrenia. These findings can assist in advancing insight into symptom-relevant pathophysiological mechanisms in schizophrenia.
Collapse
Affiliation(s)
- Esther Walton
- Department of Psychology, Georgia State University, Atlanta GA 30302,Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany,Department of Psychology, Institute of Psychology, Psychiatry and Neuroscience, King’s College London, London, SE5 8AF, United Kingdom
| | - Derrek P Hibar
- Imaging Genetics Center, Keck School of Medicine, University of Southern California, Marina del Rey, CA, United States
| | - Theo GM van Erp
- Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, California, USA
| | - Steven G Potkin
- Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, California, USA
| | - Roberto Roiz-Santiañez
- Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria–IDIVAL, Avda. Valdecilla s/n, 39008, Santander, Spain,Cibersam (Centro Investigación Biomédica en Red Salud Mental), Avda. Valdecilla s/n, 39008, Santander, Spain
| | - Benedicto Crespo-Facorro
- Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria–IDIVAL, Avda. Valdecilla s/n, 39008, Santander, Spain,Cibersam (Centro Investigación Biomédica en Red Salud Mental), Avda. Valdecilla s/n, 39008, Santander, Spain
| | - Paula Suarez-Pinilla
- Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria–IDIVAL, Avda. Valdecilla s/n, 39008, Santander, Spain,Cibersam (Centro Investigación Biomédica en Red Salud Mental), Avda. Valdecilla s/n, 39008, Santander, Spain
| | - Neeltje EM Van Haren
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Sonja MC de Zwarte
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Rene S Kahn
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Wiepke Cahn
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Nhat Trung Doan
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway
| | - Kjetil N Jørgensen
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway,Department of Psychiatric Research, Diakonhjemmet Hospital, P.O. Box 85 Vinderen, 0319 Oslo, Norway
| | - Tiril P Gurholt
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway
| | - Ingrid Agartz
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway,Department of Psychiatric Research, Diakonhjemmet Hospital, P.O. Box 85 Vinderen, 0319 Oslo, Norway,Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Ole A Andreassen
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway,NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway
| | - Lars T Westlye
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway
| | - Ingrid Melle
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway,NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway
| | - Akiah O Berg
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway,NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway
| | - Lynn Mørch-Johnsen
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway,Department of Psychiatric Research, Diakonhjemmet Hospital, P.O. Box 85 Vinderen, 0319 Oslo, Norway
| | - Ann Færden
- Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway
| | - Lena Flyckt
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Norra Stationsgatan 69, 113 64 Stockholm, Sweden
| | - Helena Fatouros-Bergman
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Norra Stationsgatan 69, 113 64 Stockholm, Sweden
| | | | - Erik G Jönsson
- NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, P.O. Box 4956 Nydalen, 0424 Oslo, Norway,Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Ryota Hashimoto
- Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University D3, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan,Department of Psychiatry, Osaka University Graduate School of Medicine D3, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Hidenaga Yamamori
- Department of Psychiatry, Osaka University Graduate School of Medicine D3, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Masaki Fukunaga
- Division of Cerebral Integration, National Institute for Physiological Sciences, 38 Nishigonaka Myodaiji, Okazaki, Aichi, 444-8585, Japan
| | - Adrian Preda
- Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, California, USA
| | - Pietro De Rossi
- NESMOS Department (Neurosciences, Mental Health and Sensory Functions), School of Medicine and Psychology, Sapienza University, Rome, Italy,Laboratory of Neuropsychiatry, Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 00179, Rome, Italy
| | - Fabrizio Piras
- Laboratory of Neuropsychiatry, Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 00179, Rome, Italy
| | - Nerisa Banaj
- Laboratory of Neuropsychiatry, Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 00179, Rome, Italy
| | - Federica Piras
- Laboratory of Neuropsychiatry, Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 00179, Rome, Italy
| | - Valentina Ciullo
- Laboratory of Neuropsychiatry, Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 00179, Rome, Italy
| | - Gianfranco Spalletta
- Laboratory of Neuropsychiatry, Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 00179, Rome, Italy,Beth K. and Stuart C. Yudofsky Division of Neuropsychiatry Menninger Department of Psychiatry and Behavioral Sciences Baylor College of Medicine Houston, TX, USA
| | - Raquel E Gur
- Brain Behavior Laboratory, University of Pennsylvania, Philadelphia PA USA 19104
| | - Ruben C Gur
- Brain Behavior Laboratory, University of Pennsylvania, Philadelphia PA USA 19104
| | - Daniel H Wolf
- Brain Behavior Laboratory, University of Pennsylvania, Philadelphia PA USA 19104
| | | | - Lauren M Beard
- Brain Behavior Laboratory, University of Pennsylvania, Philadelphia PA USA 19104
| | - Iris E Sommer
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Sanne Koops
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Oliver Gruber
- Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Germany
| | - Anja Richter
- Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Germany
| | - Bernd Krämer
- Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Germany
| | - Sinead Kelly
- Imaging Genetics Center, Keck School of Medicine, University of Southern California, Marina del Rey, CA, United States,Trinity College, Dublin, Ireland
| | - Gary Donohoe
- Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway, H91 TK33 Galway, Ireland
| | - Colm McDonald
- Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway, H91 TK33 Galway, Ireland
| | - Dara M Cannon
- Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway, H91 TK33 Galway, Ireland
| | | | | | - Annabella Di Giorgio
- Section of Psychiatry and Clinical Psychology, IRCCS Casa Sollievo della Sofferenza, S.G. Rotondo (FG), 71013 Italy
| | - Alessandro Bertolino
- Psychiatric Neuroscience Group, University of Bari ‘Aldo Moro’, Bari, 70124 Italy
| | - Stephen Lawrie
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Morningside, Edinburgh, EH10 5HF
| | - Thomas Nickson
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Morningside, Edinburgh, EH10 5HF
| | - Heather C Whalley
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Morningside, Edinburgh, EH10 5HF
| | - Emma Neilson
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Morningside, Edinburgh, EH10 5HF
| | - Vince D Calhoun
- The Mind Research Network, Albuquerque, NM 87106, United States,Department of Electrical and Computer Engineering, University of New Mexico, Albuquerque, NM 87131, United States
| | - Paul M Thompson
- Imaging Genetics Center, Keck School of Medicine, University of Southern California, Marina del Rey, CA, United States
| | - Jessica A Turner
- Department of Psychology and Neuroscience Institute, Georgia State University, Atlanta GA 30302
| | - Stefan Ehrlich
- Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany,Translational Developmental Neuroscience Section, Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany
| |
Collapse
|
127
|
Bonati U, Holiga Š, Hellbach N, Risterucci C, Bergauer T, Tang W, Hafner P, Thoeni A, Bieri O, Gerlach I, Marquet A, Khwaja O, Sambataro F, Bertolino A, Dukart J, Fischmann A, Fischer D, Czech C. Longitudinal characterization of biomarkers for spinal muscular atrophy. Ann Clin Transl Neurol 2017; 4:292-304. [PMID: 28491897 PMCID: PMC5420809 DOI: 10.1002/acn3.406] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Accepted: 03/05/2017] [Indexed: 12/27/2022] Open
Abstract
Objective Recent advances in understanding Spinal Muscular Atrophy (SMA) etiopathogenesis prompted development of potent intervention strategies and raised need for sensitive outcome measures capable of assessing disease progression and response to treatment. Several biomarkers have been proposed; nevertheless, no general consensus has been reached on the most feasible ones. We observed a wide range of measures over 1 year to assess their ability to monitor the disease status and progression. Methods 18 SMA patients and 19 healthy volunteers (HV) were followed in this 52‐weeks observational study. Quantitative‐MRI (qMRI) of both thighs and clinical evaluation of motor function was performed at baseline, 6, 9 and 12 months follow‐up. Blood samples were taken in patients for molecular characterization at screening, 9 and 12 month follow‐up. Progression, responsiveness and reliability of collected indices were quantified. Correlation analysis was performed to test for potential associations. Results QMRI indices, clinical scales and molecular measures showed high to excellent reliability. Significant differences were found between qMRI of SMA patients and HV. Significant associations were revealed between multiple qMRI measures and functional clinical scales. None of the qMRI, clinical, or molecular measures was able to detect significant disease progression over 1 year. Interpretation We probed a variety of quantitative measures for SMA in a slowly‐progressing disease population over 1 year. The presented measures demonstrated potential to provide a closer link to underlying disease biology as compared to conventional functional scales. The proposed biomarker framework can guide implementation of more sensitive endpoints in future clinical trials and prove their utility in search for novel disease‐modifying therapies.
Collapse
Affiliation(s)
- Ulrike Bonati
- Division of Neuropediatrics University of Basel Children's Hospital Spitalstrasse 334056 Basel Switzerland.,Department of Neurology University of Basel Hospital Petersgraben 44031 Basel Switzerland
| | - Štefan Holiga
- Roche Pharma and Early Development Neuroscience, Ophthalmology and Rare Diseases Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Grenzacherstrasse 1244070 Basel Switzerland.,Max Planck Institute for Human Cognitive and Brain Sciences Stephan str. 1A04103 Leipzig Germany
| | - Nicole Hellbach
- Roche Pharma and Early Development Neuroscience, Ophthalmology and Rare Diseases Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Grenzacherstrasse 1244070 Basel Switzerland
| | - Céline Risterucci
- Roche Pharma and Early Development Neuroscience, Ophthalmology and Rare Diseases Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Grenzacherstrasse 1244070 Basel Switzerland
| | - Tobias Bergauer
- Roche Pharma and Early Development Neuroscience, Ophthalmology and Rare Diseases Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Grenzacherstrasse 1244070 Basel Switzerland
| | - Wakana Tang
- Roche Molecular Diagnostics Research Genomics & Oncology Roche Molecular Systems Inc.4300 Hacienda Dr Pleasanton 94588 California USA
| | - Patricia Hafner
- Division of Neuropediatrics University of Basel Children's Hospital Spitalstrasse 334056 Basel Switzerland.,Department of Neurology University of Basel Hospital Petersgraben 44031 Basel Switzerland.,University Clinics of Internal Medicine Kantonsspital Baselland Bruderholz 4101 Switzerland
| | - Alain Thoeni
- MIAC AG c/o University of Basel Hospital Mittlere-Strasse 834031 Basel Switzerland.,Department of Radiology University of Basel Hospital Petersgraben 44031 Basel Switzerland
| | - Oliver Bieri
- Department of Radiology University of Basel Hospital Petersgraben 44031 Basel Switzerland
| | - Irene Gerlach
- Roche Pharma and Early Development Neuroscience, Ophthalmology and Rare Diseases Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Grenzacherstrasse 1244070 Basel Switzerland
| | - Anne Marquet
- Roche Pharma and Early Development Neuroscience, Ophthalmology and Rare Diseases Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Grenzacherstrasse 1244070 Basel Switzerland
| | - Omar Khwaja
- Roche Pharma and Early Development Neuroscience, Ophthalmology and Rare Diseases Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Grenzacherstrasse 1244070 Basel Switzerland
| | - Fabio Sambataro
- Roche Pharma and Early Development Neuroscience, Ophthalmology and Rare Diseases Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Grenzacherstrasse 1244070 Basel Switzerland
| | - Alessandro Bertolino
- Roche Pharma and Early Development Neuroscience, Ophthalmology and Rare Diseases Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Grenzacherstrasse 1244070 Basel Switzerland
| | - Juergen Dukart
- Roche Pharma and Early Development Neuroscience, Ophthalmology and Rare Diseases Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Grenzacherstrasse 1244070 Basel Switzerland
| | - Arne Fischmann
- Department of Radiology University of Basel Hospital Petersgraben 44031 Basel Switzerland.,Hirslanden Klinik St. Anna St. Anna-Strasse 326006 Luzern Switzerland
| | - Dirk Fischer
- Division of Neuropediatrics University of Basel Children's Hospital Spitalstrasse 334056 Basel Switzerland.,Department of Neurology University of Basel Hospital Petersgraben 44031 Basel Switzerland
| | - Christian Czech
- Roche Pharma and Early Development Neuroscience, Ophthalmology and Rare Diseases Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Grenzacherstrasse 1244070 Basel Switzerland
| |
Collapse
|
128
|
Sacchi S, Novellis VD, Paolone G, Nuzzo T, Iannotta M, Belardo C, Squillace M, Bolognesi P, Rosini E, Motta Z, Frassineti M, Bertolino A, Pollegioni L, Morari M, Maione S, Errico F, Usiello A. Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity. Sci Rep 2017; 7:46288. [PMID: 28393897 PMCID: PMC5385520 DOI: 10.1038/srep46288] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2016] [Accepted: 03/15/2017] [Indexed: 12/18/2022] Open
Abstract
D-aspartate levels in the brain are regulated by the catabolic enzyme D-aspartate oxidase (DDO). D-aspartate activates NMDA receptors, and influences brain connectivity and behaviors relevant to schizophrenia in animal models. In addition, recent evidence reported a significant reduction of D-aspartate levels in the post-mortem brain of schizophrenia-affected patients, associated to higher DDO activity. In the present work, microdialysis experiments in freely moving mice revealed that exogenously administered D-aspartate efficiently cross the blood brain barrier and stimulates L-glutamate efflux in the prefrontal cortex (PFC). Consistently, D-aspartate was able to evoke L-glutamate release in a preparation of cortical synaptosomes through presynaptic stimulation of NMDA, mGlu5 and AMPA/kainate receptors. In support of a potential therapeutic relevance of D-aspartate metabolism in schizophrenia, in vitro enzymatic assays revealed that the second-generation antipsychotic olanzapine, differently to clozapine, chlorpromazine, haloperidol, bupropion, fluoxetine and amitriptyline, inhibits the human DDO activity. In line with in vitro evidence, chronic systemic administration of olanzapine induces a significant extracellular release of D-aspartate and L-glutamate in the PFC of freely moving mice, which is suppressed in Ddo knockout animals. These results suggest that the second-generation antipsychotic olanzapine, through the inhibition of DDO activity, increases L-glutamate release in the PFC of treated mice.
Collapse
Affiliation(s)
- Silvia Sacchi
- Dipartimento di Biotecnologie e Scienze della Vita, Università degli studi dell'Insubria, 21100, Varese, Italy.,The Protein Factory, Politecnico di Milano and Università degli studi dell'Insubria, 20131, Milano, Italy
| | - Vito De Novellis
- Department of Experimental Medicine, Section of Pharmacology, The Second University of Naples (SUN), 80138, Naples, Italy
| | - Giovanna Paolone
- Department of Medical Sciences, Section of Pharmacology, University of Ferrara and National Institute of Neuroscience, 44100, Ferrara, Italy
| | - Tommaso Nuzzo
- Laboratory of Behavioural Neuroscience, Ceinge Biotecnologie Avanzate, 80145, Naples, Italy.,Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Second University of Naples (SUN), 81100, Caserta, Italy
| | - Monica Iannotta
- Department of Experimental Medicine, Section of Pharmacology, The Second University of Naples (SUN), 80138, Naples, Italy
| | - Carmela Belardo
- Department of Experimental Medicine, Section of Pharmacology, The Second University of Naples (SUN), 80138, Naples, Italy
| | - Marta Squillace
- Laboratory of Behavioural Neuroscience, Ceinge Biotecnologie Avanzate, 80145, Naples, Italy
| | - Paolo Bolognesi
- Department of Medical Sciences, Section of Pharmacology, University of Ferrara and National Institute of Neuroscience, 44100, Ferrara, Italy
| | - Elena Rosini
- Dipartimento di Biotecnologie e Scienze della Vita, Università degli studi dell'Insubria, 21100, Varese, Italy.,The Protein Factory, Politecnico di Milano and Università degli studi dell'Insubria, 20131, Milano, Italy
| | - Zoraide Motta
- Dipartimento di Biotecnologie e Scienze della Vita, Università degli studi dell'Insubria, 21100, Varese, Italy
| | - Martina Frassineti
- Department of Medical Sciences, Section of Pharmacology, University of Ferrara and National Institute of Neuroscience, 44100, Ferrara, Italy
| | - Alessandro Bertolino
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, 70121, Bari, Italy
| | - Loredano Pollegioni
- Dipartimento di Biotecnologie e Scienze della Vita, Università degli studi dell'Insubria, 21100, Varese, Italy.,The Protein Factory, Politecnico di Milano and Università degli studi dell'Insubria, 20131, Milano, Italy
| | - Michele Morari
- Department of Medical Sciences, Section of Pharmacology, University of Ferrara and National Institute of Neuroscience, 44100, Ferrara, Italy
| | - Sabatino Maione
- Department of Experimental Medicine, Section of Pharmacology, The Second University of Naples (SUN), 80138, Naples, Italy
| | - Francesco Errico
- Laboratory of Behavioural Neuroscience, Ceinge Biotecnologie Avanzate, 80145, Naples, Italy.,Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", 80131, Naples, Italy
| | - Alessandro Usiello
- Laboratory of Behavioural Neuroscience, Ceinge Biotecnologie Avanzate, 80145, Naples, Italy.,Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Second University of Naples (SUN), 81100, Caserta, Italy
| |
Collapse
|
129
|
Di Carlo P, Pergola G, Cariello M, Bonvino A, Mancini M, Taurisano P, Caforio G, Bertolino A, Blasi G. Grey Matter Volume Patterns in Thalamic Nuclei are Associated with Schizotypy in Healthy Subjects. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
IntroductionSchizotypy refers to a set of temporally stable traits that are observed in the general population and that resemble, in attenuated form, the symptoms of schizophrenia. In a previous work, we identified volumetric patterns in thalamic subregions which were associated with disease status, and trained a random forests classifier, accounting for such thalamic volumetric patterns, that discriminated healthy controls (HC) from patients with schizophrenia (SCZ) (81% accuracy) [1].Objectivesi) to assess performance of random forests classifier developed by Pergola and coworkers [1], in an independent sample of healthy subjects; ii) to test whether false positives (FP), i.e. HC classified as SCZ based on such classifier would be associated with greater schizotypy compared with true negatives (TN), i.e. HC classified as such.MethodsA total of 167 HC participated in the MRI study and filled the Schizotypal Personality Questionnaire (SPQ). We pre-processed MRI data with SPM8 and DARTEL. Then, we used thalamic grey matter volumes (GMV) as features in the random forests prediction of disease status at the single subject level. Finally, we tested SPQ scores differences between FP and TN with Mann-Whitney test.ResultsThe classification accuracy was 71%. FP had greater SPQ scores compared to TN (P = 0.007).ConclusionsClassification accuracy of our classifier in an independent sample suggests that thalamic GMV patterns are reproducible markers of disease status. Furthermore, the present results also suggest that variability of thalamic GMV patterns in HC may have relevance for subclinical phenotypes related to schizophrenia spectrum.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
130
|
Passiatore R, Antonucci L, Di Carlo P, Papalino M, Monda A, Taurisano P, Bertolino A, Pergola G, Blasi G. A thalamo-cortical genetic co-expression network is associated with thalamic functional connectivity linked with familial risk for schizophrenia. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.1617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionThe genetic architecture of schizophrenia is based on polygenic trajectories. Indeed, genes converge on molecular co-expression pathways, which may be associated with heritable characteristics of patients and their siblings, called intermediate phenotypes, such as prefrontal anomalies and thalamic dysconnectivity during attentional control [2].ObjectivesHere, we investigated in healthy humans association between co-expression of genes with coordinated thalamo-prefrontal (THA-PFC) expression and functional connectivity during attentional control.MethodsWe used Brainspan dataset to characterize a coordinated THA-PFC expression gene list by correlating post-mortem gene expression in both areas (Kendall's Tau>.76, Bonferroni P < .05). Then, we identified a PFC co-expression network1 and tested all gene sets for THA-PFC and PGC loci [3] enrichments (P < .05). SNPs associated with the first principal component of the resulting enriched gene set were combined in a Polygenic Co-Expression Index (PCI) [1]. We conducted Independent Component Analysis (ICA) on attentional control fMRI data (n = 265) and selected Independent Components (ICs) including the thalamus and being highly correlated with an attentional control network2. Multiple regressions were conducted (predictor: PCI) using a thalamic cluster previously associated with familial risk for schizophrenia [2] as ROI (FWE P < .05).ResultsIn one of the 8 ICs of interest there was a positive effect of PCI on thalamic connectivity strength in a cluster overlapping with our ROI (Z = 4.3).ConclusionDecreased co-expression of genes included in PCI predicts thalamic dysconnectivity during attentional control, suggesting a novel co-regulated molecular pathway potentially implicated in genetic risk for schizophrenia.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
131
|
Pergola G, Quarto T, Papalino M, Di Carlo P, Selvaggi P, Gelao B, Blasi G, Bertolino A. Association of Inter-individual Differences in Imaging Markers with Schizophrenia Phenotypes. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionNeuroimaging studies have identified several candidate biomarkers of schizophrenia. However, it is unclear whether the considerable variability in these neurobiological correlates between patients can be translated into the clinical setting.ObjectivesWe aimed to identify neuroimaging predictors of clinical course in patients with schizophrenia. Combined with the identification of genetically determined markers of schizophrenia risk, our studies aimed to elucidate the biological basis and the clinical relevance of inter-individual variability between patients.MethodsWe included over 150 patients with schizophrenia and 279 healthy volunteers across five neuroimaging centers in the framework of the IMAGEMEND project [1]. We performed multiple studies on MRI scans using random forests and ROC curves to predict clinical course. Data from healthy controls served to normalize the data from the clinical population and to provide a benchmark for the findings.ResultsWe identified ensembles of neuroimaging markers and of genetic variants predictive of clinical course. Results highlight that (i) brain imaging carries significant clinical information, (ii) clinical information at baseline can considerably increase prediction accuracy.ConclusionThe methodological challenges and the results will be discussed in the context of recent findings from other multi-site studies. We conclude that brain imaging data on their own right are relevant to stratify patients in terms of clinical course; however, complementing these data with other modalities such as genetics and clinical information is necessary to further develop the field towards clinical application of the predictions.Disclosure of interestGiulio Pergola is the academic supervisor of a Hoffmann-La Roche Collaboration grant that partially funds his salary.
Collapse
|
132
|
Bucci P, Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Maj M. The Impact of Premorbid Functioning on Outcome Indices in a Large Sample of Italian Patients with Schizophrenia. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionAn impairment of premorbid adjustment (PA) has been regarded among poor prognostic indicators of schizophrenia. Some discrepancies in the literature suggest the usefulness of further characterizations of its impact on different aspects of the disease.AimsThe present study aimed to investigate the association of poor PA with psychopathology, neurocognition and real-life functioning in patients with schizophrenia recruited within the multicenter study of the Italian network for research on psychoses. functioning during childhood and adolescence (early adjustment) was assessed also in a group of healthy controls (HC) and one of unaffected relatives of patients (UR).MethodsGroup comparisons were performed between patients with poor and those with good PA. Differences in frequency of poor early adjustment were investigated among patients, HC and UR.ResultsPatients with poor PA, as compared to those with good PA, showed earlier age of onset, more severe negative symptoms and disorganization, greater impairment on all cognitive domains with the exception of attention/vigilance and worse real-life functioning in the considered areas (interpersonal relationships, community activities and work abilities). The pattern of poor early adjustment was more frequent in patients with respect to UR and HC and, to a less degree, in UR with respect to HC.ConclusionsOur findings confirm that poor PA in schizophrenia is associated with poorer illness outcome, and offer a further characterization of PA impact on different psychopathological and cognitive domains. They also suggest that poor early adjustment is a candidate endophenotype of schizophrenia, occurring in patients and their unaffected relatives.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
133
|
Pergola G, Trizio S, Di Carlo P, Taurisano P, Mancini M, Amoroso N, Nettis MA, Andriola I, Caforio G, Popolizio T, Rampino A, Di Giorgio A, Bertolino A, Blasi G. Grey matter volume patterns in thalamic nuclei are associated with familial risk for schizophrenia. Schizophr Res 2017; 180:13-20. [PMID: 27449252 DOI: 10.1016/j.schres.2016.07.005] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/19/2016] [Revised: 07/05/2016] [Accepted: 07/07/2016] [Indexed: 12/19/2022]
Abstract
Previous evidence suggests reduced thalamic grey matter volume (GMV) in patients with schizophrenia (SCZ). However, it is not considered an intermediate phenotype for schizophrenia, possibly because previous studies did not assess the contribution of individual thalamic nuclei and employed univariate statistics. Here, we hypothesized that multivariate statistics would reveal an association of GMV in different thalamic nuclei with familial risk for schizophrenia. We also hypothesized that accounting for the heterogeneity of thalamic GMV in healthy controls would improve the detection of subjects at familial risk for the disorder. We acquired MRI scans for 96 clinically stable SCZ, 55 non-affected siblings of patients with schizophrenia (SIB), and 249 HC. The thalamus was parceled into seven regions of interest (ROIs). After a canonical univariate analysis, we used GMV estimates of thalamic ROIs, together with total thalamic GMV and premorbid intelligence, as features in Random Forests to classify HC, SIB, and SCZ. Then, we computed a Misclassification Index for each individual and tested the improvement in SIB detection after excluding a subsample of HC misclassified as patients. Random Forests discriminated SCZ from HC (accuracy=81%) and SIB from HC (accuracy=75%). Left anteromedial thalamic volumes were significantly associated with both multivariate classifications (p<0.05). Excluding HC misclassified as SCZ improved greatly HC vs. SIB classification (Cohen's d=1.39). These findings suggest that multivariate statistics identify a familial background associated with thalamic GMV reduction in SCZ. They also suggest the relevance of inter-individual variability of GMV patterns for the discrimination of individuals at familial risk for the disorder.
Collapse
Affiliation(s)
- Giulio Pergola
- Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Silvestro Trizio
- Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Pasquale Di Carlo
- Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Paolo Taurisano
- Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Marina Mancini
- Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Nicola Amoroso
- National Institute of Nuclear of Physics-Branch of Bari, Via E. Orabona 4, 70125 Bari, Italy; Interuniversity Department of Physics 'M. Merlin', University of Bari 'Aldo Moro', Via E. Orabona 4, 70125 Bari, Italy
| | - Maria Antonietta Nettis
- Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Ileana Andriola
- Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Grazia Caforio
- Psychiatry Unit, Bari University Hospital, Piazza Giulio Cesare 11, 70124, Bari, Italy
| | - Teresa Popolizio
- IRCCS "Casa Sollievo della Sofferenza", Viale Cappuccini, 1, I-71013 San Giovanni Rotondo, Italy
| | - Antonio Rampino
- Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy; Psychiatry Unit, Bari University Hospital, Piazza Giulio Cesare 11, 70124, Bari, Italy
| | - Annabella Di Giorgio
- IRCCS "Casa Sollievo della Sofferenza", Viale Cappuccini, 1, I-71013 San Giovanni Rotondo, Italy
| | - Alessandro Bertolino
- Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy; Psychiatry Unit, Bari University Hospital, Piazza Giulio Cesare 11, 70124, Bari, Italy
| | - Giuseppe Blasi
- Psychiatry Unit, Bari University Hospital, Piazza Giulio Cesare 11, 70124, Bari, Italy; IRCCS "Casa Sollievo della Sofferenza", Viale Cappuccini, 1, I-71013 San Giovanni Rotondo, Italy.
| |
Collapse
|
134
|
Pergola G, Di Carlo P, D'Ambrosio E, Gelao B, Fazio L, Papalino M, Monda A, Scozia G, Pietrangelo B, Attrotto M, Apud JA, Chen Q, Mattay VS, Rampino A, Caforio G, Weinberger DR, Blasi G, Bertolino A. DRD2 co-expression network and a related polygenic index predict imaging, behavioral and clinical phenotypes linked to schizophrenia. Transl Psychiatry 2017; 7:e1006. [PMID: 28094815 PMCID: PMC5545721 DOI: 10.1038/tp.2016.253] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2016] [Revised: 09/28/2016] [Accepted: 10/13/2016] [Indexed: 12/14/2022] Open
Abstract
Genetic risk for schizophrenia (SCZ) is determined by many genetic loci whose compound biological effects are difficult to determine. We hypothesized that co-expression pathways of SCZ risk genes are associated with system-level brain function and clinical phenotypes of SCZ. We examined genetic variants related to the dopamine D2 receptor gene DRD2 co-expression pathway and associated them with working memory (WM) behavior, the related brain activity and treatment response. Using two independent post-mortem prefrontal messenger RNA (mRNA) data sets (total N=249), we identified a DRD2 co-expression pathway enriched for SCZ risk genes. Next, we identified non-coding single-nucleotide polymorphisms (SNPs) associated with co-expression of this pathway. These SNPs were associated with regulatory genetic loci in the dorsolateral prefrontal cortex (P<0.05). We summarized their compound effect on co-expression into a Polygenic Co-expression Index (PCI), which predicted DRD2 pathway co-expression in both mRNA data sets (all P<0.05). We associated the PCI with brain activity during WM performance in two independent samples of healthy individuals (total N=368) and 29 patients with SCZ who performed the n-back task. Greater predicted DRD2 pathway prefrontal co-expression was associated with greater prefrontal activity and longer WM reaction times (all corrected P<0.05), thus indicating inefficient WM processing. Blind prediction of treatment response to antipsychotics in two independent samples of patients with SCZ suggested better clinical course of patientswith greater PCI (total N=87; P<0.05). The findings on this DRD2 co-expression pathway are a proof of concept that gene co-expression can parse SCZ risk genes into biological pathways associated with intermediate phenotypes as well as with clinically meaningful information.
Collapse
Affiliation(s)
- G Pergola
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - P Di Carlo
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - E D'Ambrosio
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, USA
| | - B Gelao
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - L Fazio
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - M Papalino
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - A Monda
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - G Scozia
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - B Pietrangelo
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - M Attrotto
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - J A Apud
- National Institutes of Health, National Institute of Mental Health, Clinical and Translational Neuroscience Branch, NIMH, Bethesda, MD, USA
| | - Q Chen
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, USA
| | - V S Mattay
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, USA
- Departments of Neurology and Radiology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - A Rampino
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
- Institute of Psychiatry, Department of Neuroscience, Sense Organs and Locomotive System, Bari University Hospital, Bari, Italy
| | - G Caforio
- Institute of Psychiatry, Department of Neuroscience, Sense Organs and Locomotive System, Bari University Hospital, Bari, Italy
| | - D R Weinberger
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, USA
- Departments of Psychiatry, Neurology, Neuroscience and The Mckusick-Nathans Institute of Genomic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - G Blasi
- Institute of Psychiatry, Department of Neuroscience, Sense Organs and Locomotive System, Bari University Hospital, Bari, Italy
| | - A Bertolino
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
- Institute of Psychiatry, Department of Neuroscience, Sense Organs and Locomotive System, Bari University Hospital, Bari, Italy
| |
Collapse
|
135
|
Quarto T, Fasano MC, Taurisano P, Fazio L, Antonucci LA, Gelao B, Romano R, Mancini M, Porcelli A, Masellis R, Pallesen KJ, Bertolino A, Blasi G, Brattico E. Interaction between DRD2 variation and sound environment on mood and emotion-related brain activity. Neuroscience 2016; 341:9-17. [PMID: 27867061 DOI: 10.1016/j.neuroscience.2016.11.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 11/04/2016] [Accepted: 11/07/2016] [Indexed: 02/02/2023]
Abstract
Sounds, like music and noise, are capable of reliably affecting individuals' mood and emotions. However, these effects are highly variable across individuals. A putative source of variability is genetic background. Here we explored the interaction between a functional polymorphism of the dopamine D2 receptor gene (DRD2 rs1076560, G>T, previously associated with the relative expression of D2S/L isoforms) and sound environment on mood and emotion-related brain activity. Thirty-eight healthy subjects were genotyped for DRD2 rs1076560 (G/G=26; G/T=12) and underwent functional magnetic resonance imaging (fMRI) during performance of an implicit emotion-processing task while listening to music or noise. Individual variation in mood induction was assessed before and after the task. Results showed mood improvement after music exposure in DRD2GG subjects and mood deterioration after noise exposure in GT subjects. Moreover, the music, as opposed to noise environment, decreased the striatal activity of GT subjects as well as the prefrontal activity of GG subjects while processing emotional faces. These findings suggest that genetic variability of dopamine receptors affects sound environment modulations of mood and emotion processing.
Collapse
Affiliation(s)
- T Quarto
- Cognitive Brain Research Unit, Institute of Behavioral Science, University of Helsinki, Helsinki, Finland; Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - M C Fasano
- Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy; Center for Music in the Brain (MIB), Department of Clinical Medicine, Aarhus University & Royal Academy of Music Aarhus/Aalborg, Aarhus, Denmark
| | - P Taurisano
- Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - L Fazio
- Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - L A Antonucci
- Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy; Department of Education Science, Psychology and Communication Science, University of Bari "Aldo Moro", Bari, Italy
| | - B Gelao
- Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - R Romano
- Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - M Mancini
- Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - A Porcelli
- Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - R Masellis
- Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - K J Pallesen
- The Research Clinic for Functional Disorders and Psychosomatics, Aarhus University, Aarhus, Denmark
| | - A Bertolino
- Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - G Blasi
- Department of Basic Medical Sciences, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - E Brattico
- Cognitive Brain Research Unit, Institute of Behavioral Science, University of Helsinki, Helsinki, Finland; Center for Music in the Brain (MIB), Department of Clinical Medicine, Aarhus University & Royal Academy of Music Aarhus/Aalborg, Aarhus, Denmark.
| |
Collapse
|
136
|
Dukart J, Sambataro F, Bertolino A. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers. J Alzheimers Dis 2016; 49:1143-59. [PMID: 26599054 DOI: 10.3233/jad-150570] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
A variety of imaging, neuropsychological, and genetic biomarkers have been suggested as potential biomarkers for the identification of mild cognitive impairment (MCI) in patients who later develop Alzheimer's disease (AD). Here, we systematically evaluated the most promising combinations of these biomarkers regarding discrimination between stable and converter MCI and reflection of disease staging. Alzheimer's Disease Neuroimaging Initiative data of AD (n = 144), controls (n = 112), stable (n = 265) and converter (n = 177) MCI, for which apolipoprotein E status, neuropsychological evaluation, and structural, glucose, and amyloid imaging were available, were included in this study. Naïve Bayes classifiers were built on AD and controls data for all possible combinations of these biomarkers, with and without stratification by amyloid status. All classifiers were then applied to the MCI cohorts. We obtained an accuracy of 76% for discrimination between converter and stable MCI with glucose positron emission tomography as a single biomarker. This accuracy increased to about 87% when including further imaging modalities and genetic information. We also identified several biomarker combinations as strong predictors of time to conversion. Use of amyloid validated training data resulted in increased sensitivities and decreased specificities for differentiation between stable and converter MCI when amyloid was included as a biomarker but not for other classifier combinations. Our results indicate that fully independent classifiers built only on AD and controls data and combining imaging, genetic, and/or neuropsychological biomarkers can more reliably discriminate between stable and converter MCI than single modality classifiers. Several biomarker combinations are identified as strongly predictive for the time to conversion to AD.
Collapse
Affiliation(s)
- Juergen Dukart
- F. Hoffmann-La Roche, Roche Innovation Centre Basel, Basel, Switzerland.,Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
| | - Fabio Sambataro
- F. Hoffmann-La Roche, Roche Innovation Centre Basel, Basel, Switzerland
| | - Alessandro Bertolino
- F. Hoffmann-La Roche, Roche Innovation Centre Basel, Basel, Switzerland.,Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari, Bari, Italy
| |
Collapse
|
137
|
Rocca P, Galderisi S, Rossi A, Bertolino A, Rucci P, Gibertoni D, Montemagni C, Sigaudo M, Mucci A, Bucci P, Acciavatti T, Aguglia E, Amore M, Bellomo A, De Ronchi D, Dell'Osso L, Di Fabio F, Girardi P, Goracci A, Marchesi C, Monteleone P, Niolu C, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Zeppegno P, Maj M. Social cognition in people with schizophrenia: a cluster-analytic approach. Psychol Med 2016; 46:2717-2729. [PMID: 27649341 DOI: 10.1017/s0033291716001100] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND The study aimed to subtype patients with schizophrenia on the basis of social cognition (SC), and to identify cut-offs that best discriminate among subtypes in 809 out-patients recruited in the context of the Italian Network for Research on Psychoses. METHOD A two-step cluster analysis of The Awareness of Social Inference Test (TASIT), the Facial Emotion Identification Test and Mayer-Salovey-Caruso Emotional Intelligence Test scores was performed. Classification and regression tree analysis was used to identify the cut-offs of variables that best discriminated among clusters. RESULTS We identified three clusters, characterized by unimpaired (42%), impaired (50.4%) and very impaired (7.5%) SC. Three theory-of-mind domains were more important for the cluster definition as compared with emotion perception and emotional intelligence. Patients more able to understand simple sarcasm (⩾14 for TASIT-SS) were very likely to belong to the unimpaired SC cluster. Compared with patients in the impaired SC cluster, those in the very impaired SC cluster performed significantly worse in lie scenes (TASIT-LI <10), but not in simple sarcasm. Moreover, functioning, neurocognition, disorganization and SC had a linear relationship across the three clusters, while positive symptoms were significantly lower in patients with unimpaired SC as compared with patients with impaired and very impaired SC. On the other hand, negative symptoms were highest in patients with impaired levels of SC. CONCLUSIONS If replicated, the identification of such subtypes in clinical practice may help in tailoring rehabilitation efforts to the person's strengths to gain more benefit to the person.
Collapse
Affiliation(s)
- P Rocca
- Department of Neuroscience, Section of Psychiatry,University of Turin,Turin,Italy
| | - S Galderisi
- Department of Psychiatry,University of Naples SUN,Naples,Italy
| | - A Rossi
- Department of Biotechnological and Applied Clinical Sciences, Section of Psychiatry,University of L'Aquila,L'Aquila,Italy
| | - A Bertolino
- Department of Neurological and Psychiatric Sciences,University of Bari,Bari,Italy
| | - P Rucci
- Department of Biomedical and Neuromotor Sciences,University of Bologna,Bologna,Italy
| | - D Gibertoni
- Department of Biomedical and Neuromotor Sciences,University of Bologna,Bologna,Italy
| | - C Montemagni
- Department of Neuroscience, Section of Psychiatry,University of Turin,Turin,Italy
| | - M Sigaudo
- Department of Neuroscience, Section of Psychiatry,University of Turin,Turin,Italy
| | - A Mucci
- Department of Psychiatry,University of Naples SUN,Naples,Italy
| | - P Bucci
- Department of Psychiatry,University of Naples SUN,Naples,Italy
| | - T Acciavatti
- Department of Neuroscience and Imaging, Chair of Psychiatry,G. d'Annunzio University,Chieti,Italy
| | - E Aguglia
- Department of Clinical and Molecular Biomedicine, Psychiatry Unit,University of Catania,Catania,Italy
| | - M Amore
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, Section of Psychiatry,University of Genoa,Genoa,Italy
| | - A Bellomo
- Department of Medical Sciences, Psychiatry Unit,University of Foggia,Foggia,Italy
| | - D De Ronchi
- Department of Biomedical and Neuromotor Sciences, Section of Psychiatry,University of Bologna,Bologna,Italy
| | - L Dell'Osso
- Department of Clinical and Experimental Medicine, Section of Psychiatry,University of Pisa,Pisa,Italy
| | - F Di Fabio
- Department of Neurology and Psychiatry,Sapienza University of Rome,Rome,Italy
| | - P Girardi
- Department of Neurosciences, Mental Health and Sensory Organs,S. Andrea Hospital, Sapienza University of Rome,Rome,Italy
| | - A Goracci
- Department of Molecular Medicine and Clinical Department of Mental Health,University of Siena,Siena,Italy
| | - C Marchesi
- Department of Neuroscience, Psychiatry Unit,University of Parma,Parma,Italy
| | - P Monteleone
- Department of Medicine and Surgery, Chair of Psychiatry,University of Salerno,Salerno,Italy
| | - C Niolu
- Department of Systems Medicine, Chair of Psychiatry,Tor Vergata University of Rome,Rome,Italy
| | - F Pinna
- Department of Public Health, Clinical and Molecular Medicine, Section of Psychiatry,University of Cagliari,Cagliari,Italy
| | - R Roncone
- Department of Life, Health and Environmental Sciences, Unit of Psychiatry,University of L'Aquila,L'Aquila,Italy
| | - E Sacchetti
- Psychiatric Unit,School of Medicine, University of Brescia,Brescia,Italy
| | - P Santonastaso
- Psychiatric Clinic, Department of Neurosciences,University of Padua,Padua,Italy
| | - P Zeppegno
- Department of Translational Medicine, Psychiatric Unit,University of Eastern Piedmont,Novara,Italy
| | - M Maj
- Department of Psychiatry,University of Naples SUN,Naples,Italy
| |
Collapse
|
138
|
Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Blasi G, Comparelli A, Di Giannantonio M, Goracci A, Marchesi C, Monteleone P, Montemagni C, Pinna F, Roncone R, Siracusano A, Stratta P, Torti MC, Vita A, Zeppegno P, Chieffi M, Maj M. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophr Res 2016; 175:154-160. [PMID: 27209527 DOI: 10.1016/j.schres.2016.04.043] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Revised: 04/20/2016] [Accepted: 04/25/2016] [Indexed: 11/25/2022]
Abstract
RATIONALE Variables influencing real-life functioning have repeatedly been modeled in schizophrenia subjects but not systematically investigated in their unaffected first-degree relatives (SRs), in whom milder forms of deficits reported in schizophrenia have been observed, but confounders of clinical cohorts are not in play. Demonstrating that pathways to functional outcome are similar between patients and SRs would validate structural models developed in schizophrenia subjects. The present multicenter study aimed to explore whether variables associated with real-life functioning are similar in schizophrenia patients and their unaffected relatives. METHODS The study sample included 921 schizophrenia patients, 379 SRs and 780 healthy controls. Structural Equation Models (SEMs) were used in patients and SRs to test associations of psychopathological dimensions, neurocognition, social cognition, resilience, perceived stigma and functional capacity with real-life functioning domains, impaired in both patients and SRs. RESULTS Interpersonal Relationships and Work Skills were the only functional domains impaired in both patients and SRs. For both domains, functional impairment in patients was found to predict impairment in unaffected relatives, suggesting the involvement of similar illness-related vulnerability factors. In both groups variables significantly associated with Interpersonal Relationships included Social Cognition, Neurocognition, Avolition, Resilience, Disorganization, Perceived Stigma and Gender, and those significantly associated with Work Skills included Social Cognition, Neurocognition and Disorganization. CONCLUSIONS Pathways to functional outcome for Interpersonal relationships and Work skills are similar between schizophrenia patients and their unaffected first-degree relatives. These findings validate, in the absence of confounders of clinical cohorts, structural models of determinants of functional outcome in people with schizophrenia.
Collapse
Affiliation(s)
- Silvana Galderisi
- Department of Psychiatry, University of Naples SUN, Largo Madonna delle Grazie, 80138 Naples, Italy.
| | - Alessandro Rossi
- Department of Biotechnological and Applied Clinical Sciences, Section of Psychiatry, University of L'Aquila, L'Aquila, Italy
| | - Paola Rocca
- Department of Neuroscience, Section of Psychiatry, University of Turin, Turin, Italy
| | - Alessandro Bertolino
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - Armida Mucci
- Department of Psychiatry, University of Naples SUN, Largo Madonna delle Grazie, 80138 Naples, Italy
| | - Paola Bucci
- Department of Psychiatry, University of Naples SUN, Largo Madonna delle Grazie, 80138 Naples, Italy
| | - Paola Rucci
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | - Dino Gibertoni
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | - Eugenio Aguglia
- Department of Clinical and Molecular Biomedicine, Psychiatry Unit, University of Catania, Catania, Italy
| | - Mario Amore
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, Section of Psychiatry, University of Genoa, Genoa, Italy
| | - Giuseppe Blasi
- Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - Anna Comparelli
- Department of Neurosciences, Mental Health and Sensory Organs, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy
| | - Massimo Di Giannantonio
- Department of Neuroscience and Imaging, Chair of Psychiatry, G. d'Annunzio University, Chieti, Italy
| | - Arianna Goracci
- Department of Molecular Medicine and Clinical Department of Mental Health, University of Siena, Siena, Italy
| | - Carlo Marchesi
- Department of Neuroscience, Psychiatry Unit, University of Parma, Parma, Italy
| | - Palmiero Monteleone
- Department of Medicine and Surgery, Chair of Psychiatry, University of Salerno, Salerno, Italy
| | - Cristiana Montemagni
- Department of Neuroscience, Section of Psychiatry, University of Turin, Turin, Italy
| | - Federica Pinna
- Department of Public Health, Clinical and Molecular Medicine, Section of Psychiatry, University of Cagliari, Cagliari, Italy
| | - Rita Roncone
- Department of Life, Health and Environmental Sciences, Unit of Psychiatry, University of L'Aquila, L'Aquila, Italy
| | - Alberto Siracusano
- Department of Systems Medicine, Chair of Psychiatry, Tor Vergata University of Rome, Rome, Italy
| | - Paolo Stratta
- Department of Biotechnological and Applied Clinical Sciences, Section of Psychiatry, University of L'Aquila, L'Aquila, Italy
| | - Maria Chiara Torti
- Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy
| | - Antonio Vita
- Psychiatric Unit, School of Medicine, University of Brescia, and Department of Mental Health, Spedali Civili Hospital, Brescia, Italy
| | - Patrizia Zeppegno
- Department of Translational Medicine, Psychiatric Unit, University of Eastern Piedmont, Novara, Italy
| | - Marcello Chieffi
- Department of Psychiatry, University of Naples SUN, Largo Madonna delle Grazie, 80138 Naples, Italy
| | - Mario Maj
- Department of Psychiatry, University of Naples SUN, Largo Madonna delle Grazie, 80138 Naples, Italy
| | | |
Collapse
|
139
|
Mazzola V, Arciero G, Fazio L, Lanciano T, Gelao B, Popolizio T, Vuilleumier P, Bondolfi G, Bertolino A. What Impact does An Angry Context have Upon Us? The Effect of Anger on Functional Connectivity of the Right Insula and Superior Temporal Gyri. Front Behav Neurosci 2016; 10:109. [PMID: 27375449 PMCID: PMC4893496 DOI: 10.3389/fnbeh.2016.00109] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2016] [Accepted: 05/20/2016] [Indexed: 11/29/2022] Open
Abstract
Being in a social world requires an understanding of other people that is co-determined in its meaning by the situation at hand. Therefore, we investigated the underlying neural activation occurring when we encounter someone acting in angry or joyful situation. We hypothesized a dynamic interplay between the right insula, both involved in mapping visceral states associated with emotional experiences and autonomic control, and the bilateral superior temporal gyri (STG), part of the “social brain”, when facing angry vs. joyful situations. Twenty participants underwent a functional magnetic resonance imaging (fMRI) scanning session while watching video clips of actors grasping objects in joyful and angry situations. The analyses of functional connectivity, psychophysiological interaction (PPI) and dynamic causal modeling (DCM), all revealed changes in functional connectivity associated with the angry situation. Indeed, the DCM model showed that the modulatory effect of anger increased the ipsilateral forward connection from the right insula to the right STG, while it suppressed the contralateral one. Our findings reveal a critical role played by the right insula when we are engaged in angry situations. In addition, they suggest that facing angry people modulates the effective connectivity between these two nodes associated, respectively, with autonomic responses and bodily movements and human-agent motion recognition. Taken together, these results add knowledge to the current understanding of hierarchical brain network for social cognition.
Collapse
Affiliation(s)
- Viridiana Mazzola
- Department of Mental Health, Psychiatry de Liaison, University Hospitals of GenevaGeneva, Switzerland; Laboratory for Behavioral Neurology and Imaging of Cognition, Department of Neurology, University Hospital and Department of Neuroscience, Medical School University of GenevaGeneva, Switzerland
| | - Giampiero Arciero
- Department of Mental Health, Psychiatry de Liaison, University Hospitals of GenevaGeneva, Switzerland; Institute of Post-Rationalist Psychology IPRARome, Italy
| | - Leonardo Fazio
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro" Bari, Italy
| | - Tiziana Lanciano
- Department of Education, Psychology, Communication, University of Bari Bari, Italy
| | - Barbara Gelao
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro" Bari, Italy
| | - Teresa Popolizio
- Department of Neuroradiology, "Casa Sollievo della Sofferenza" IRCCSS San Giovanni Rotondo, FG, Italy
| | - Patrik Vuilleumier
- Laboratory for Behavioral Neurology and Imaging of Cognition, Department of Neurology, University Hospital and Department of Neuroscience, Medical School University of Geneva Geneva, Switzerland
| | - Guido Bondolfi
- Department of Mental Health, Psychiatry de Liaison, University Hospitals of GenevaGeneva, Switzerland; Department of Psychiatry, University of GenevaGeneva, Switzerland
| | - Alessandro Bertolino
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro" Bari, Italy
| |
Collapse
|
140
|
Cao H, Bertolino A, Walter H, Schneider M, Schäfer A, Taurisano P, Blasi G, Haddad L, Grimm O, Otto K, Dixson L, Erk S, Mohnke S, Heinz A, Romanczuk-Seiferth N, Mühleisen TW, Mattheisen M, Witt SH, Cichon S, Noethen M, Rietschel M, Tost H, Meyer-Lindenberg A. Altered Functional Subnetwork During Emotional Face Processing: A Potential Intermediate Phenotype for Schizophrenia. JAMA Psychiatry 2016; 73:598-605. [PMID: 27145286 DOI: 10.1001/jamapsychiatry.2016.0161] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE Although deficits in emotional processing are prominent in schizophrenia, it has been difficult to identify neural mechanisms related to the genetic risk for this highly heritable illness. Prior studies have not found consistent regional activation or connectivity alterations in first-degree relatives compared with healthy controls, suggesting that a more comprehensive search for connectomic biomarkers is warranted. OBJECTIVES To identify a potential systems-level intermediate phenotype linked to emotion processing in schizophrenia and to examine the psychological association, task specificity, test-retest reliability, and clinical validity of the identified phenotype. DESIGN, SETTING, AND PARTICIPATIONS The study was performed in university research hospitals from June 1, 2008, through December 31, 2013. We examined 58 unaffected first-degree relatives of patients with schizophrenia and 94 healthy controls with an emotional face-matching functional magnetic resonance imaging paradigm. Test-retest reliability was analyzed with an independent sample of 26 healthy participants. A clinical association study was performed in 31 patients with schizophrenia and 45 healthy controls. Data analysis was performed from January 1 to September 30, 2014. MAIN OUTCOMES AND MEASURES Conventional amygdala activity and seeded connectivity measures, graph-based global and local network connectivity measures, Spearman rank correlation, intraclass correlation, and gray matter volumes. RESULTS Among the 152 volunteers included in the relative-control sample, 58 were unaffected first-degree relatives of patients with schizophrenia (mean [SD] age, 33.29 [12.56]; 38 were women), and 94 were healthy controls without a first-degree relative with mental illness (mean [SD] age, 32.69 [10.09] years; 55 were women). A graph-theoretical connectivity approach identified significantly decreased connectivity in a subnetwork that primarily included the limbic cortex, visual cortex, and subcortex during emotional face processing (cluster-level P corrected for familywise error = .006) in relatives compared with controls. The connectivity of the same subnetwork was significantly decreased in patients with schizophrenia (F = 6.29, P = .01). Furthermore, we found that this subnetwork connectivity measure was negatively correlated with trait anxiety scores (P = .04), test-retest reliable (intraclass correlation coefficient = 0.57), specific to emotional face processing (F = 17.97, P < .001), and independent of gray matter volumes of the identified brain areas (F = 1.84, P = .18). Replicating previous results, no significant group differences were found in face-related amygdala activation and amygdala-anterior cingulate cortex connectivity (P corrected for familywise error =.37 and .11, respectively). CONCLUSIONS AND RELEVANCE Our results indicate that altered connectivity in a visual-limbic subnetwork during emotional face processing may be a functional connectomic intermediate phenotype for schizophrenia. The phenotype is reliable, task specific, related to trait anxiety, and associated with manifest illness. These data encourage the further investigation of this phenotype in clinical and pharmacologic studies.
Collapse
Affiliation(s)
- Hengyi Cao
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Alessandro Bertolino
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro," Bari, Italy3Biomarkers and Clinical Imaging, Hoffmann-La Roche, Basel, Switzerland
| | - Henrik Walter
- Department of Psychiatry and Psychotherapy, Universitätsmedizin Charité, Berlin, Germany
| | - Michael Schneider
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Axel Schäfer
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Paolo Taurisano
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro," Bari, Italy
| | - Giuseppe Blasi
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro," Bari, Italy
| | - Leila Haddad
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Oliver Grimm
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Kristina Otto
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Luanna Dixson
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Susanne Erk
- Department of Psychiatry and Psychotherapy, Universitätsmedizin Charité, Berlin, Germany
| | - Sebastian Mohnke
- Department of Psychiatry and Psychotherapy, Universitätsmedizin Charité, Berlin, Germany
| | - Andreas Heinz
- Department of Psychiatry and Psychotherapy, Universitätsmedizin Charité, Berlin, Germany
| | | | - Thomas W Mühleisen
- Institute of Human Genetics, University of Bonn, Bonn, Germany6Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany7Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany
| | - Manuel Mattheisen
- Department of Genomic Mathematics, University of Bonn, Bonn, Germany9Department of Biomedicine, University of Aarhus, Aarhus, Denmark
| | - Stephanie H Witt
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Sven Cichon
- Institute of Human Genetics, University of Bonn, Bonn, Germany6Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany7Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany11Department of Biomedic
| | - Markus Noethen
- Institute of Human Genetics, University of Bonn, Bonn, Germany6Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany7Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany
| | - Marcella Rietschel
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Heike Tost
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Andreas Meyer-Lindenberg
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| |
Collapse
|
141
|
Taurisano P, Antonucci LA, Fazio L, Rampino A, Romano R, Porcelli A, Masellis R, Colizzi M, Quarto T, Torretta S, Di Giorgio A, Pergola G, Bertolino A, Blasi G. Prefrontal activity during working memory is modulated by the interaction of variation in CB1 and COX2 coding genes and correlates with frequency of cannabis use. Cortex 2016; 81:231-8. [PMID: 27261878 DOI: 10.1016/j.cortex.2016.05.010] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 04/19/2016] [Accepted: 05/13/2016] [Indexed: 02/02/2023]
Abstract
The CB1 cannabinoid receptor is targeted in the brain by endocannabinoids under physiological conditions as well as by delta9-tetrahydrocannabinol under cannabis use. Furthermore, its signaling appears to affect brain cognitive processing. Recent findings highlight a crucial role of cyclooxygenase-2 (COX-2) in the mechanism of intraneuronal CB1 signaling transduction, while others indicate that two single nucleotide polymorphisms (SNPs) (rs1406977 and rs20417) modulate expression of CB1 (CNR1) and COX-2 (PTGS2) coding genes, respectively. Here, our aim was to use fMRI to investigate in healthy humans whether these SNPs interact in modulating prefrontal activity during working memory processing and if this modulation is linked with cannabis use. We recruited 242 healthy subjects genotyped for CNR1 rs1406977 and PTGS2 rs20417 that performed the N-back working memory task during fMRI and were interviewed using the Cannabis Experience Questionnaire (CEQ). We found that the interaction between CNR1 rs1406977 and PTGS2 rs20417 is associated with dorsolateral prefrontal cortex (DLPFC) activity such that specific genotype configurations (CNR1 C carriers/PTGS2 C carriers and CNR1 TT/PTGS2 GG) predict lower cortical response versus others in spite of similar behavioral accuracy. Furthermore, DLPFC activity in the cluster associated with the CNR1 by PTGS2 interaction was negatively correlated with behavioral efficiency and positively correlated with frequency of cannabis use in cannabis users. These results suggest that a genetically modulated balancing of signaling within the CB1-COX-2 pathway may reflect on more or less efficient patterns of prefrontal activity during working memory. Frequency of cannabis use may be a factor for further modulation of CNR1/PTGS2-mediated cortical processing associated with this cognitive process.
Collapse
Affiliation(s)
- Paolo Taurisano
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy; IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy
| | - Linda A Antonucci
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy; Department of Educational Sciences, Psychology and Communication Science, University of Bari 'Aldo Moro', Bari, Italy
| | - Leonardo Fazio
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy; IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy
| | - Antonio Rampino
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy
| | - Raffaella Romano
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy
| | - Annamaria Porcelli
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy
| | - Rita Masellis
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy
| | - Marco Colizzi
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Tiziana Quarto
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy; Cognitive Brain Research Unit, Institute of Behavioral Science, University of Helsinki, Finland
| | - Silvia Torretta
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy
| | | | - Giulio Pergola
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy
| | - Alessandro Bertolino
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy; pRED, NORD DTA, Hoffman-La Roche, Ltd., Basel, Switzerland.
| | - Giuseppe Blasi
- Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
| |
Collapse
|
142
|
Antonucci LA, Taurisano P, Fazio L, Gelao B, Romano R, Quarto T, Porcelli A, Mancini M, Di Giorgio A, Caforio G, Pergola G, Popolizio T, Bertolino A, Blasi G. Association of familial risk for schizophrenia with thalamic and medial prefrontal functional connectivity during attentional control. Schizophr Res 2016; 173:23-9. [PMID: 27012899 DOI: 10.1016/j.schres.2016.03.014] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Revised: 03/08/2016] [Accepted: 03/14/2016] [Indexed: 10/22/2022]
Abstract
Anomalies in behavioral correlates of attentional processing and related brain activity are crucial correlates of schizophrenia and associated with familial risk for this brain disorder. However, it is not clear how brain functional connectivity during attentional processes is key for schizophrenia and linked with trait vs. state related variables. To address this issue, we investigated patterns of functional connections during attentional control in healthy siblings of patients with schizophrenia, who share with probands genetic features but not variables related to the state of the disorder. 356 controls, 55 patients with schizophrenia on stable treatment with antipsychotics and 40 healthy siblings of patients with this brain disorder underwent the Variable Attentional Control (VAC) task during fMRI. Independent Component Analysis (ICA) is allowed to identify independent components (IC) of BOLD signal recorded during task performance. Results indicated reduced connectivity strength in patients with schizophrenia as well as in their healthy siblings in left thalamus within an attentional control component and greater connectivity in right medial prefrontal cortex (PFC) within the so-called Default Mode Network (DMN) compared to healthy individuals. These results suggest a relationship between familial risk for schizophrenia and brain functional networks during attentional control, such that this biological phenotype may be considered a useful intermediate phenotype in order to link genes effects to aspects of the pathophysiology of this brain disorder.
Collapse
Affiliation(s)
- Linda A Antonucci
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy; Department of Educational Science, Psychology and Communication Science, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy
| | - Paolo Taurisano
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy
| | - Leonardo Fazio
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy
| | - Barbara Gelao
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy
| | - Raffaella Romano
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy
| | - Tiziana Quarto
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy; Cognitive Brain Research Unit, Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland
| | - Annamaria Porcelli
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy
| | - Marina Mancini
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy
| | | | - Grazia Caforio
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy; Psychiatry Unit, Bari University Hospital, 70124 Bari, Italy
| | - Giulio Pergola
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy
| | - Teresa Popolizio
- IRCCS "Casa Sollievo della Sofferenza", 71013 S. Giovanni Rotondo (FG), Italy
| | - Alessandro Bertolino
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy; Psychiatry Unit, Bari University Hospital, 70124 Bari, Italy
| | - Giuseppe Blasi
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, Università degli Studi di Bari "Aldo Moro", 70124 Bari, Italy; Psychiatry Unit, Bari University Hospital, 70124 Bari, Italy.
| |
Collapse
|
143
|
Pergola G, Di Carlo P, Andriola I, Gelao B, Torretta S, Attrotto MT, Fazio L, Raio A, Albergo D, Masellis R, Rampino A, Blasi G, Bertolino A. Combined effect of genetic variants in the GluN2B coding gene (GRIN2B) on prefrontal function during working memory performance. Psychol Med 2016; 46:1135-1150. [PMID: 26690829 DOI: 10.1017/s0033291715002639] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND The GluN2B subunit of N-methyl-d-aspartate receptors is crucially involved in the physiology of the prefrontal cortex during working memory (WM). Consistently, genetic variants in the GluN2B coding gene (GRIN2B) have been associated with cognitive phenotypes. However, it is unclear how GRIN2B genetic variation affects gene expression and prefrontal cognitive processing. Using a composite score, we tested the combined effect of GRIN2B variants on prefrontal activity during WM performance in healthy subjects. METHOD We computed a composite score to combine the effects of single nucleotide polymorphisms on post-mortem prefrontal GRIN2B mRNA expression. We then computed the composite score in independent samples of healthy participants in a peripheral blood expression study (n = 46), in a WM behavioural study (n = 116) and in a WM functional magnetic resonance imaging study (n = 122). RESULTS Five polymorphisms were associated with GRIN2B expression: rs2160517, rs219931, rs11055792, rs17833967 and rs12814951 (all corrected p < 0.05). The score computed to account for their combined effect reliably indexed gene expression. GRIN2B composite score correlated negatively with intelligence quotient, WM behavioural efficiency and dorsolateral prefrontal cortex activity. Moreover, there was a non-linear association between GRIN2B genetic score and prefrontal activity, i.e. both high and low putative genetic score levels were associated with high blood oxygen level-dependent signals in the prefrontal cortex. CONCLUSIONS Multiple genetic variants in GRIN2B are jointly associated with gene expression, prefrontal function and behaviour during WM. These results support the role of GRIN2B genetic variants in WM prefrontal activity in human adults.
Collapse
Affiliation(s)
- G Pergola
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - P Di Carlo
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - I Andriola
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - B Gelao
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - S Torretta
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - M T Attrotto
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - L Fazio
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - A Raio
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - D Albergo
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - R Masellis
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - A Rampino
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - G Blasi
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| | - A Bertolino
- Department of Basic Medical Sciences,Neuroscience and Sensory Organs,University of Bari 'Aldo Moro',Piazza Giulio Cesare 11,70124 Bari,Italy
| |
Collapse
|
144
|
Cordone S, Del Percio C, Marzano N, Noce G, Bagnoli C, Rossini P, Soricelli A, Famá F, Bartres Faz D, Blin O, Payoux P, Bordet R, Müller B, Tsolaki M, Parnetti L, Hegerl U, Hensch T, Dukart J, Bertolino A, Forloni G, Richardson J, Frisoni G, Babiloni C. ID 286 – Auditory oddball event-related potentials cortical sources are related to cerebrospinal fluid (CSF)® amyloid (A®) level in amnesic MCI subjects. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
145
|
Noce G, Del Percio C, Marzano N, Cordone S, Bagnoli C, Rossini P, Soricelli A, Nobili F, Bartres Faz D, Blin O, Payoux P, Bordet R, Müller B, Tsolaki M, Parnetti L, Hegerl U, Hensch T, Dukar J, Bertolino A, Forloni G, Richardson J, Frisoni G, Babiloni C. ID 284 – Abnormal delta cortical sources of resting state eyes closed EEG rhythms correlate with cerebrospinal fluid (CSF) ® amyloid (A®) level in amnesic MCI subjects. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
146
|
Chieffi M, Mucci A, Rossi A, Rocca P, Bertolino A, Galderisi S, Maj M. A multicentric study on cognitive functions in a large sample of patients with schizophrenia and their unaffected first-degree relatives. Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
IntroductionNeurocognition may represent an indicator of genetic risk and poor outcome in schizophrenia patients (SCZ) predicting real life functioning.ObjectivesAs cognitive performance of unaffected first-degree relatives (UR) is intermediate between SCZ and healthy controls (HC), neurocognitive impairment may represent a marker of vulnerability to schizophrenia.AimsTo investigate social and neurocognition in all subjects and their impact on functional capacity of patients as markers of vulnerability.MethodsSample: 922 SCZ, 379 UR and 780 HC. Assessment: MATRICS Consensus Cognitive Battery (neurocognition), Facial Emotion Identification Test and Awareness of Social Inference Test (social cognition) and Specific Level of Functioning Scale (social functioning). Analyses: Structural Equation Model (SEM) analyses to model the impact of all variables on functional outcome.ResultsSCZ scored worse in all domains than UR and HC. UR had significant impairments in all cognitive domains with respect to HC. Cognitive functioning had direct and indirect impacts on functional outcome mainly through social cognition and functional capacity. Social cognition had a direct impact on outcome, independent of neurocognition.ConclusionSCZ and UR display similar patterns of social and neurocognition deficits. Our results confirm a strong impact of neurocogniton on functional outcome. Social cognition has become an interesting object of study and its conceptualization as trait variable and the existence of a continuum between SCZ and UR are hypotheses for further research.AcknowledgementsThe study was carried out within the project “Multicenter study on factors influencing real-life social functioning of people with a diagnosis of schizophrenia” of the Italian Network for Research on Psychoses.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
147
|
Babiloni C, Del Percio C, Marzano N, Cordone S, Noce G, Bagnoli C, Rossini PM, Soricelli A, Nobili FM, Faz DB, Blin O, Payoux P, Bordet R, Mueller B, Tsolaki M, Parnetti L, Hegerl U, Hensch T, Dukart J, Bertolino A, Forloni G, Frasca A, Richardson J, Bastlund JF, Clausen B, Bentivoglio M, Fabene P, Bertini G, Dix S, Kelley J, Drinkenburg W, Frisoni G. Cortical generation of on-going “Delta” and “Alpha” EEG rhythms in mouse models of Alzheimer’s disease and Alzheimer’s disease patients at prodromic stages. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
148
|
Mucci A, Galderisi S, Rossi A, Rocca P, Bertolino A, Bucci P, Maj M. Relationships between neurocognition, social cognition and functional outcome in schizophrenia. Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.970] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
IntroductionThe inter-relationships of neurocognition, social cognition, residual psychopathology and real-life functioning are poorly understood. A large multicenter study was carried out by the Italian Network for Research on Psychoses to model relationships between neurocognitive deficits, psychopathology and real-life functioning, taking into account the role of functional capacity and social cognition.MethodsA structural equation model was used to investigate direct and indirect effects of neurocognition and psychopathology on real-life functioning. Social cognition and functional capacity were modeled as mediators.ResultsIn 921 patients with schizophrenia, neurocognition had both direct and indirect effects, through functional capacity and social cognition, on real-life functioning. Neurocognition predicted to a large extent social cognition on which depression and disorganization had a modest effect. Social cognition showed a significant direct impact on real-life functioning.ConclusionOur results support a strong link between neurocognition and functional outcome, independent of psychopathology. Social cognition accounted for unique incremental variance in real-life functioning.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
149
|
Ursini G, Cavalleri T, Fazio L, Angrisano T, Iacovelli L, Porcelli A, Maddalena G, Punzi G, Mancini M, Gelao B, Romano R, Masellis R, Calabrese F, Rampino A, Taurisano P, Di Giorgio A, Keller S, Tarantini L, Sinibaldi L, Quarto T, Popolizio T, Caforio G, Blasi G, Riva MA, De Blasi A, Chiariotti L, Bollati V, Bertolino A. BDNF rs6265 methylation and genotype interact on risk for schizophrenia. Epigenetics 2016; 11:11-23. [PMID: 26889735 DOI: 10.1080/15592294.2015.1117736] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Epigenetic mechanisms can mediate gene-environment interactions relevant for complex disorders. The BDNF gene is crucial for development and brain plasticity, is sensitive to environmental stressors, such as hypoxia, and harbors the functional SNP rs6265 (Val(66)Met), which creates or abolishes a CpG dinucleotide for DNA methylation. We found that methylation at the BDNF rs6265 Val allele in peripheral blood of healthy subjects is associated with hypoxia-related early life events (hOCs) and intermediate phenotypes for schizophrenia in a distinctive manner, depending on rs6265 genotype: in ValVal individuals increased methylation is associated with exposure to hOCs and impaired working memory (WM) accuracy, while the opposite is true for ValMet subjects. Also, rs6265 methylation and hOCs interact in modulating WM-related prefrontal activity, another intermediate phenotype for schizophrenia, with an analogous opposite direction in the 2 genotypes. Consistently, rs6265 methylation has a different association with schizophrenia risk in ValVals and ValMets. The relationships of methylation with BDNF levels and of genotype with BHLHB2 binding likely contribute to these opposite effects of methylation. We conclude that BDNF rs6265 methylation interacts with genotype to bridge early environmental exposures to adult phenotypes, relevant for schizophrenia. The study of epigenetic changes in regions containing genetic variation relevant for human diseases may have beneficial implications for the understanding of how genes are actually translated into phenotypes.
Collapse
Affiliation(s)
- Gianluca Ursini
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy.,b Lieber Institute for Brain Development, Johns Hopkins University Medical Campus , Baltimore , MD , US
| | - Tommaso Cavalleri
- c Department of Clinical and Community Sciences, Università degli Studi di Milano , Milan , Italy.,d Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Maggiore Hospital, Mangiagalli and Regina Elena Foundation , Milan , Italy
| | - Leonardo Fazio
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy
| | - Tiziana Angrisano
- e Istituto di Endocrinologia e Oncologia Sperimentale, IEOS, CNR, and Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli 'Federico II' , Naples
| | - Luisa Iacovelli
- f Department of Physiology and Pharmacology 'V. Erspamer', University of Rome 'Sapienza' , Rome , Italy
| | - Annamaria Porcelli
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy
| | - Giancarlo Maddalena
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy
| | - Giovanna Punzi
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy.,b Lieber Institute for Brain Development, Johns Hopkins University Medical Campus , Baltimore , MD , US
| | - Marina Mancini
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy
| | - Barbara Gelao
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy
| | - Raffaella Romano
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy
| | - Rita Masellis
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy
| | - Francesca Calabrese
- g Center of Neuropharmacology; Dipartimento di Scienze Farmacologiche e Biomolecolari; Università degli Studi di Milano , Milan , Italy
| | - Antonio Rampino
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy
| | - Paolo Taurisano
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy
| | - Annabella Di Giorgio
- h Department of Neuroradiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) 'Casa Sollievo della Sofferenza' , San Giovanni Rotondo , Italy
| | - Simona Keller
- e Istituto di Endocrinologia e Oncologia Sperimentale, IEOS, CNR, and Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli 'Federico II' , Naples
| | - Letizia Tarantini
- c Department of Clinical and Community Sciences, Università degli Studi di Milano , Milan , Italy.,d Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Maggiore Hospital, Mangiagalli and Regina Elena Foundation , Milan , Italy
| | - Lorenzo Sinibaldi
- i Mendel Laboratory, Istituto di Ricoveroe Cura a Carattere Scientifico (IRCCS) 'Casa Sollievo della Sofferenza' , San Giovanni Rotondo , Italy
| | - Tiziana Quarto
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy.,j Cognitive Brain Research Unit, Institute of Behavioral Sciences, University of Helsinki , Helsinki , Finland
| | - Teresa Popolizio
- h Department of Neuroradiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) 'Casa Sollievo della Sofferenza' , San Giovanni Rotondo , Italy
| | - Grazia Caforio
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy
| | - Giuseppe Blasi
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy
| | - Marco A Riva
- g Center of Neuropharmacology; Dipartimento di Scienze Farmacologiche e Biomolecolari; Università degli Studi di Milano , Milan , Italy
| | - Antonio De Blasi
- k Department of Molecular Medicine, University of Rome 'Sapienza' , Rome , Italy
| | - Lorenzo Chiariotti
- e Istituto di Endocrinologia e Oncologia Sperimentale, IEOS, CNR, and Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli 'Federico II' , Naples
| | - Valentina Bollati
- c Department of Clinical and Community Sciences, Università degli Studi di Milano , Milan , Italy.,d Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Maggiore Hospital, Mangiagalli and Regina Elena Foundation , Milan , Italy
| | - Alessandro Bertolino
- a Psychiatric Neuroscience Group, Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari 'Aldo Moro' , Bari , Italy.,h Department of Neuroradiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) 'Casa Sollievo della Sofferenza' , San Giovanni Rotondo , Italy
| |
Collapse
|
150
|
Quarto T, Blasi G, Maddalena C, Viscanti G, Lanciano T, Soleti E, Mangiulli I, Taurisano P, Fazio L, Bertolino A, Curci A. Association between Ability Emotional Intelligence and Left Insula during Social Judgment of Facial Emotions. PLoS One 2016; 11:e0148621. [PMID: 26859495 PMCID: PMC4747486 DOI: 10.1371/journal.pone.0148621] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Accepted: 01/21/2016] [Indexed: 11/19/2022] Open
Abstract
The human ability of identifying, processing and regulating emotions from social stimuli is generally referred as Emotional Intelligence (EI). Within EI, Ability EI identifies a performance measure assessing individual skills at perceiving, using, understanding and managing emotions. Previous models suggest that a brain "somatic marker circuitry" (SMC) sustains emotional sub-processes included in EI. Three primary brain regions are included: the amygdala, the insula and the ventromedial prefrontal cortex (vmPFC). Here, our aim was to investigate the relationship between Ability EI scores and SMC activity during social judgment of emotional faces. Sixty-three healthy subjects completed a test measuring Ability EI and underwent fMRI during a social decision task (i.e. approach or avoid) about emotional faces with different facial expressions. Imaging data revealed that EI scores are associated with left insula activity during social judgment of emotional faces as a function of facial expression. Specifically, higher EI scores are associated with greater left insula activity during social judgment of fearful faces but also with lower activity of this region during social judgment of angry faces. These findings indicate that the association between Ability EI and the SMC activity during social behavior is region- and emotion-specific.
Collapse
Affiliation(s)
- Tiziana Quarto
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
- Cognitive Brain Research Unit, Institute of Behavioral Science, University of Helsinki, Helsinki, Finland
| | - Giuseppe Blasi
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Chiara Maddalena
- Department of Education Science, Psychology and Communication Science, University of Bari "Aldo Moro", Bari, Italy
| | - Giovanna Viscanti
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Tiziana Lanciano
- Department of Education Science, Psychology and Communication Science, University of Bari "Aldo Moro", Bari, Italy
| | - Emanuela Soleti
- Department of Education Science, Psychology and Communication Science, University of Bari "Aldo Moro", Bari, Italy
| | - Ivan Mangiulli
- Department of Education Science, Psychology and Communication Science, University of Bari "Aldo Moro", Bari, Italy
| | - Paolo Taurisano
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Leonardo Fazio
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
| | - Alessandro Bertolino
- Psychiatric Neuroscience Group, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy
- pRED, NORD DTA, Hoffman-La Roche Ltd, Basel, Switzerland
| | - Antonietta Curci
- Department of Education Science, Psychology and Communication Science, University of Bari "Aldo Moro", Bari, Italy
- * E-mail:
| |
Collapse
|